INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58501, 8564, 'Ivabradine', 'Kidney Diseases', 'No dosage adjustment is required for patients with creatinine clearance 15 to 60 mL/min.  Care should be exercised when using this agent in patients with creatinine clearance below 15 mL/min as no data are available.', '2', '"Product Information. Corlanor (ivabradine)." Amgen USA  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58502, 14165, 'Ivabradine', 'Kidney Diseases', 'No dosage adjustment is required for patients with creatinine clearance 15 to 60 mL/min.  Care should be exercised when using this agent in patients with creatinine clearance below 15 mL/min as no data are available.', '2', '"Product Information. Corlanor (ivabradine)." Amgen USA  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58503, 14166, 'Ivabradine', 'Kidney Diseases', 'No dosage adjustment is required for patients with creatinine clearance 15 to 60 mL/min.  Care should be exercised when using this agent in patients with creatinine clearance below 15 mL/min as no data are available.', '2', '"Product Information. Corlanor (ivabradine)." Amgen USA  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58504, 15457, 'Ivabradine', 'Kidney Diseases', 'No dosage adjustment is required for patients with creatinine clearance 15 to 60 mL/min.  Care should be exercised when using this agent in patients with creatinine clearance below 15 mL/min as no data are available.', '2', '"Product Information. Corlanor (ivabradine)." Amgen USA  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58505, 25293, 'Ivabradine', 'Kidney Diseases', 'No dosage adjustment is required for patients with creatinine clearance 15 to 60 mL/min.  Care should be exercised when using this agent in patients with creatinine clearance below 15 mL/min as no data are available.', '2', '"Product Information. Corlanor (ivabradine)." Amgen USA  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58506, 25294, 'Ivabradine', 'Kidney Diseases', 'No dosage adjustment is required for patients with creatinine clearance 15 to 60 mL/min.  Care should be exercised when using this agent in patients with creatinine clearance below 15 mL/min as no data are available.', '2', '"Product Information. Corlanor (ivabradine)." Amgen USA  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58507, 26561, 'Ivabradine', 'Kidney Diseases', 'No dosage adjustment is required for patients with creatinine clearance 15 to 60 mL/min.  Care should be exercised when using this agent in patients with creatinine clearance below 15 mL/min as no data are available.', '2', '"Product Information. Corlanor (ivabradine)." Amgen USA  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58508, 26562, 'Ivabradine', 'Kidney Diseases', 'No dosage adjustment is required for patients with creatinine clearance 15 to 60 mL/min.  Care should be exercised when using this agent in patients with creatinine clearance below 15 mL/min as no data are available.', '2', '"Product Information. Corlanor (ivabradine)." Amgen USA  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58509, 30085, 'Ivabradine', 'Kidney Diseases', 'No dosage adjustment is required for patients with creatinine clearance 15 to 60 mL/min.  Care should be exercised when using this agent in patients with creatinine clearance below 15 mL/min as no data are available.', '2', '"Product Information. Corlanor (ivabradine)." Amgen USA  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58510, 30086, 'Ivabradine', 'Kidney Diseases', 'No dosage adjustment is required for patients with creatinine clearance 15 to 60 mL/min.  Care should be exercised when using this agent in patients with creatinine clearance below 15 mL/min as no data are available.', '2', '"Product Information. Corlanor (ivabradine)." Amgen USA  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58511, 0, 'Ivacaftor', 'Cataract', 'Cases of non- congenital lens opacities or cataracts have been reported in pediatric patients treated with ivacaftor, and although other risk factors could be present in some cases, a possible risk attributable to this medication cannot be excluded.  Baseline and ophthalmological examinations are recommended in pediatric patients initiating treatment.  Caution is advised in patients with ophthalmologic conditions.', '2', '"Product Information. Kalydeco (ivacaftor)." Vertex Pharmaceuticals  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58512, 0, 'Ivacaftor', 'Hepatic Insufficiency', 'Elevated transaminases have been reported in patients with cystic fibrosis receiving ivacaftor.  It is recommended that liver function tests are assessed prior to treatment, every 3 months during the first year, and annually thereafter.  Patients with increased levels should be closely monitored until the abnormalities resolve, and dosing should be interrupted in patients with ALT or AST of greater than 5 times the upper limit of normal (ULN).  In patients with hepatic impairment, no dose adjustment is necessary in patients with mild impairment, but a reduced dose of ivacaftor is recommended in patients with moderate impairment (see prescribing information for dosing recommendations).  Studies have not been conducted in patients with severe hepatic impairment, but exposure is expected to be higher than in patients with moderate impairment.  Therefore, caution should be used on these patients, and a reduced dose is recommended after weighing the risks and benefits of treatment.', '2', '"Product Information. Kalydeco (ivacaftor)." Vertex Pharmaceuticals  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58513, 0, 'Ivacaftor', 'Kidney Diseases', 'Ivacaftor has not been studied in patients with renal impairment.  No dose adjustment is necessary for patients with mild or moderate renal impairment, however, caution is recommended in patients with severe renal impairment or end-stage renal disease.', '2', '"Product Information. Kalydeco (ivacaftor)." Vertex Pharmaceuticals  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58514, 959, 'Itraconazole', 'Heart Failure', 'Itraconazole may possess a dose-related negative inotropic effect.  Transient, asymptomatic decreases in left ventricular ejection fraction were observed with IV administration in healthy volunteers; these resolved before the next infusion.  Additionally, cases of congestive heart failure (CHF), peripheral edema, and pulmonary edema have been reported during postmarketing experience in patients treated for onychomycosis and/or systemic fungal infections.  Itraconazole should not be used to treat onychomycosis in patients with evidence of ventricular dysfunction such as CHF or history of CHF; itraconazole should not be used for other indications in such patients unless the benefit clearly outweighs the risk.  The risks and benefits of itraconazole therapy should be reviewed carefully in patients with risk factors for CHF (including cardiac disease [e.g., ischemic and valvular disease], significant pulmonary disease [e.g., chronic obstructive pulmonary disease], renal failure and other edematous disorders).  Patients with risk factors for CHF should be advised of the signs/symptoms of CHF, treated with caution, and monitored for signs/symptoms of CHF during therapy.', '3', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58515, 6667, 'Itraconazole', 'Heart Failure', 'Itraconazole may possess a dose-related negative inotropic effect.  Transient, asymptomatic decreases in left ventricular ejection fraction were observed with IV administration in healthy volunteers; these resolved before the next infusion.  Additionally, cases of congestive heart failure (CHF), peripheral edema, and pulmonary edema have been reported during postmarketing experience in patients treated for onychomycosis and/or systemic fungal infections.  Itraconazole should not be used to treat onychomycosis in patients with evidence of ventricular dysfunction such as CHF or history of CHF; itraconazole should not be used for other indications in such patients unless the benefit clearly outweighs the risk.  The risks and benefits of itraconazole therapy should be reviewed carefully in patients with risk factors for CHF (including cardiac disease [e.g., ischemic and valvular disease], significant pulmonary disease [e.g., chronic obstructive pulmonary disease], renal failure and other edematous disorders).  Patients with risk factors for CHF should be advised of the signs/symptoms of CHF, treated with caution, and monitored for signs/symptoms of CHF during therapy.', '3', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58516, 6669, 'Itraconazole', 'Heart Failure', 'Itraconazole may possess a dose-related negative inotropic effect.  Transient, asymptomatic decreases in left ventricular ejection fraction were observed with IV administration in healthy volunteers; these resolved before the next infusion.  Additionally, cases of congestive heart failure (CHF), peripheral edema, and pulmonary edema have been reported during postmarketing experience in patients treated for onychomycosis and/or systemic fungal infections.  Itraconazole should not be used to treat onychomycosis in patients with evidence of ventricular dysfunction such as CHF or history of CHF; itraconazole should not be used for other indications in such patients unless the benefit clearly outweighs the risk.  The risks and benefits of itraconazole therapy should be reviewed carefully in patients with risk factors for CHF (including cardiac disease [e.g., ischemic and valvular disease], significant pulmonary disease [e.g., chronic obstructive pulmonary disease], renal failure and other edematous disorders).  Patients with risk factors for CHF should be advised of the signs/symptoms of CHF, treated with caution, and monitored for signs/symptoms of CHF during therapy.', '3', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58517, 6670, 'Itraconazole', 'Heart Failure', 'Itraconazole may possess a dose-related negative inotropic effect.  Transient, asymptomatic decreases in left ventricular ejection fraction were observed with IV administration in healthy volunteers; these resolved before the next infusion.  Additionally, cases of congestive heart failure (CHF), peripheral edema, and pulmonary edema have been reported during postmarketing experience in patients treated for onychomycosis and/or systemic fungal infections.  Itraconazole should not be used to treat onychomycosis in patients with evidence of ventricular dysfunction such as CHF or history of CHF; itraconazole should not be used for other indications in such patients unless the benefit clearly outweighs the risk.  The risks and benefits of itraconazole therapy should be reviewed carefully in patients with risk factors for CHF (including cardiac disease [e.g., ischemic and valvular disease], significant pulmonary disease [e.g., chronic obstructive pulmonary disease], renal failure and other edematous disorders).  Patients with risk factors for CHF should be advised of the signs/symptoms of CHF, treated with caution, and monitored for signs/symptoms of CHF during therapy.', '3', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58518, 6674, 'Itraconazole', 'Heart Failure', 'Itraconazole may possess a dose-related negative inotropic effect.  Transient, asymptomatic decreases in left ventricular ejection fraction were observed with IV administration in healthy volunteers; these resolved before the next infusion.  Additionally, cases of congestive heart failure (CHF), peripheral edema, and pulmonary edema have been reported during postmarketing experience in patients treated for onychomycosis and/or systemic fungal infections.  Itraconazole should not be used to treat onychomycosis in patients with evidence of ventricular dysfunction such as CHF or history of CHF; itraconazole should not be used for other indications in such patients unless the benefit clearly outweighs the risk.  The risks and benefits of itraconazole therapy should be reviewed carefully in patients with risk factors for CHF (including cardiac disease [e.g., ischemic and valvular disease], significant pulmonary disease [e.g., chronic obstructive pulmonary disease], renal failure and other edematous disorders).  Patients with risk factors for CHF should be advised of the signs/symptoms of CHF, treated with caution, and monitored for signs/symptoms of CHF during therapy.', '3', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58519, 6675, 'Itraconazole', 'Heart Failure', 'Itraconazole may possess a dose-related negative inotropic effect.  Transient, asymptomatic decreases in left ventricular ejection fraction were observed with IV administration in healthy volunteers; these resolved before the next infusion.  Additionally, cases of congestive heart failure (CHF), peripheral edema, and pulmonary edema have been reported during postmarketing experience in patients treated for onychomycosis and/or systemic fungal infections.  Itraconazole should not be used to treat onychomycosis in patients with evidence of ventricular dysfunction such as CHF or history of CHF; itraconazole should not be used for other indications in such patients unless the benefit clearly outweighs the risk.  The risks and benefits of itraconazole therapy should be reviewed carefully in patients with risk factors for CHF (including cardiac disease [e.g., ischemic and valvular disease], significant pulmonary disease [e.g., chronic obstructive pulmonary disease], renal failure and other edematous disorders).  Patients with risk factors for CHF should be advised of the signs/symptoms of CHF, treated with caution, and monitored for signs/symptoms of CHF during therapy.', '3', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58520, 6676, 'Itraconazole', 'Heart Failure', 'Itraconazole may possess a dose-related negative inotropic effect.  Transient, asymptomatic decreases in left ventricular ejection fraction were observed with IV administration in healthy volunteers; these resolved before the next infusion.  Additionally, cases of congestive heart failure (CHF), peripheral edema, and pulmonary edema have been reported during postmarketing experience in patients treated for onychomycosis and/or systemic fungal infections.  Itraconazole should not be used to treat onychomycosis in patients with evidence of ventricular dysfunction such as CHF or history of CHF; itraconazole should not be used for other indications in such patients unless the benefit clearly outweighs the risk.  The risks and benefits of itraconazole therapy should be reviewed carefully in patients with risk factors for CHF (including cardiac disease [e.g., ischemic and valvular disease], significant pulmonary disease [e.g., chronic obstructive pulmonary disease], renal failure and other edematous disorders).  Patients with risk factors for CHF should be advised of the signs/symptoms of CHF, treated with caution, and monitored for signs/symptoms of CHF during therapy.', '3', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58521, 6678, 'Itraconazole', 'Heart Failure', 'Itraconazole may possess a dose-related negative inotropic effect.  Transient, asymptomatic decreases in left ventricular ejection fraction were observed with IV administration in healthy volunteers; these resolved before the next infusion.  Additionally, cases of congestive heart failure (CHF), peripheral edema, and pulmonary edema have been reported during postmarketing experience in patients treated for onychomycosis and/or systemic fungal infections.  Itraconazole should not be used to treat onychomycosis in patients with evidence of ventricular dysfunction such as CHF or history of CHF; itraconazole should not be used for other indications in such patients unless the benefit clearly outweighs the risk.  The risks and benefits of itraconazole therapy should be reviewed carefully in patients with risk factors for CHF (including cardiac disease [e.g., ischemic and valvular disease], significant pulmonary disease [e.g., chronic obstructive pulmonary disease], renal failure and other edematous disorders).  Patients with risk factors for CHF should be advised of the signs/symptoms of CHF, treated with caution, and monitored for signs/symptoms of CHF during therapy.', '3', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58522, 10830, 'Itraconazole', 'Heart Failure', 'Itraconazole may possess a dose-related negative inotropic effect.  Transient, asymptomatic decreases in left ventricular ejection fraction were observed with IV administration in healthy volunteers; these resolved before the next infusion.  Additionally, cases of congestive heart failure (CHF), peripheral edema, and pulmonary edema have been reported during postmarketing experience in patients treated for onychomycosis and/or systemic fungal infections.  Itraconazole should not be used to treat onychomycosis in patients with evidence of ventricular dysfunction such as CHF or history of CHF; itraconazole should not be used for other indications in such patients unless the benefit clearly outweighs the risk.  The risks and benefits of itraconazole therapy should be reviewed carefully in patients with risk factors for CHF (including cardiac disease [e.g., ischemic and valvular disease], significant pulmonary disease [e.g., chronic obstructive pulmonary disease], renal failure and other edematous disorders).  Patients with risk factors for CHF should be advised of the signs/symptoms of CHF, treated with caution, and monitored for signs/symptoms of CHF during therapy.', '3', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58523, 14419, 'Itraconazole', 'Heart Failure', 'Itraconazole may possess a dose-related negative inotropic effect.  Transient, asymptomatic decreases in left ventricular ejection fraction were observed with IV administration in healthy volunteers; these resolved before the next infusion.  Additionally, cases of congestive heart failure (CHF), peripheral edema, and pulmonary edema have been reported during postmarketing experience in patients treated for onychomycosis and/or systemic fungal infections.  Itraconazole should not be used to treat onychomycosis in patients with evidence of ventricular dysfunction such as CHF or history of CHF; itraconazole should not be used for other indications in such patients unless the benefit clearly outweighs the risk.  The risks and benefits of itraconazole therapy should be reviewed carefully in patients with risk factors for CHF (including cardiac disease [e.g., ischemic and valvular disease], significant pulmonary disease [e.g., chronic obstructive pulmonary disease], renal failure and other edematous disorders).  Patients with risk factors for CHF should be advised of the signs/symptoms of CHF, treated with caution, and monitored for signs/symptoms of CHF during therapy.', '3', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58524, 19475, 'Itraconazole', 'Heart Failure', 'Itraconazole may possess a dose-related negative inotropic effect.  Transient, asymptomatic decreases in left ventricular ejection fraction were observed with IV administration in healthy volunteers; these resolved before the next infusion.  Additionally, cases of congestive heart failure (CHF), peripheral edema, and pulmonary edema have been reported during postmarketing experience in patients treated for onychomycosis and/or systemic fungal infections.  Itraconazole should not be used to treat onychomycosis in patients with evidence of ventricular dysfunction such as CHF or history of CHF; itraconazole should not be used for other indications in such patients unless the benefit clearly outweighs the risk.  The risks and benefits of itraconazole therapy should be reviewed carefully in patients with risk factors for CHF (including cardiac disease [e.g., ischemic and valvular disease], significant pulmonary disease [e.g., chronic obstructive pulmonary disease], renal failure and other edematous disorders).  Patients with risk factors for CHF should be advised of the signs/symptoms of CHF, treated with caution, and monitored for signs/symptoms of CHF during therapy.', '3', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58525, 19476, 'Itraconazole', 'Heart Failure', 'Itraconazole may possess a dose-related negative inotropic effect.  Transient, asymptomatic decreases in left ventricular ejection fraction were observed with IV administration in healthy volunteers; these resolved before the next infusion.  Additionally, cases of congestive heart failure (CHF), peripheral edema, and pulmonary edema have been reported during postmarketing experience in patients treated for onychomycosis and/or systemic fungal infections.  Itraconazole should not be used to treat onychomycosis in patients with evidence of ventricular dysfunction such as CHF or history of CHF; itraconazole should not be used for other indications in such patients unless the benefit clearly outweighs the risk.  The risks and benefits of itraconazole therapy should be reviewed carefully in patients with risk factors for CHF (including cardiac disease [e.g., ischemic and valvular disease], significant pulmonary disease [e.g., chronic obstructive pulmonary disease], renal failure and other edematous disorders).  Patients with risk factors for CHF should be advised of the signs/symptoms of CHF, treated with caution, and monitored for signs/symptoms of CHF during therapy.', '3', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58526, 21063, 'Itraconazole', 'Heart Failure', 'Itraconazole may possess a dose-related negative inotropic effect.  Transient, asymptomatic decreases in left ventricular ejection fraction were observed with IV administration in healthy volunteers; these resolved before the next infusion.  Additionally, cases of congestive heart failure (CHF), peripheral edema, and pulmonary edema have been reported during postmarketing experience in patients treated for onychomycosis and/or systemic fungal infections.  Itraconazole should not be used to treat onychomycosis in patients with evidence of ventricular dysfunction such as CHF or history of CHF; itraconazole should not be used for other indications in such patients unless the benefit clearly outweighs the risk.  The risks and benefits of itraconazole therapy should be reviewed carefully in patients with risk factors for CHF (including cardiac disease [e.g., ischemic and valvular disease], significant pulmonary disease [e.g., chronic obstructive pulmonary disease], renal failure and other edematous disorders).  Patients with risk factors for CHF should be advised of the signs/symptoms of CHF, treated with caution, and monitored for signs/symptoms of CHF during therapy.', '3', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58527, 21065, 'Itraconazole', 'Heart Failure', 'Itraconazole may possess a dose-related negative inotropic effect.  Transient, asymptomatic decreases in left ventricular ejection fraction were observed with IV administration in healthy volunteers; these resolved before the next infusion.  Additionally, cases of congestive heart failure (CHF), peripheral edema, and pulmonary edema have been reported during postmarketing experience in patients treated for onychomycosis and/or systemic fungal infections.  Itraconazole should not be used to treat onychomycosis in patients with evidence of ventricular dysfunction such as CHF or history of CHF; itraconazole should not be used for other indications in such patients unless the benefit clearly outweighs the risk.  The risks and benefits of itraconazole therapy should be reviewed carefully in patients with risk factors for CHF (including cardiac disease [e.g., ischemic and valvular disease], significant pulmonary disease [e.g., chronic obstructive pulmonary disease], renal failure and other edematous disorders).  Patients with risk factors for CHF should be advised of the signs/symptoms of CHF, treated with caution, and monitored for signs/symptoms of CHF during therapy.', '3', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58528, 21067, 'Itraconazole', 'Heart Failure', 'Itraconazole may possess a dose-related negative inotropic effect.  Transient, asymptomatic decreases in left ventricular ejection fraction were observed with IV administration in healthy volunteers; these resolved before the next infusion.  Additionally, cases of congestive heart failure (CHF), peripheral edema, and pulmonary edema have been reported during postmarketing experience in patients treated for onychomycosis and/or systemic fungal infections.  Itraconazole should not be used to treat onychomycosis in patients with evidence of ventricular dysfunction such as CHF or history of CHF; itraconazole should not be used for other indications in such patients unless the benefit clearly outweighs the risk.  The risks and benefits of itraconazole therapy should be reviewed carefully in patients with risk factors for CHF (including cardiac disease [e.g., ischemic and valvular disease], significant pulmonary disease [e.g., chronic obstructive pulmonary disease], renal failure and other edematous disorders).  Patients with risk factors for CHF should be advised of the signs/symptoms of CHF, treated with caution, and monitored for signs/symptoms of CHF during therapy.', '3', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58529, 21070, 'Itraconazole', 'Heart Failure', 'Itraconazole may possess a dose-related negative inotropic effect.  Transient, asymptomatic decreases in left ventricular ejection fraction were observed with IV administration in healthy volunteers; these resolved before the next infusion.  Additionally, cases of congestive heart failure (CHF), peripheral edema, and pulmonary edema have been reported during postmarketing experience in patients treated for onychomycosis and/or systemic fungal infections.  Itraconazole should not be used to treat onychomycosis in patients with evidence of ventricular dysfunction such as CHF or history of CHF; itraconazole should not be used for other indications in such patients unless the benefit clearly outweighs the risk.  The risks and benefits of itraconazole therapy should be reviewed carefully in patients with risk factors for CHF (including cardiac disease [e.g., ischemic and valvular disease], significant pulmonary disease [e.g., chronic obstructive pulmonary disease], renal failure and other edematous disorders).  Patients with risk factors for CHF should be advised of the signs/symptoms of CHF, treated with caution, and monitored for signs/symptoms of CHF during therapy.', '3', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58530, 27421, 'Itraconazole', 'Heart Failure', 'Itraconazole may possess a dose-related negative inotropic effect.  Transient, asymptomatic decreases in left ventricular ejection fraction were observed with IV administration in healthy volunteers; these resolved before the next infusion.  Additionally, cases of congestive heart failure (CHF), peripheral edema, and pulmonary edema have been reported during postmarketing experience in patients treated for onychomycosis and/or systemic fungal infections.  Itraconazole should not be used to treat onychomycosis in patients with evidence of ventricular dysfunction such as CHF or history of CHF; itraconazole should not be used for other indications in such patients unless the benefit clearly outweighs the risk.  The risks and benefits of itraconazole therapy should be reviewed carefully in patients with risk factors for CHF (including cardiac disease [e.g., ischemic and valvular disease], significant pulmonary disease [e.g., chronic obstructive pulmonary disease], renal failure and other edematous disorders).  Patients with risk factors for CHF should be advised of the signs/symptoms of CHF, treated with caution, and monitored for signs/symptoms of CHF during therapy.', '3', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58531, 28046, 'Itraconazole', 'Heart Failure', 'Itraconazole may possess a dose-related negative inotropic effect.  Transient, asymptomatic decreases in left ventricular ejection fraction were observed with IV administration in healthy volunteers; these resolved before the next infusion.  Additionally, cases of congestive heart failure (CHF), peripheral edema, and pulmonary edema have been reported during postmarketing experience in patients treated for onychomycosis and/or systemic fungal infections.  Itraconazole should not be used to treat onychomycosis in patients with evidence of ventricular dysfunction such as CHF or history of CHF; itraconazole should not be used for other indications in such patients unless the benefit clearly outweighs the risk.  The risks and benefits of itraconazole therapy should be reviewed carefully in patients with risk factors for CHF (including cardiac disease [e.g., ischemic and valvular disease], significant pulmonary disease [e.g., chronic obstructive pulmonary disease], renal failure and other edematous disorders).  Patients with risk factors for CHF should be advised of the signs/symptoms of CHF, treated with caution, and monitored for signs/symptoms of CHF during therapy.', '3', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58532, 959, 'Itraconazole', 'Liver Diseases', 'Limited data are available on the use of oral itraconazole in patients with liver dysfunction.  Itraconazole has been associated with rare cases of serious hepatotoxicity (including liver failure and death).  Caution is recommended when this drug is used in patients with liver dysfunction; such patients should be carefully monitored during therapy.  Treatment with itraconazole is strongly discouraged in patients with elevated or abnormal liver enzymes, with active liver disease, or who had liver toxicity with other drugs unless the situation is serious or life-threatening and the expected benefit exceeds the risk.  Liver function monitoring is recommended for patients with preexisting hepatic function abnormalities or those who had liver toxicity with other drugs.', '3', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58533, 6667, 'Itraconazole', 'Liver Diseases', 'Limited data are available on the use of oral itraconazole in patients with liver dysfunction.  Itraconazole has been associated with rare cases of serious hepatotoxicity (including liver failure and death).  Caution is recommended when this drug is used in patients with liver dysfunction; such patients should be carefully monitored during therapy.  Treatment with itraconazole is strongly discouraged in patients with elevated or abnormal liver enzymes, with active liver disease, or who had liver toxicity with other drugs unless the situation is serious or life-threatening and the expected benefit exceeds the risk.  Liver function monitoring is recommended for patients with preexisting hepatic function abnormalities or those who had liver toxicity with other drugs.', '3', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58534, 6669, 'Itraconazole', 'Liver Diseases', 'Limited data are available on the use of oral itraconazole in patients with liver dysfunction.  Itraconazole has been associated with rare cases of serious hepatotoxicity (including liver failure and death).  Caution is recommended when this drug is used in patients with liver dysfunction; such patients should be carefully monitored during therapy.  Treatment with itraconazole is strongly discouraged in patients with elevated or abnormal liver enzymes, with active liver disease, or who had liver toxicity with other drugs unless the situation is serious or life-threatening and the expected benefit exceeds the risk.  Liver function monitoring is recommended for patients with preexisting hepatic function abnormalities or those who had liver toxicity with other drugs.', '3', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58535, 6670, 'Itraconazole', 'Liver Diseases', 'Limited data are available on the use of oral itraconazole in patients with liver dysfunction.  Itraconazole has been associated with rare cases of serious hepatotoxicity (including liver failure and death).  Caution is recommended when this drug is used in patients with liver dysfunction; such patients should be carefully monitored during therapy.  Treatment with itraconazole is strongly discouraged in patients with elevated or abnormal liver enzymes, with active liver disease, or who had liver toxicity with other drugs unless the situation is serious or life-threatening and the expected benefit exceeds the risk.  Liver function monitoring is recommended for patients with preexisting hepatic function abnormalities or those who had liver toxicity with other drugs.', '3', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58536, 6674, 'Itraconazole', 'Liver Diseases', 'Limited data are available on the use of oral itraconazole in patients with liver dysfunction.  Itraconazole has been associated with rare cases of serious hepatotoxicity (including liver failure and death).  Caution is recommended when this drug is used in patients with liver dysfunction; such patients should be carefully monitored during therapy.  Treatment with itraconazole is strongly discouraged in patients with elevated or abnormal liver enzymes, with active liver disease, or who had liver toxicity with other drugs unless the situation is serious or life-threatening and the expected benefit exceeds the risk.  Liver function monitoring is recommended for patients with preexisting hepatic function abnormalities or those who had liver toxicity with other drugs.', '3', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58537, 6675, 'Itraconazole', 'Liver Diseases', 'Limited data are available on the use of oral itraconazole in patients with liver dysfunction.  Itraconazole has been associated with rare cases of serious hepatotoxicity (including liver failure and death).  Caution is recommended when this drug is used in patients with liver dysfunction; such patients should be carefully monitored during therapy.  Treatment with itraconazole is strongly discouraged in patients with elevated or abnormal liver enzymes, with active liver disease, or who had liver toxicity with other drugs unless the situation is serious or life-threatening and the expected benefit exceeds the risk.  Liver function monitoring is recommended for patients with preexisting hepatic function abnormalities or those who had liver toxicity with other drugs.', '3', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58538, 6676, 'Itraconazole', 'Liver Diseases', 'Limited data are available on the use of oral itraconazole in patients with liver dysfunction.  Itraconazole has been associated with rare cases of serious hepatotoxicity (including liver failure and death).  Caution is recommended when this drug is used in patients with liver dysfunction; such patients should be carefully monitored during therapy.  Treatment with itraconazole is strongly discouraged in patients with elevated or abnormal liver enzymes, with active liver disease, or who had liver toxicity with other drugs unless the situation is serious or life-threatening and the expected benefit exceeds the risk.  Liver function monitoring is recommended for patients with preexisting hepatic function abnormalities or those who had liver toxicity with other drugs.', '3', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58539, 6678, 'Itraconazole', 'Liver Diseases', 'Limited data are available on the use of oral itraconazole in patients with liver dysfunction.  Itraconazole has been associated with rare cases of serious hepatotoxicity (including liver failure and death).  Caution is recommended when this drug is used in patients with liver dysfunction; such patients should be carefully monitored during therapy.  Treatment with itraconazole is strongly discouraged in patients with elevated or abnormal liver enzymes, with active liver disease, or who had liver toxicity with other drugs unless the situation is serious or life-threatening and the expected benefit exceeds the risk.  Liver function monitoring is recommended for patients with preexisting hepatic function abnormalities or those who had liver toxicity with other drugs.', '3', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58540, 10830, 'Itraconazole', 'Liver Diseases', 'Limited data are available on the use of oral itraconazole in patients with liver dysfunction.  Itraconazole has been associated with rare cases of serious hepatotoxicity (including liver failure and death).  Caution is recommended when this drug is used in patients with liver dysfunction; such patients should be carefully monitored during therapy.  Treatment with itraconazole is strongly discouraged in patients with elevated or abnormal liver enzymes, with active liver disease, or who had liver toxicity with other drugs unless the situation is serious or life-threatening and the expected benefit exceeds the risk.  Liver function monitoring is recommended for patients with preexisting hepatic function abnormalities or those who had liver toxicity with other drugs.', '3', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58541, 14419, 'Itraconazole', 'Liver Diseases', 'Limited data are available on the use of oral itraconazole in patients with liver dysfunction.  Itraconazole has been associated with rare cases of serious hepatotoxicity (including liver failure and death).  Caution is recommended when this drug is used in patients with liver dysfunction; such patients should be carefully monitored during therapy.  Treatment with itraconazole is strongly discouraged in patients with elevated or abnormal liver enzymes, with active liver disease, or who had liver toxicity with other drugs unless the situation is serious or life-threatening and the expected benefit exceeds the risk.  Liver function monitoring is recommended for patients with preexisting hepatic function abnormalities or those who had liver toxicity with other drugs.', '3', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58542, 19475, 'Itraconazole', 'Liver Diseases', 'Limited data are available on the use of oral itraconazole in patients with liver dysfunction.  Itraconazole has been associated with rare cases of serious hepatotoxicity (including liver failure and death).  Caution is recommended when this drug is used in patients with liver dysfunction; such patients should be carefully monitored during therapy.  Treatment with itraconazole is strongly discouraged in patients with elevated or abnormal liver enzymes, with active liver disease, or who had liver toxicity with other drugs unless the situation is serious or life-threatening and the expected benefit exceeds the risk.  Liver function monitoring is recommended for patients with preexisting hepatic function abnormalities or those who had liver toxicity with other drugs.', '3', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58543, 19476, 'Itraconazole', 'Liver Diseases', 'Limited data are available on the use of oral itraconazole in patients with liver dysfunction.  Itraconazole has been associated with rare cases of serious hepatotoxicity (including liver failure and death).  Caution is recommended when this drug is used in patients with liver dysfunction; such patients should be carefully monitored during therapy.  Treatment with itraconazole is strongly discouraged in patients with elevated or abnormal liver enzymes, with active liver disease, or who had liver toxicity with other drugs unless the situation is serious or life-threatening and the expected benefit exceeds the risk.  Liver function monitoring is recommended for patients with preexisting hepatic function abnormalities or those who had liver toxicity with other drugs.', '3', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58544, 21063, 'Itraconazole', 'Liver Diseases', 'Limited data are available on the use of oral itraconazole in patients with liver dysfunction.  Itraconazole has been associated with rare cases of serious hepatotoxicity (including liver failure and death).  Caution is recommended when this drug is used in patients with liver dysfunction; such patients should be carefully monitored during therapy.  Treatment with itraconazole is strongly discouraged in patients with elevated or abnormal liver enzymes, with active liver disease, or who had liver toxicity with other drugs unless the situation is serious or life-threatening and the expected benefit exceeds the risk.  Liver function monitoring is recommended for patients with preexisting hepatic function abnormalities or those who had liver toxicity with other drugs.', '3', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58545, 21065, 'Itraconazole', 'Liver Diseases', 'Limited data are available on the use of oral itraconazole in patients with liver dysfunction.  Itraconazole has been associated with rare cases of serious hepatotoxicity (including liver failure and death).  Caution is recommended when this drug is used in patients with liver dysfunction; such patients should be carefully monitored during therapy.  Treatment with itraconazole is strongly discouraged in patients with elevated or abnormal liver enzymes, with active liver disease, or who had liver toxicity with other drugs unless the situation is serious or life-threatening and the expected benefit exceeds the risk.  Liver function monitoring is recommended for patients with preexisting hepatic function abnormalities or those who had liver toxicity with other drugs.', '3', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58546, 21067, 'Itraconazole', 'Liver Diseases', 'Limited data are available on the use of oral itraconazole in patients with liver dysfunction.  Itraconazole has been associated with rare cases of serious hepatotoxicity (including liver failure and death).  Caution is recommended when this drug is used in patients with liver dysfunction; such patients should be carefully monitored during therapy.  Treatment with itraconazole is strongly discouraged in patients with elevated or abnormal liver enzymes, with active liver disease, or who had liver toxicity with other drugs unless the situation is serious or life-threatening and the expected benefit exceeds the risk.  Liver function monitoring is recommended for patients with preexisting hepatic function abnormalities or those who had liver toxicity with other drugs.', '3', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58547, 21070, 'Itraconazole', 'Liver Diseases', 'Limited data are available on the use of oral itraconazole in patients with liver dysfunction.  Itraconazole has been associated with rare cases of serious hepatotoxicity (including liver failure and death).  Caution is recommended when this drug is used in patients with liver dysfunction; such patients should be carefully monitored during therapy.  Treatment with itraconazole is strongly discouraged in patients with elevated or abnormal liver enzymes, with active liver disease, or who had liver toxicity with other drugs unless the situation is serious or life-threatening and the expected benefit exceeds the risk.  Liver function monitoring is recommended for patients with preexisting hepatic function abnormalities or those who had liver toxicity with other drugs.', '3', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58548, 27421, 'Itraconazole', 'Liver Diseases', 'Limited data are available on the use of oral itraconazole in patients with liver dysfunction.  Itraconazole has been associated with rare cases of serious hepatotoxicity (including liver failure and death).  Caution is recommended when this drug is used in patients with liver dysfunction; such patients should be carefully monitored during therapy.  Treatment with itraconazole is strongly discouraged in patients with elevated or abnormal liver enzymes, with active liver disease, or who had liver toxicity with other drugs unless the situation is serious or life-threatening and the expected benefit exceeds the risk.  Liver function monitoring is recommended for patients with preexisting hepatic function abnormalities or those who had liver toxicity with other drugs.', '3', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58549, 28046, 'Itraconazole', 'Liver Diseases', 'Limited data are available on the use of oral itraconazole in patients with liver dysfunction.  Itraconazole has been associated with rare cases of serious hepatotoxicity (including liver failure and death).  Caution is recommended when this drug is used in patients with liver dysfunction; such patients should be carefully monitored during therapy.  Treatment with itraconazole is strongly discouraged in patients with elevated or abnormal liver enzymes, with active liver disease, or who had liver toxicity with other drugs unless the situation is serious or life-threatening and the expected benefit exceeds the risk.  Liver function monitoring is recommended for patients with preexisting hepatic function abnormalities or those who had liver toxicity with other drugs.', '3', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58550, 959, 'Itraconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58551, 6667, 'Itraconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58552, 6669, 'Itraconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58553, 6670, 'Itraconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58554, 6674, 'Itraconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58555, 6675, 'Itraconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58556, 6676, 'Itraconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58557, 6678, 'Itraconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58558, 10830, 'Itraconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58559, 14419, 'Itraconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58560, 19475, 'Itraconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58561, 19476, 'Itraconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58562, 21063, 'Itraconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58563, 21065, 'Itraconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58564, 21067, 'Itraconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58565, 21070, 'Itraconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58566, 27421, 'Itraconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58567, 28046, 'Itraconazole', 'Long QT Syndrome', 'Some azole antifungals have been associated with prolongation of the QT interval on the ECG.  Rare cases of QT prolongation and torsade de pointes have been reported during postmarketing experience; such reports usually involved seriously ill patients with multiple confounding risk factors, such as structural heart disease, electrolyte abnormalities, and concomitant medications.  These drugs should be administered with caution to patients with potentially proarrhythmic conditions.  Concomitant use with other medications that have potential to increase the risk of cardiotoxicity should be avoided.', '2', '"Product Information. Nizoral (ketoconazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Diflucan (fluconazole)." Roerig Division  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals  (2002):|"Product Information. Noxafil (posaconazole)." Schering-Plough Corporation  (2006):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58568, 959, 'Itraconazole', 'Achlorhydria', 'Itraconazole 100-mg capsules should be administered after a full meal.  Under fasted conditions, absorption of itraconazole from the 100-mg capsule formulation was diminished with decreased gastric acidity.  Studies conducted under fasted conditions showed that taking the 100-mg capsule formulation with 8 ounces of a non-diet cola beverage enhanced absorption of itraconazole in AIDS patients with relative or absolute achlorhydria; this increase relative to the effects of a full meal is unknown.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58569, 6667, 'Itraconazole', 'Achlorhydria', 'Itraconazole 100-mg capsules should be administered after a full meal.  Under fasted conditions, absorption of itraconazole from the 100-mg capsule formulation was diminished with decreased gastric acidity.  Studies conducted under fasted conditions showed that taking the 100-mg capsule formulation with 8 ounces of a non-diet cola beverage enhanced absorption of itraconazole in AIDS patients with relative or absolute achlorhydria; this increase relative to the effects of a full meal is unknown.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58570, 6669, 'Itraconazole', 'Achlorhydria', 'Itraconazole 100-mg capsules should be administered after a full meal.  Under fasted conditions, absorption of itraconazole from the 100-mg capsule formulation was diminished with decreased gastric acidity.  Studies conducted under fasted conditions showed that taking the 100-mg capsule formulation with 8 ounces of a non-diet cola beverage enhanced absorption of itraconazole in AIDS patients with relative or absolute achlorhydria; this increase relative to the effects of a full meal is unknown.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58571, 6670, 'Itraconazole', 'Achlorhydria', 'Itraconazole 100-mg capsules should be administered after a full meal.  Under fasted conditions, absorption of itraconazole from the 100-mg capsule formulation was diminished with decreased gastric acidity.  Studies conducted under fasted conditions showed that taking the 100-mg capsule formulation with 8 ounces of a non-diet cola beverage enhanced absorption of itraconazole in AIDS patients with relative or absolute achlorhydria; this increase relative to the effects of a full meal is unknown.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58572, 6674, 'Itraconazole', 'Achlorhydria', 'Itraconazole 100-mg capsules should be administered after a full meal.  Under fasted conditions, absorption of itraconazole from the 100-mg capsule formulation was diminished with decreased gastric acidity.  Studies conducted under fasted conditions showed that taking the 100-mg capsule formulation with 8 ounces of a non-diet cola beverage enhanced absorption of itraconazole in AIDS patients with relative or absolute achlorhydria; this increase relative to the effects of a full meal is unknown.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58573, 6675, 'Itraconazole', 'Achlorhydria', 'Itraconazole 100-mg capsules should be administered after a full meal.  Under fasted conditions, absorption of itraconazole from the 100-mg capsule formulation was diminished with decreased gastric acidity.  Studies conducted under fasted conditions showed that taking the 100-mg capsule formulation with 8 ounces of a non-diet cola beverage enhanced absorption of itraconazole in AIDS patients with relative or absolute achlorhydria; this increase relative to the effects of a full meal is unknown.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58574, 6676, 'Itraconazole', 'Achlorhydria', 'Itraconazole 100-mg capsules should be administered after a full meal.  Under fasted conditions, absorption of itraconazole from the 100-mg capsule formulation was diminished with decreased gastric acidity.  Studies conducted under fasted conditions showed that taking the 100-mg capsule formulation with 8 ounces of a non-diet cola beverage enhanced absorption of itraconazole in AIDS patients with relative or absolute achlorhydria; this increase relative to the effects of a full meal is unknown.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58575, 6678, 'Itraconazole', 'Achlorhydria', 'Itraconazole 100-mg capsules should be administered after a full meal.  Under fasted conditions, absorption of itraconazole from the 100-mg capsule formulation was diminished with decreased gastric acidity.  Studies conducted under fasted conditions showed that taking the 100-mg capsule formulation with 8 ounces of a non-diet cola beverage enhanced absorption of itraconazole in AIDS patients with relative or absolute achlorhydria; this increase relative to the effects of a full meal is unknown.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58576, 10830, 'Itraconazole', 'Achlorhydria', 'Itraconazole 100-mg capsules should be administered after a full meal.  Under fasted conditions, absorption of itraconazole from the 100-mg capsule formulation was diminished with decreased gastric acidity.  Studies conducted under fasted conditions showed that taking the 100-mg capsule formulation with 8 ounces of a non-diet cola beverage enhanced absorption of itraconazole in AIDS patients with relative or absolute achlorhydria; this increase relative to the effects of a full meal is unknown.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58577, 14419, 'Itraconazole', 'Achlorhydria', 'Itraconazole 100-mg capsules should be administered after a full meal.  Under fasted conditions, absorption of itraconazole from the 100-mg capsule formulation was diminished with decreased gastric acidity.  Studies conducted under fasted conditions showed that taking the 100-mg capsule formulation with 8 ounces of a non-diet cola beverage enhanced absorption of itraconazole in AIDS patients with relative or absolute achlorhydria; this increase relative to the effects of a full meal is unknown.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58578, 19475, 'Itraconazole', 'Achlorhydria', 'Itraconazole 100-mg capsules should be administered after a full meal.  Under fasted conditions, absorption of itraconazole from the 100-mg capsule formulation was diminished with decreased gastric acidity.  Studies conducted under fasted conditions showed that taking the 100-mg capsule formulation with 8 ounces of a non-diet cola beverage enhanced absorption of itraconazole in AIDS patients with relative or absolute achlorhydria; this increase relative to the effects of a full meal is unknown.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58579, 19476, 'Itraconazole', 'Achlorhydria', 'Itraconazole 100-mg capsules should be administered after a full meal.  Under fasted conditions, absorption of itraconazole from the 100-mg capsule formulation was diminished with decreased gastric acidity.  Studies conducted under fasted conditions showed that taking the 100-mg capsule formulation with 8 ounces of a non-diet cola beverage enhanced absorption of itraconazole in AIDS patients with relative or absolute achlorhydria; this increase relative to the effects of a full meal is unknown.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58580, 21063, 'Itraconazole', 'Achlorhydria', 'Itraconazole 100-mg capsules should be administered after a full meal.  Under fasted conditions, absorption of itraconazole from the 100-mg capsule formulation was diminished with decreased gastric acidity.  Studies conducted under fasted conditions showed that taking the 100-mg capsule formulation with 8 ounces of a non-diet cola beverage enhanced absorption of itraconazole in AIDS patients with relative or absolute achlorhydria; this increase relative to the effects of a full meal is unknown.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58581, 21065, 'Itraconazole', 'Achlorhydria', 'Itraconazole 100-mg capsules should be administered after a full meal.  Under fasted conditions, absorption of itraconazole from the 100-mg capsule formulation was diminished with decreased gastric acidity.  Studies conducted under fasted conditions showed that taking the 100-mg capsule formulation with 8 ounces of a non-diet cola beverage enhanced absorption of itraconazole in AIDS patients with relative or absolute achlorhydria; this increase relative to the effects of a full meal is unknown.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58582, 21067, 'Itraconazole', 'Achlorhydria', 'Itraconazole 100-mg capsules should be administered after a full meal.  Under fasted conditions, absorption of itraconazole from the 100-mg capsule formulation was diminished with decreased gastric acidity.  Studies conducted under fasted conditions showed that taking the 100-mg capsule formulation with 8 ounces of a non-diet cola beverage enhanced absorption of itraconazole in AIDS patients with relative or absolute achlorhydria; this increase relative to the effects of a full meal is unknown.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58583, 21070, 'Itraconazole', 'Achlorhydria', 'Itraconazole 100-mg capsules should be administered after a full meal.  Under fasted conditions, absorption of itraconazole from the 100-mg capsule formulation was diminished with decreased gastric acidity.  Studies conducted under fasted conditions showed that taking the 100-mg capsule formulation with 8 ounces of a non-diet cola beverage enhanced absorption of itraconazole in AIDS patients with relative or absolute achlorhydria; this increase relative to the effects of a full meal is unknown.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58584, 27421, 'Itraconazole', 'Achlorhydria', 'Itraconazole 100-mg capsules should be administered after a full meal.  Under fasted conditions, absorption of itraconazole from the 100-mg capsule formulation was diminished with decreased gastric acidity.  Studies conducted under fasted conditions showed that taking the 100-mg capsule formulation with 8 ounces of a non-diet cola beverage enhanced absorption of itraconazole in AIDS patients with relative or absolute achlorhydria; this increase relative to the effects of a full meal is unknown.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58585, 28046, 'Itraconazole', 'Achlorhydria', 'Itraconazole 100-mg capsules should be administered after a full meal.  Under fasted conditions, absorption of itraconazole from the 100-mg capsule formulation was diminished with decreased gastric acidity.  Studies conducted under fasted conditions showed that taking the 100-mg capsule formulation with 8 ounces of a non-diet cola beverage enhanced absorption of itraconazole in AIDS patients with relative or absolute achlorhydria; this increase relative to the effects of a full meal is unknown.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58586, 959, 'Itraconazole', 'Cystic Fibrosis', 'In a study using itraconazole oral solution in cystic fibrosis patients, therapeutic drug levels varied and were not reached in some patients.  Alternative therapy should be considered for patients who do not respond to itraconazole oral solution or itraconazole 100-mg capsules.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58587, 6667, 'Itraconazole', 'Cystic Fibrosis', 'In a study using itraconazole oral solution in cystic fibrosis patients, therapeutic drug levels varied and were not reached in some patients.  Alternative therapy should be considered for patients who do not respond to itraconazole oral solution or itraconazole 100-mg capsules.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58588, 6669, 'Itraconazole', 'Cystic Fibrosis', 'In a study using itraconazole oral solution in cystic fibrosis patients, therapeutic drug levels varied and were not reached in some patients.  Alternative therapy should be considered for patients who do not respond to itraconazole oral solution or itraconazole 100-mg capsules.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58589, 6670, 'Itraconazole', 'Cystic Fibrosis', 'In a study using itraconazole oral solution in cystic fibrosis patients, therapeutic drug levels varied and were not reached in some patients.  Alternative therapy should be considered for patients who do not respond to itraconazole oral solution or itraconazole 100-mg capsules.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58590, 6674, 'Itraconazole', 'Cystic Fibrosis', 'In a study using itraconazole oral solution in cystic fibrosis patients, therapeutic drug levels varied and were not reached in some patients.  Alternative therapy should be considered for patients who do not respond to itraconazole oral solution or itraconazole 100-mg capsules.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58591, 6675, 'Itraconazole', 'Cystic Fibrosis', 'In a study using itraconazole oral solution in cystic fibrosis patients, therapeutic drug levels varied and were not reached in some patients.  Alternative therapy should be considered for patients who do not respond to itraconazole oral solution or itraconazole 100-mg capsules.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58592, 6676, 'Itraconazole', 'Cystic Fibrosis', 'In a study using itraconazole oral solution in cystic fibrosis patients, therapeutic drug levels varied and were not reached in some patients.  Alternative therapy should be considered for patients who do not respond to itraconazole oral solution or itraconazole 100-mg capsules.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58593, 6678, 'Itraconazole', 'Cystic Fibrosis', 'In a study using itraconazole oral solution in cystic fibrosis patients, therapeutic drug levels varied and were not reached in some patients.  Alternative therapy should be considered for patients who do not respond to itraconazole oral solution or itraconazole 100-mg capsules.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58594, 10830, 'Itraconazole', 'Cystic Fibrosis', 'In a study using itraconazole oral solution in cystic fibrosis patients, therapeutic drug levels varied and were not reached in some patients.  Alternative therapy should be considered for patients who do not respond to itraconazole oral solution or itraconazole 100-mg capsules.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58595, 14419, 'Itraconazole', 'Cystic Fibrosis', 'In a study using itraconazole oral solution in cystic fibrosis patients, therapeutic drug levels varied and were not reached in some patients.  Alternative therapy should be considered for patients who do not respond to itraconazole oral solution or itraconazole 100-mg capsules.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58596, 19475, 'Itraconazole', 'Cystic Fibrosis', 'In a study using itraconazole oral solution in cystic fibrosis patients, therapeutic drug levels varied and were not reached in some patients.  Alternative therapy should be considered for patients who do not respond to itraconazole oral solution or itraconazole 100-mg capsules.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58597, 19476, 'Itraconazole', 'Cystic Fibrosis', 'In a study using itraconazole oral solution in cystic fibrosis patients, therapeutic drug levels varied and were not reached in some patients.  Alternative therapy should be considered for patients who do not respond to itraconazole oral solution or itraconazole 100-mg capsules.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58598, 21063, 'Itraconazole', 'Cystic Fibrosis', 'In a study using itraconazole oral solution in cystic fibrosis patients, therapeutic drug levels varied and were not reached in some patients.  Alternative therapy should be considered for patients who do not respond to itraconazole oral solution or itraconazole 100-mg capsules.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58599, 21065, 'Itraconazole', 'Cystic Fibrosis', 'In a study using itraconazole oral solution in cystic fibrosis patients, therapeutic drug levels varied and were not reached in some patients.  Alternative therapy should be considered for patients who do not respond to itraconazole oral solution or itraconazole 100-mg capsules.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58600, 21067, 'Itraconazole', 'Cystic Fibrosis', 'In a study using itraconazole oral solution in cystic fibrosis patients, therapeutic drug levels varied and were not reached in some patients.  Alternative therapy should be considered for patients who do not respond to itraconazole oral solution or itraconazole 100-mg capsules.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58601, 21070, 'Itraconazole', 'Cystic Fibrosis', 'In a study using itraconazole oral solution in cystic fibrosis patients, therapeutic drug levels varied and were not reached in some patients.  Alternative therapy should be considered for patients who do not respond to itraconazole oral solution or itraconazole 100-mg capsules.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58602, 27421, 'Itraconazole', 'Cystic Fibrosis', 'In a study using itraconazole oral solution in cystic fibrosis patients, therapeutic drug levels varied and were not reached in some patients.  Alternative therapy should be considered for patients who do not respond to itraconazole oral solution or itraconazole 100-mg capsules.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58603, 28046, 'Itraconazole', 'Cystic Fibrosis', 'In a study using itraconazole oral solution in cystic fibrosis patients, therapeutic drug levels varied and were not reached in some patients.  Alternative therapy should be considered for patients who do not respond to itraconazole oral solution or itraconazole 100-mg capsules.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58604, 959, 'Itraconazole', 'Immune Deficiency Disease', 'The oral bioavailability of itraconazole 100-mg capsules may be decreased in some immunocompromised patients (e.g., neutropenic patients, AIDS patients, organ transplant recipients); in addition, since hypochlorhydria has been reported in HIV-infected patients, the absorption of itraconazole may be reduced in these patients.  The dose of itraconazole 100-mg capsules should be adjusted based on the clinical response of such patients.Itraconazole oral solution is not recommended for initial treatment in severely neutropenic patients at immediate risk of systemic candidiasis.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58605, 6667, 'Itraconazole', 'Immune Deficiency Disease', 'The oral bioavailability of itraconazole 100-mg capsules may be decreased in some immunocompromised patients (e.g., neutropenic patients, AIDS patients, organ transplant recipients); in addition, since hypochlorhydria has been reported in HIV-infected patients, the absorption of itraconazole may be reduced in these patients.  The dose of itraconazole 100-mg capsules should be adjusted based on the clinical response of such patients.Itraconazole oral solution is not recommended for initial treatment in severely neutropenic patients at immediate risk of systemic candidiasis.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58606, 6669, 'Itraconazole', 'Immune Deficiency Disease', 'The oral bioavailability of itraconazole 100-mg capsules may be decreased in some immunocompromised patients (e.g., neutropenic patients, AIDS patients, organ transplant recipients); in addition, since hypochlorhydria has been reported in HIV-infected patients, the absorption of itraconazole may be reduced in these patients.  The dose of itraconazole 100-mg capsules should be adjusted based on the clinical response of such patients.Itraconazole oral solution is not recommended for initial treatment in severely neutropenic patients at immediate risk of systemic candidiasis.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58607, 6670, 'Itraconazole', 'Immune Deficiency Disease', 'The oral bioavailability of itraconazole 100-mg capsules may be decreased in some immunocompromised patients (e.g., neutropenic patients, AIDS patients, organ transplant recipients); in addition, since hypochlorhydria has been reported in HIV-infected patients, the absorption of itraconazole may be reduced in these patients.  The dose of itraconazole 100-mg capsules should be adjusted based on the clinical response of such patients.Itraconazole oral solution is not recommended for initial treatment in severely neutropenic patients at immediate risk of systemic candidiasis.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58608, 6674, 'Itraconazole', 'Immune Deficiency Disease', 'The oral bioavailability of itraconazole 100-mg capsules may be decreased in some immunocompromised patients (e.g., neutropenic patients, AIDS patients, organ transplant recipients); in addition, since hypochlorhydria has been reported in HIV-infected patients, the absorption of itraconazole may be reduced in these patients.  The dose of itraconazole 100-mg capsules should be adjusted based on the clinical response of such patients.Itraconazole oral solution is not recommended for initial treatment in severely neutropenic patients at immediate risk of systemic candidiasis.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58609, 6675, 'Itraconazole', 'Immune Deficiency Disease', 'The oral bioavailability of itraconazole 100-mg capsules may be decreased in some immunocompromised patients (e.g., neutropenic patients, AIDS patients, organ transplant recipients); in addition, since hypochlorhydria has been reported in HIV-infected patients, the absorption of itraconazole may be reduced in these patients.  The dose of itraconazole 100-mg capsules should be adjusted based on the clinical response of such patients.Itraconazole oral solution is not recommended for initial treatment in severely neutropenic patients at immediate risk of systemic candidiasis.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58610, 6676, 'Itraconazole', 'Immune Deficiency Disease', 'The oral bioavailability of itraconazole 100-mg capsules may be decreased in some immunocompromised patients (e.g., neutropenic patients, AIDS patients, organ transplant recipients); in addition, since hypochlorhydria has been reported in HIV-infected patients, the absorption of itraconazole may be reduced in these patients.  The dose of itraconazole 100-mg capsules should be adjusted based on the clinical response of such patients.Itraconazole oral solution is not recommended for initial treatment in severely neutropenic patients at immediate risk of systemic candidiasis.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58611, 6678, 'Itraconazole', 'Immune Deficiency Disease', 'The oral bioavailability of itraconazole 100-mg capsules may be decreased in some immunocompromised patients (e.g., neutropenic patients, AIDS patients, organ transplant recipients); in addition, since hypochlorhydria has been reported in HIV-infected patients, the absorption of itraconazole may be reduced in these patients.  The dose of itraconazole 100-mg capsules should be adjusted based on the clinical response of such patients.Itraconazole oral solution is not recommended for initial treatment in severely neutropenic patients at immediate risk of systemic candidiasis.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58612, 10830, 'Itraconazole', 'Immune Deficiency Disease', 'The oral bioavailability of itraconazole 100-mg capsules may be decreased in some immunocompromised patients (e.g., neutropenic patients, AIDS patients, organ transplant recipients); in addition, since hypochlorhydria has been reported in HIV-infected patients, the absorption of itraconazole may be reduced in these patients.  The dose of itraconazole 100-mg capsules should be adjusted based on the clinical response of such patients.Itraconazole oral solution is not recommended for initial treatment in severely neutropenic patients at immediate risk of systemic candidiasis.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58613, 14419, 'Itraconazole', 'Immune Deficiency Disease', 'The oral bioavailability of itraconazole 100-mg capsules may be decreased in some immunocompromised patients (e.g., neutropenic patients, AIDS patients, organ transplant recipients); in addition, since hypochlorhydria has been reported in HIV-infected patients, the absorption of itraconazole may be reduced in these patients.  The dose of itraconazole 100-mg capsules should be adjusted based on the clinical response of such patients.Itraconazole oral solution is not recommended for initial treatment in severely neutropenic patients at immediate risk of systemic candidiasis.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58614, 19475, 'Itraconazole', 'Immune Deficiency Disease', 'The oral bioavailability of itraconazole 100-mg capsules may be decreased in some immunocompromised patients (e.g., neutropenic patients, AIDS patients, organ transplant recipients); in addition, since hypochlorhydria has been reported in HIV-infected patients, the absorption of itraconazole may be reduced in these patients.  The dose of itraconazole 100-mg capsules should be adjusted based on the clinical response of such patients.Itraconazole oral solution is not recommended for initial treatment in severely neutropenic patients at immediate risk of systemic candidiasis.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58615, 19476, 'Itraconazole', 'Immune Deficiency Disease', 'The oral bioavailability of itraconazole 100-mg capsules may be decreased in some immunocompromised patients (e.g., neutropenic patients, AIDS patients, organ transplant recipients); in addition, since hypochlorhydria has been reported in HIV-infected patients, the absorption of itraconazole may be reduced in these patients.  The dose of itraconazole 100-mg capsules should be adjusted based on the clinical response of such patients.Itraconazole oral solution is not recommended for initial treatment in severely neutropenic patients at immediate risk of systemic candidiasis.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58616, 21063, 'Itraconazole', 'Immune Deficiency Disease', 'The oral bioavailability of itraconazole 100-mg capsules may be decreased in some immunocompromised patients (e.g., neutropenic patients, AIDS patients, organ transplant recipients); in addition, since hypochlorhydria has been reported in HIV-infected patients, the absorption of itraconazole may be reduced in these patients.  The dose of itraconazole 100-mg capsules should be adjusted based on the clinical response of such patients.Itraconazole oral solution is not recommended for initial treatment in severely neutropenic patients at immediate risk of systemic candidiasis.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58617, 21065, 'Itraconazole', 'Immune Deficiency Disease', 'The oral bioavailability of itraconazole 100-mg capsules may be decreased in some immunocompromised patients (e.g., neutropenic patients, AIDS patients, organ transplant recipients); in addition, since hypochlorhydria has been reported in HIV-infected patients, the absorption of itraconazole may be reduced in these patients.  The dose of itraconazole 100-mg capsules should be adjusted based on the clinical response of such patients.Itraconazole oral solution is not recommended for initial treatment in severely neutropenic patients at immediate risk of systemic candidiasis.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58618, 21067, 'Itraconazole', 'Immune Deficiency Disease', 'The oral bioavailability of itraconazole 100-mg capsules may be decreased in some immunocompromised patients (e.g., neutropenic patients, AIDS patients, organ transplant recipients); in addition, since hypochlorhydria has been reported in HIV-infected patients, the absorption of itraconazole may be reduced in these patients.  The dose of itraconazole 100-mg capsules should be adjusted based on the clinical response of such patients.Itraconazole oral solution is not recommended for initial treatment in severely neutropenic patients at immediate risk of systemic candidiasis.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58619, 21070, 'Itraconazole', 'Immune Deficiency Disease', 'The oral bioavailability of itraconazole 100-mg capsules may be decreased in some immunocompromised patients (e.g., neutropenic patients, AIDS patients, organ transplant recipients); in addition, since hypochlorhydria has been reported in HIV-infected patients, the absorption of itraconazole may be reduced in these patients.  The dose of itraconazole 100-mg capsules should be adjusted based on the clinical response of such patients.Itraconazole oral solution is not recommended for initial treatment in severely neutropenic patients at immediate risk of systemic candidiasis.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58620, 27421, 'Itraconazole', 'Immune Deficiency Disease', 'The oral bioavailability of itraconazole 100-mg capsules may be decreased in some immunocompromised patients (e.g., neutropenic patients, AIDS patients, organ transplant recipients); in addition, since hypochlorhydria has been reported in HIV-infected patients, the absorption of itraconazole may be reduced in these patients.  The dose of itraconazole 100-mg capsules should be adjusted based on the clinical response of such patients.Itraconazole oral solution is not recommended for initial treatment in severely neutropenic patients at immediate risk of systemic candidiasis.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58621, 28046, 'Itraconazole', 'Immune Deficiency Disease', 'The oral bioavailability of itraconazole 100-mg capsules may be decreased in some immunocompromised patients (e.g., neutropenic patients, AIDS patients, organ transplant recipients); in addition, since hypochlorhydria has been reported in HIV-infected patients, the absorption of itraconazole may be reduced in these patients.  The dose of itraconazole 100-mg capsules should be adjusted based on the clinical response of such patients.Itraconazole oral solution is not recommended for initial treatment in severely neutropenic patients at immediate risk of systemic candidiasis.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58622, 959, 'Itraconazole', 'Kidney Diseases', 'Limited data are available on the use of oral itraconazole in patients with renal dysfunction; itraconazole exposure may be lower in some of these patients.  Caution is advised when using itraconazole in patients with renal dysfunction and dose adjustment may be needed.  Patients with renal dysfunction should be carefully monitored when using the 65-mg capsule formulation.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58623, 6667, 'Itraconazole', 'Kidney Diseases', 'Limited data are available on the use of oral itraconazole in patients with renal dysfunction; itraconazole exposure may be lower in some of these patients.  Caution is advised when using itraconazole in patients with renal dysfunction and dose adjustment may be needed.  Patients with renal dysfunction should be carefully monitored when using the 65-mg capsule formulation.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58624, 6669, 'Itraconazole', 'Kidney Diseases', 'Limited data are available on the use of oral itraconazole in patients with renal dysfunction; itraconazole exposure may be lower in some of these patients.  Caution is advised when using itraconazole in patients with renal dysfunction and dose adjustment may be needed.  Patients with renal dysfunction should be carefully monitored when using the 65-mg capsule formulation.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58625, 6670, 'Itraconazole', 'Kidney Diseases', 'Limited data are available on the use of oral itraconazole in patients with renal dysfunction; itraconazole exposure may be lower in some of these patients.  Caution is advised when using itraconazole in patients with renal dysfunction and dose adjustment may be needed.  Patients with renal dysfunction should be carefully monitored when using the 65-mg capsule formulation.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58626, 6674, 'Itraconazole', 'Kidney Diseases', 'Limited data are available on the use of oral itraconazole in patients with renal dysfunction; itraconazole exposure may be lower in some of these patients.  Caution is advised when using itraconazole in patients with renal dysfunction and dose adjustment may be needed.  Patients with renal dysfunction should be carefully monitored when using the 65-mg capsule formulation.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58627, 6675, 'Itraconazole', 'Kidney Diseases', 'Limited data are available on the use of oral itraconazole in patients with renal dysfunction; itraconazole exposure may be lower in some of these patients.  Caution is advised when using itraconazole in patients with renal dysfunction and dose adjustment may be needed.  Patients with renal dysfunction should be carefully monitored when using the 65-mg capsule formulation.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58628, 6676, 'Itraconazole', 'Kidney Diseases', 'Limited data are available on the use of oral itraconazole in patients with renal dysfunction; itraconazole exposure may be lower in some of these patients.  Caution is advised when using itraconazole in patients with renal dysfunction and dose adjustment may be needed.  Patients with renal dysfunction should be carefully monitored when using the 65-mg capsule formulation.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58629, 6678, 'Itraconazole', 'Kidney Diseases', 'Limited data are available on the use of oral itraconazole in patients with renal dysfunction; itraconazole exposure may be lower in some of these patients.  Caution is advised when using itraconazole in patients with renal dysfunction and dose adjustment may be needed.  Patients with renal dysfunction should be carefully monitored when using the 65-mg capsule formulation.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58630, 10830, 'Itraconazole', 'Kidney Diseases', 'Limited data are available on the use of oral itraconazole in patients with renal dysfunction; itraconazole exposure may be lower in some of these patients.  Caution is advised when using itraconazole in patients with renal dysfunction and dose adjustment may be needed.  Patients with renal dysfunction should be carefully monitored when using the 65-mg capsule formulation.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58631, 14419, 'Itraconazole', 'Kidney Diseases', 'Limited data are available on the use of oral itraconazole in patients with renal dysfunction; itraconazole exposure may be lower in some of these patients.  Caution is advised when using itraconazole in patients with renal dysfunction and dose adjustment may be needed.  Patients with renal dysfunction should be carefully monitored when using the 65-mg capsule formulation.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58632, 19475, 'Itraconazole', 'Kidney Diseases', 'Limited data are available on the use of oral itraconazole in patients with renal dysfunction; itraconazole exposure may be lower in some of these patients.  Caution is advised when using itraconazole in patients with renal dysfunction and dose adjustment may be needed.  Patients with renal dysfunction should be carefully monitored when using the 65-mg capsule formulation.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58633, 19476, 'Itraconazole', 'Kidney Diseases', 'Limited data are available on the use of oral itraconazole in patients with renal dysfunction; itraconazole exposure may be lower in some of these patients.  Caution is advised when using itraconazole in patients with renal dysfunction and dose adjustment may be needed.  Patients with renal dysfunction should be carefully monitored when using the 65-mg capsule formulation.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58634, 21063, 'Itraconazole', 'Kidney Diseases', 'Limited data are available on the use of oral itraconazole in patients with renal dysfunction; itraconazole exposure may be lower in some of these patients.  Caution is advised when using itraconazole in patients with renal dysfunction and dose adjustment may be needed.  Patients with renal dysfunction should be carefully monitored when using the 65-mg capsule formulation.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58635, 21065, 'Itraconazole', 'Kidney Diseases', 'Limited data are available on the use of oral itraconazole in patients with renal dysfunction; itraconazole exposure may be lower in some of these patients.  Caution is advised when using itraconazole in patients with renal dysfunction and dose adjustment may be needed.  Patients with renal dysfunction should be carefully monitored when using the 65-mg capsule formulation.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58636, 21067, 'Itraconazole', 'Kidney Diseases', 'Limited data are available on the use of oral itraconazole in patients with renal dysfunction; itraconazole exposure may be lower in some of these patients.  Caution is advised when using itraconazole in patients with renal dysfunction and dose adjustment may be needed.  Patients with renal dysfunction should be carefully monitored when using the 65-mg capsule formulation.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58637, 21070, 'Itraconazole', 'Kidney Diseases', 'Limited data are available on the use of oral itraconazole in patients with renal dysfunction; itraconazole exposure may be lower in some of these patients.  Caution is advised when using itraconazole in patients with renal dysfunction and dose adjustment may be needed.  Patients with renal dysfunction should be carefully monitored when using the 65-mg capsule formulation.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58638, 27421, 'Itraconazole', 'Kidney Diseases', 'Limited data are available on the use of oral itraconazole in patients with renal dysfunction; itraconazole exposure may be lower in some of these patients.  Caution is advised when using itraconazole in patients with renal dysfunction and dose adjustment may be needed.  Patients with renal dysfunction should be carefully monitored when using the 65-mg capsule formulation.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58639, 28046, 'Itraconazole', 'Kidney Diseases', 'Limited data are available on the use of oral itraconazole in patients with renal dysfunction; itraconazole exposure may be lower in some of these patients.  Caution is advised when using itraconazole in patients with renal dysfunction and dose adjustment may be needed.  Patients with renal dysfunction should be carefully monitored when using the 65-mg capsule formulation.', '2', '"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2002):|"Product Information. Sporanox (itraconazole)." Janssen Pharmaceuticals  (2022):|"Product Information. Tolsura (itraconazole)." Mayne Pharma Inc  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58640, 3926, 'Isoxsuprine', 'Hemorrhage', 'The use of isoxsuprine is contraindicated in patients with arterial bleeding.  The alpha adrenoreceptor antagonism of isoxsuprine produces vasodilation that may exacerbate arterial bleeding.', '3', '"Product Information. Vasodilan (isoxsuprine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58641, 29016, 'Isoxsuprine', 'Hemorrhage', 'The use of isoxsuprine is contraindicated in patients with arterial bleeding.  The alpha adrenoreceptor antagonism of isoxsuprine produces vasodilation that may exacerbate arterial bleeding.', '3', '"Product Information. Vasodilan (isoxsuprine)." Bristol-Myers Squibb  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58642, 0, 'Istradefylline', 'Liver Failure', 'Istradefylline has not been studied in patients with severe hepatic impairment (Child-Pugh Class C), and its use should be avoided in these patients.  In patients with moderate hepatic impairment (Child-Pugh B), the steady-state exposures were predicted to be 3.3-fold higher.  Therefore, the maximum recommended dosage of istradefylline in patients with moderate hepatic impairment (Child-Pugh B) is 20 mg once daily.  Patients should be closely monitored for adverse events when receiving treatment.  No dose adjustment is needed in patients with mild hepatic impairment.', '3', '"Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58643, 0, 'Istradefylline', 'Kidney Failure, Chronic', 'Istradefylline has not been evaluated in patients with end-stage renal disease (ESRD) (CrCl <15 mL/min) or ESRD requiring hemodialysis.  Caution is advised if prescribed in these patients.  No dosage adjustment is needed in patients with mild, moderate or severe renal impairment.', '2', '"Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58644, 0, 'Istradefylline', 'Psychotic Disorders', 'Because of the potential risk of exacerbating psychosis, patients with a major psychotic disorder should not be treated with istradefylline.  Consider dosage reduction or discontinuation if a patient develops hallucinations or psychotic behaviors while taking this drug.', '2', '"Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58645, 2053, 'Isosorbide dinitrate', 'Myocardial Infarction', 'The benefits of organic nitrates and nitrites in patients with acute myocardial infarction (AMI) or congestive heart failure have not been established and its use is not recommended in these settings.  If used, it should be accompanied by careful clinical and hemodynamic monitoring to avoid the hazards of systemic hypotension and tachycardia, which in AMI can exacerbate myocardial ischemia.  In general, oral or long-acting formulations of these drugs should not be used in the early management of AMI because of the difficulty in precisely controlling and rapidly terminating their hemodynamic effects should adverse reactions occur.  Sublingual and other immediate- onset nitrates or nitrites should typically be avoided in suspected AMI with marked bradycardia or tachycardia, and should be used with extreme caution, if at all, in patients with right ventricular or inferior wall infarction.  Rarely, sublingual nitroglycerin has produced hypotension accompanied by paradoxical bradycardia in patients with AMI and especially right ventricular infarction.  The latter group of patients are also particularly dependent on adequate right ventricular preload to maintain cardiac output and can experience profound hypotension with nitrate or nitrite administration due to reduction of right ventricular preload.', '3', 'Scardi S, Zingone B, Pandullo C "Myocardial infarction following sublingual administration of isosorbide dinitrate." Int J Cardiol 26 (1990):  378-9|Berisso MZ, Cavallini A, Iannetti M "Sudden death during continuous Holter monitoring out of hospital after nitroglycerin consumption." Am J Cardiol 54 (1984):  677-9|Buckley R, Roberts R "Symptomatic bradycardia following the administration of sublingual nitroglycerin." Am J Emerg Med 11 (1993):  253-5|Ong EA, Canlas C, Smith W "Nitroglycerin-induced asystole ." Arch Intern Med 145 (1985):  954|von Arnim T, Autenrieth G, Bolte HD "Acute myocardial infarction during continuous electrocardiographic ST segment recording. Possible role of bradycardia and hypotension induced by glyceryl trinitrate." Br Heart J 51 (1984):  575-7|Lancaster L, Fenster PE "Complete heart block after sublingual nitroglycerin." Chest 84 (1983):  111-2|Brandes W, Santiago T, Limacher M "Nitroglycerin-induced hypotension, bradycardia, and asystole: report of a case and review of the literature." Clin Cardiol 13 (1990):  741-4|"Product Information. Isordil (isosorbide dinitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. ISMO (isosorbide mononitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58646, 3639, 'Isosorbide dinitrate', 'Myocardial Infarction', 'The benefits of organic nitrates and nitrites in patients with acute myocardial infarction (AMI) or congestive heart failure have not been established and its use is not recommended in these settings.  If used, it should be accompanied by careful clinical and hemodynamic monitoring to avoid the hazards of systemic hypotension and tachycardia, which in AMI can exacerbate myocardial ischemia.  In general, oral or long-acting formulations of these drugs should not be used in the early management of AMI because of the difficulty in precisely controlling and rapidly terminating their hemodynamic effects should adverse reactions occur.  Sublingual and other immediate- onset nitrates or nitrites should typically be avoided in suspected AMI with marked bradycardia or tachycardia, and should be used with extreme caution, if at all, in patients with right ventricular or inferior wall infarction.  Rarely, sublingual nitroglycerin has produced hypotension accompanied by paradoxical bradycardia in patients with AMI and especially right ventricular infarction.  The latter group of patients are also particularly dependent on adequate right ventricular preload to maintain cardiac output and can experience profound hypotension with nitrate or nitrite administration due to reduction of right ventricular preload.', '3', 'Scardi S, Zingone B, Pandullo C "Myocardial infarction following sublingual administration of isosorbide dinitrate." Int J Cardiol 26 (1990):  378-9|Berisso MZ, Cavallini A, Iannetti M "Sudden death during continuous Holter monitoring out of hospital after nitroglycerin consumption." Am J Cardiol 54 (1984):  677-9|Buckley R, Roberts R "Symptomatic bradycardia following the administration of sublingual nitroglycerin." Am J Emerg Med 11 (1993):  253-5|Ong EA, Canlas C, Smith W "Nitroglycerin-induced asystole ." Arch Intern Med 145 (1985):  954|von Arnim T, Autenrieth G, Bolte HD "Acute myocardial infarction during continuous electrocardiographic ST segment recording. Possible role of bradycardia and hypotension induced by glyceryl trinitrate." Br Heart J 51 (1984):  575-7|Lancaster L, Fenster PE "Complete heart block after sublingual nitroglycerin." Chest 84 (1983):  111-2|Brandes W, Santiago T, Limacher M "Nitroglycerin-induced hypotension, bradycardia, and asystole: report of a case and review of the literature." Clin Cardiol 13 (1990):  741-4|"Product Information. Isordil (isosorbide dinitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. ISMO (isosorbide mononitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58647, 3707, 'Isosorbide dinitrate', 'Myocardial Infarction', 'The benefits of organic nitrates and nitrites in patients with acute myocardial infarction (AMI) or congestive heart failure have not been established and its use is not recommended in these settings.  If used, it should be accompanied by careful clinical and hemodynamic monitoring to avoid the hazards of systemic hypotension and tachycardia, which in AMI can exacerbate myocardial ischemia.  In general, oral or long-acting formulations of these drugs should not be used in the early management of AMI because of the difficulty in precisely controlling and rapidly terminating their hemodynamic effects should adverse reactions occur.  Sublingual and other immediate- onset nitrates or nitrites should typically be avoided in suspected AMI with marked bradycardia or tachycardia, and should be used with extreme caution, if at all, in patients with right ventricular or inferior wall infarction.  Rarely, sublingual nitroglycerin has produced hypotension accompanied by paradoxical bradycardia in patients with AMI and especially right ventricular infarction.  The latter group of patients are also particularly dependent on adequate right ventricular preload to maintain cardiac output and can experience profound hypotension with nitrate or nitrite administration due to reduction of right ventricular preload.', '3', 'Scardi S, Zingone B, Pandullo C "Myocardial infarction following sublingual administration of isosorbide dinitrate." Int J Cardiol 26 (1990):  378-9|Berisso MZ, Cavallini A, Iannetti M "Sudden death during continuous Holter monitoring out of hospital after nitroglycerin consumption." Am J Cardiol 54 (1984):  677-9|Buckley R, Roberts R "Symptomatic bradycardia following the administration of sublingual nitroglycerin." Am J Emerg Med 11 (1993):  253-5|Ong EA, Canlas C, Smith W "Nitroglycerin-induced asystole ." Arch Intern Med 145 (1985):  954|von Arnim T, Autenrieth G, Bolte HD "Acute myocardial infarction during continuous electrocardiographic ST segment recording. Possible role of bradycardia and hypotension induced by glyceryl trinitrate." Br Heart J 51 (1984):  575-7|Lancaster L, Fenster PE "Complete heart block after sublingual nitroglycerin." Chest 84 (1983):  111-2|Brandes W, Santiago T, Limacher M "Nitroglycerin-induced hypotension, bradycardia, and asystole: report of a case and review of the literature." Clin Cardiol 13 (1990):  741-4|"Product Information. Isordil (isosorbide dinitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. ISMO (isosorbide mononitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58648, 3708, 'Isosorbide dinitrate', 'Myocardial Infarction', 'The benefits of organic nitrates and nitrites in patients with acute myocardial infarction (AMI) or congestive heart failure have not been established and its use is not recommended in these settings.  If used, it should be accompanied by careful clinical and hemodynamic monitoring to avoid the hazards of systemic hypotension and tachycardia, which in AMI can exacerbate myocardial ischemia.  In general, oral or long-acting formulations of these drugs should not be used in the early management of AMI because of the difficulty in precisely controlling and rapidly terminating their hemodynamic effects should adverse reactions occur.  Sublingual and other immediate- onset nitrates or nitrites should typically be avoided in suspected AMI with marked bradycardia or tachycardia, and should be used with extreme caution, if at all, in patients with right ventricular or inferior wall infarction.  Rarely, sublingual nitroglycerin has produced hypotension accompanied by paradoxical bradycardia in patients with AMI and especially right ventricular infarction.  The latter group of patients are also particularly dependent on adequate right ventricular preload to maintain cardiac output and can experience profound hypotension with nitrate or nitrite administration due to reduction of right ventricular preload.', '3', 'Scardi S, Zingone B, Pandullo C "Myocardial infarction following sublingual administration of isosorbide dinitrate." Int J Cardiol 26 (1990):  378-9|Berisso MZ, Cavallini A, Iannetti M "Sudden death during continuous Holter monitoring out of hospital after nitroglycerin consumption." Am J Cardiol 54 (1984):  677-9|Buckley R, Roberts R "Symptomatic bradycardia following the administration of sublingual nitroglycerin." Am J Emerg Med 11 (1993):  253-5|Ong EA, Canlas C, Smith W "Nitroglycerin-induced asystole ." Arch Intern Med 145 (1985):  954|von Arnim T, Autenrieth G, Bolte HD "Acute myocardial infarction during continuous electrocardiographic ST segment recording. Possible role of bradycardia and hypotension induced by glyceryl trinitrate." Br Heart J 51 (1984):  575-7|Lancaster L, Fenster PE "Complete heart block after sublingual nitroglycerin." Chest 84 (1983):  111-2|Brandes W, Santiago T, Limacher M "Nitroglycerin-induced hypotension, bradycardia, and asystole: report of a case and review of the literature." Clin Cardiol 13 (1990):  741-4|"Product Information. Isordil (isosorbide dinitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. ISMO (isosorbide mononitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58649, 3709, 'Isosorbide dinitrate', 'Myocardial Infarction', 'The benefits of organic nitrates and nitrites in patients with acute myocardial infarction (AMI) or congestive heart failure have not been established and its use is not recommended in these settings.  If used, it should be accompanied by careful clinical and hemodynamic monitoring to avoid the hazards of systemic hypotension and tachycardia, which in AMI can exacerbate myocardial ischemia.  In general, oral or long-acting formulations of these drugs should not be used in the early management of AMI because of the difficulty in precisely controlling and rapidly terminating their hemodynamic effects should adverse reactions occur.  Sublingual and other immediate- onset nitrates or nitrites should typically be avoided in suspected AMI with marked bradycardia or tachycardia, and should be used with extreme caution, if at all, in patients with right ventricular or inferior wall infarction.  Rarely, sublingual nitroglycerin has produced hypotension accompanied by paradoxical bradycardia in patients with AMI and especially right ventricular infarction.  The latter group of patients are also particularly dependent on adequate right ventricular preload to maintain cardiac output and can experience profound hypotension with nitrate or nitrite administration due to reduction of right ventricular preload.', '3', 'Scardi S, Zingone B, Pandullo C "Myocardial infarction following sublingual administration of isosorbide dinitrate." Int J Cardiol 26 (1990):  378-9|Berisso MZ, Cavallini A, Iannetti M "Sudden death during continuous Holter monitoring out of hospital after nitroglycerin consumption." Am J Cardiol 54 (1984):  677-9|Buckley R, Roberts R "Symptomatic bradycardia following the administration of sublingual nitroglycerin." Am J Emerg Med 11 (1993):  253-5|Ong EA, Canlas C, Smith W "Nitroglycerin-induced asystole ." Arch Intern Med 145 (1985):  954|von Arnim T, Autenrieth G, Bolte HD "Acute myocardial infarction during continuous electrocardiographic ST segment recording. Possible role of bradycardia and hypotension induced by glyceryl trinitrate." Br Heart J 51 (1984):  575-7|Lancaster L, Fenster PE "Complete heart block after sublingual nitroglycerin." Chest 84 (1983):  111-2|Brandes W, Santiago T, Limacher M "Nitroglycerin-induced hypotension, bradycardia, and asystole: report of a case and review of the literature." Clin Cardiol 13 (1990):  741-4|"Product Information. Isordil (isosorbide dinitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. ISMO (isosorbide mononitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58650, 3984, 'Isosorbide dinitrate', 'Myocardial Infarction', 'The benefits of organic nitrates and nitrites in patients with acute myocardial infarction (AMI) or congestive heart failure have not been established and its use is not recommended in these settings.  If used, it should be accompanied by careful clinical and hemodynamic monitoring to avoid the hazards of systemic hypotension and tachycardia, which in AMI can exacerbate myocardial ischemia.  In general, oral or long-acting formulations of these drugs should not be used in the early management of AMI because of the difficulty in precisely controlling and rapidly terminating their hemodynamic effects should adverse reactions occur.  Sublingual and other immediate- onset nitrates or nitrites should typically be avoided in suspected AMI with marked bradycardia or tachycardia, and should be used with extreme caution, if at all, in patients with right ventricular or inferior wall infarction.  Rarely, sublingual nitroglycerin has produced hypotension accompanied by paradoxical bradycardia in patients with AMI and especially right ventricular infarction.  The latter group of patients are also particularly dependent on adequate right ventricular preload to maintain cardiac output and can experience profound hypotension with nitrate or nitrite administration due to reduction of right ventricular preload.', '3', 'Scardi S, Zingone B, Pandullo C "Myocardial infarction following sublingual administration of isosorbide dinitrate." Int J Cardiol 26 (1990):  378-9|Berisso MZ, Cavallini A, Iannetti M "Sudden death during continuous Holter monitoring out of hospital after nitroglycerin consumption." Am J Cardiol 54 (1984):  677-9|Buckley R, Roberts R "Symptomatic bradycardia following the administration of sublingual nitroglycerin." Am J Emerg Med 11 (1993):  253-5|Ong EA, Canlas C, Smith W "Nitroglycerin-induced asystole ." Arch Intern Med 145 (1985):  954|von Arnim T, Autenrieth G, Bolte HD "Acute myocardial infarction during continuous electrocardiographic ST segment recording. Possible role of bradycardia and hypotension induced by glyceryl trinitrate." Br Heart J 51 (1984):  575-7|Lancaster L, Fenster PE "Complete heart block after sublingual nitroglycerin." Chest 84 (1983):  111-2|Brandes W, Santiago T, Limacher M "Nitroglycerin-induced hypotension, bradycardia, and asystole: report of a case and review of the literature." Clin Cardiol 13 (1990):  741-4|"Product Information. Isordil (isosorbide dinitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. ISMO (isosorbide mononitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58651, 6608, 'Isosorbide dinitrate', 'Myocardial Infarction', 'The benefits of organic nitrates and nitrites in patients with acute myocardial infarction (AMI) or congestive heart failure have not been established and its use is not recommended in these settings.  If used, it should be accompanied by careful clinical and hemodynamic monitoring to avoid the hazards of systemic hypotension and tachycardia, which in AMI can exacerbate myocardial ischemia.  In general, oral or long-acting formulations of these drugs should not be used in the early management of AMI because of the difficulty in precisely controlling and rapidly terminating their hemodynamic effects should adverse reactions occur.  Sublingual and other immediate- onset nitrates or nitrites should typically be avoided in suspected AMI with marked bradycardia or tachycardia, and should be used with extreme caution, if at all, in patients with right ventricular or inferior wall infarction.  Rarely, sublingual nitroglycerin has produced hypotension accompanied by paradoxical bradycardia in patients with AMI and especially right ventricular infarction.  The latter group of patients are also particularly dependent on adequate right ventricular preload to maintain cardiac output and can experience profound hypotension with nitrate or nitrite administration due to reduction of right ventricular preload.', '3', 'Scardi S, Zingone B, Pandullo C "Myocardial infarction following sublingual administration of isosorbide dinitrate." Int J Cardiol 26 (1990):  378-9|Berisso MZ, Cavallini A, Iannetti M "Sudden death during continuous Holter monitoring out of hospital after nitroglycerin consumption." Am J Cardiol 54 (1984):  677-9|Buckley R, Roberts R "Symptomatic bradycardia following the administration of sublingual nitroglycerin." Am J Emerg Med 11 (1993):  253-5|Ong EA, Canlas C, Smith W "Nitroglycerin-induced asystole ." Arch Intern Med 145 (1985):  954|von Arnim T, Autenrieth G, Bolte HD "Acute myocardial infarction during continuous electrocardiographic ST segment recording. Possible role of bradycardia and hypotension induced by glyceryl trinitrate." Br Heart J 51 (1984):  575-7|Lancaster L, Fenster PE "Complete heart block after sublingual nitroglycerin." Chest 84 (1983):  111-2|Brandes W, Santiago T, Limacher M "Nitroglycerin-induced hypotension, bradycardia, and asystole: report of a case and review of the literature." Clin Cardiol 13 (1990):  741-4|"Product Information. Isordil (isosorbide dinitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. ISMO (isosorbide mononitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58652, 14162, 'Isosorbide dinitrate', 'Myocardial Infarction', 'The benefits of organic nitrates and nitrites in patients with acute myocardial infarction (AMI) or congestive heart failure have not been established and its use is not recommended in these settings.  If used, it should be accompanied by careful clinical and hemodynamic monitoring to avoid the hazards of systemic hypotension and tachycardia, which in AMI can exacerbate myocardial ischemia.  In general, oral or long-acting formulations of these drugs should not be used in the early management of AMI because of the difficulty in precisely controlling and rapidly terminating their hemodynamic effects should adverse reactions occur.  Sublingual and other immediate- onset nitrates or nitrites should typically be avoided in suspected AMI with marked bradycardia or tachycardia, and should be used with extreme caution, if at all, in patients with right ventricular or inferior wall infarction.  Rarely, sublingual nitroglycerin has produced hypotension accompanied by paradoxical bradycardia in patients with AMI and especially right ventricular infarction.  The latter group of patients are also particularly dependent on adequate right ventricular preload to maintain cardiac output and can experience profound hypotension with nitrate or nitrite administration due to reduction of right ventricular preload.', '3', 'Scardi S, Zingone B, Pandullo C "Myocardial infarction following sublingual administration of isosorbide dinitrate." Int J Cardiol 26 (1990):  378-9|Berisso MZ, Cavallini A, Iannetti M "Sudden death during continuous Holter monitoring out of hospital after nitroglycerin consumption." Am J Cardiol 54 (1984):  677-9|Buckley R, Roberts R "Symptomatic bradycardia following the administration of sublingual nitroglycerin." Am J Emerg Med 11 (1993):  253-5|Ong EA, Canlas C, Smith W "Nitroglycerin-induced asystole ." Arch Intern Med 145 (1985):  954|von Arnim T, Autenrieth G, Bolte HD "Acute myocardial infarction during continuous electrocardiographic ST segment recording. Possible role of bradycardia and hypotension induced by glyceryl trinitrate." Br Heart J 51 (1984):  575-7|Lancaster L, Fenster PE "Complete heart block after sublingual nitroglycerin." Chest 84 (1983):  111-2|Brandes W, Santiago T, Limacher M "Nitroglycerin-induced hypotension, bradycardia, and asystole: report of a case and review of the literature." Clin Cardiol 13 (1990):  741-4|"Product Information. Isordil (isosorbide dinitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. ISMO (isosorbide mononitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58653, 15837, 'Isosorbide dinitrate', 'Myocardial Infarction', 'The benefits of organic nitrates and nitrites in patients with acute myocardial infarction (AMI) or congestive heart failure have not been established and its use is not recommended in these settings.  If used, it should be accompanied by careful clinical and hemodynamic monitoring to avoid the hazards of systemic hypotension and tachycardia, which in AMI can exacerbate myocardial ischemia.  In general, oral or long-acting formulations of these drugs should not be used in the early management of AMI because of the difficulty in precisely controlling and rapidly terminating their hemodynamic effects should adverse reactions occur.  Sublingual and other immediate- onset nitrates or nitrites should typically be avoided in suspected AMI with marked bradycardia or tachycardia, and should be used with extreme caution, if at all, in patients with right ventricular or inferior wall infarction.  Rarely, sublingual nitroglycerin has produced hypotension accompanied by paradoxical bradycardia in patients with AMI and especially right ventricular infarction.  The latter group of patients are also particularly dependent on adequate right ventricular preload to maintain cardiac output and can experience profound hypotension with nitrate or nitrite administration due to reduction of right ventricular preload.', '3', 'Scardi S, Zingone B, Pandullo C "Myocardial infarction following sublingual administration of isosorbide dinitrate." Int J Cardiol 26 (1990):  378-9|Berisso MZ, Cavallini A, Iannetti M "Sudden death during continuous Holter monitoring out of hospital after nitroglycerin consumption." Am J Cardiol 54 (1984):  677-9|Buckley R, Roberts R "Symptomatic bradycardia following the administration of sublingual nitroglycerin." Am J Emerg Med 11 (1993):  253-5|Ong EA, Canlas C, Smith W "Nitroglycerin-induced asystole ." Arch Intern Med 145 (1985):  954|von Arnim T, Autenrieth G, Bolte HD "Acute myocardial infarction during continuous electrocardiographic ST segment recording. Possible role of bradycardia and hypotension induced by glyceryl trinitrate." Br Heart J 51 (1984):  575-7|Lancaster L, Fenster PE "Complete heart block after sublingual nitroglycerin." Chest 84 (1983):  111-2|Brandes W, Santiago T, Limacher M "Nitroglycerin-induced hypotension, bradycardia, and asystole: report of a case and review of the literature." Clin Cardiol 13 (1990):  741-4|"Product Information. Isordil (isosorbide dinitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. ISMO (isosorbide mononitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58654, 15838, 'Isosorbide dinitrate', 'Myocardial Infarction', 'The benefits of organic nitrates and nitrites in patients with acute myocardial infarction (AMI) or congestive heart failure have not been established and its use is not recommended in these settings.  If used, it should be accompanied by careful clinical and hemodynamic monitoring to avoid the hazards of systemic hypotension and tachycardia, which in AMI can exacerbate myocardial ischemia.  In general, oral or long-acting formulations of these drugs should not be used in the early management of AMI because of the difficulty in precisely controlling and rapidly terminating their hemodynamic effects should adverse reactions occur.  Sublingual and other immediate- onset nitrates or nitrites should typically be avoided in suspected AMI with marked bradycardia or tachycardia, and should be used with extreme caution, if at all, in patients with right ventricular or inferior wall infarction.  Rarely, sublingual nitroglycerin has produced hypotension accompanied by paradoxical bradycardia in patients with AMI and especially right ventricular infarction.  The latter group of patients are also particularly dependent on adequate right ventricular preload to maintain cardiac output and can experience profound hypotension with nitrate or nitrite administration due to reduction of right ventricular preload.', '3', 'Scardi S, Zingone B, Pandullo C "Myocardial infarction following sublingual administration of isosorbide dinitrate." Int J Cardiol 26 (1990):  378-9|Berisso MZ, Cavallini A, Iannetti M "Sudden death during continuous Holter monitoring out of hospital after nitroglycerin consumption." Am J Cardiol 54 (1984):  677-9|Buckley R, Roberts R "Symptomatic bradycardia following the administration of sublingual nitroglycerin." Am J Emerg Med 11 (1993):  253-5|Ong EA, Canlas C, Smith W "Nitroglycerin-induced asystole ." Arch Intern Med 145 (1985):  954|von Arnim T, Autenrieth G, Bolte HD "Acute myocardial infarction during continuous electrocardiographic ST segment recording. Possible role of bradycardia and hypotension induced by glyceryl trinitrate." Br Heart J 51 (1984):  575-7|Lancaster L, Fenster PE "Complete heart block after sublingual nitroglycerin." Chest 84 (1983):  111-2|Brandes W, Santiago T, Limacher M "Nitroglycerin-induced hypotension, bradycardia, and asystole: report of a case and review of the literature." Clin Cardiol 13 (1990):  741-4|"Product Information. Isordil (isosorbide dinitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. ISMO (isosorbide mononitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58655, 16808, 'Isosorbide dinitrate', 'Myocardial Infarction', 'The benefits of organic nitrates and nitrites in patients with acute myocardial infarction (AMI) or congestive heart failure have not been established and its use is not recommended in these settings.  If used, it should be accompanied by careful clinical and hemodynamic monitoring to avoid the hazards of systemic hypotension and tachycardia, which in AMI can exacerbate myocardial ischemia.  In general, oral or long-acting formulations of these drugs should not be used in the early management of AMI because of the difficulty in precisely controlling and rapidly terminating their hemodynamic effects should adverse reactions occur.  Sublingual and other immediate- onset nitrates or nitrites should typically be avoided in suspected AMI with marked bradycardia or tachycardia, and should be used with extreme caution, if at all, in patients with right ventricular or inferior wall infarction.  Rarely, sublingual nitroglycerin has produced hypotension accompanied by paradoxical bradycardia in patients with AMI and especially right ventricular infarction.  The latter group of patients are also particularly dependent on adequate right ventricular preload to maintain cardiac output and can experience profound hypotension with nitrate or nitrite administration due to reduction of right ventricular preload.', '3', 'Scardi S, Zingone B, Pandullo C "Myocardial infarction following sublingual administration of isosorbide dinitrate." Int J Cardiol 26 (1990):  378-9|Berisso MZ, Cavallini A, Iannetti M "Sudden death during continuous Holter monitoring out of hospital after nitroglycerin consumption." Am J Cardiol 54 (1984):  677-9|Buckley R, Roberts R "Symptomatic bradycardia following the administration of sublingual nitroglycerin." Am J Emerg Med 11 (1993):  253-5|Ong EA, Canlas C, Smith W "Nitroglycerin-induced asystole ." Arch Intern Med 145 (1985):  954|von Arnim T, Autenrieth G, Bolte HD "Acute myocardial infarction during continuous electrocardiographic ST segment recording. Possible role of bradycardia and hypotension induced by glyceryl trinitrate." Br Heart J 51 (1984):  575-7|Lancaster L, Fenster PE "Complete heart block after sublingual nitroglycerin." Chest 84 (1983):  111-2|Brandes W, Santiago T, Limacher M "Nitroglycerin-induced hypotension, bradycardia, and asystole: report of a case and review of the literature." Clin Cardiol 13 (1990):  741-4|"Product Information. Isordil (isosorbide dinitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. ISMO (isosorbide mononitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58656, 21002, 'Isosorbide dinitrate', 'Myocardial Infarction', 'The benefits of organic nitrates and nitrites in patients with acute myocardial infarction (AMI) or congestive heart failure have not been established and its use is not recommended in these settings.  If used, it should be accompanied by careful clinical and hemodynamic monitoring to avoid the hazards of systemic hypotension and tachycardia, which in AMI can exacerbate myocardial ischemia.  In general, oral or long-acting formulations of these drugs should not be used in the early management of AMI because of the difficulty in precisely controlling and rapidly terminating their hemodynamic effects should adverse reactions occur.  Sublingual and other immediate- onset nitrates or nitrites should typically be avoided in suspected AMI with marked bradycardia or tachycardia, and should be used with extreme caution, if at all, in patients with right ventricular or inferior wall infarction.  Rarely, sublingual nitroglycerin has produced hypotension accompanied by paradoxical bradycardia in patients with AMI and especially right ventricular infarction.  The latter group of patients are also particularly dependent on adequate right ventricular preload to maintain cardiac output and can experience profound hypotension with nitrate or nitrite administration due to reduction of right ventricular preload.', '3', 'Scardi S, Zingone B, Pandullo C "Myocardial infarction following sublingual administration of isosorbide dinitrate." Int J Cardiol 26 (1990):  378-9|Berisso MZ, Cavallini A, Iannetti M "Sudden death during continuous Holter monitoring out of hospital after nitroglycerin consumption." Am J Cardiol 54 (1984):  677-9|Buckley R, Roberts R "Symptomatic bradycardia following the administration of sublingual nitroglycerin." Am J Emerg Med 11 (1993):  253-5|Ong EA, Canlas C, Smith W "Nitroglycerin-induced asystole ." Arch Intern Med 145 (1985):  954|von Arnim T, Autenrieth G, Bolte HD "Acute myocardial infarction during continuous electrocardiographic ST segment recording. Possible role of bradycardia and hypotension induced by glyceryl trinitrate." Br Heart J 51 (1984):  575-7|Lancaster L, Fenster PE "Complete heart block after sublingual nitroglycerin." Chest 84 (1983):  111-2|Brandes W, Santiago T, Limacher M "Nitroglycerin-induced hypotension, bradycardia, and asystole: report of a case and review of the literature." Clin Cardiol 13 (1990):  741-4|"Product Information. Isordil (isosorbide dinitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. ISMO (isosorbide mononitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58657, 21007, 'Isosorbide dinitrate', 'Myocardial Infarction', 'The benefits of organic nitrates and nitrites in patients with acute myocardial infarction (AMI) or congestive heart failure have not been established and its use is not recommended in these settings.  If used, it should be accompanied by careful clinical and hemodynamic monitoring to avoid the hazards of systemic hypotension and tachycardia, which in AMI can exacerbate myocardial ischemia.  In general, oral or long-acting formulations of these drugs should not be used in the early management of AMI because of the difficulty in precisely controlling and rapidly terminating their hemodynamic effects should adverse reactions occur.  Sublingual and other immediate- onset nitrates or nitrites should typically be avoided in suspected AMI with marked bradycardia or tachycardia, and should be used with extreme caution, if at all, in patients with right ventricular or inferior wall infarction.  Rarely, sublingual nitroglycerin has produced hypotension accompanied by paradoxical bradycardia in patients with AMI and especially right ventricular infarction.  The latter group of patients are also particularly dependent on adequate right ventricular preload to maintain cardiac output and can experience profound hypotension with nitrate or nitrite administration due to reduction of right ventricular preload.', '3', 'Scardi S, Zingone B, Pandullo C "Myocardial infarction following sublingual administration of isosorbide dinitrate." Int J Cardiol 26 (1990):  378-9|Berisso MZ, Cavallini A, Iannetti M "Sudden death during continuous Holter monitoring out of hospital after nitroglycerin consumption." Am J Cardiol 54 (1984):  677-9|Buckley R, Roberts R "Symptomatic bradycardia following the administration of sublingual nitroglycerin." Am J Emerg Med 11 (1993):  253-5|Ong EA, Canlas C, Smith W "Nitroglycerin-induced asystole ." Arch Intern Med 145 (1985):  954|von Arnim T, Autenrieth G, Bolte HD "Acute myocardial infarction during continuous electrocardiographic ST segment recording. Possible role of bradycardia and hypotension induced by glyceryl trinitrate." Br Heart J 51 (1984):  575-7|Lancaster L, Fenster PE "Complete heart block after sublingual nitroglycerin." Chest 84 (1983):  111-2|Brandes W, Santiago T, Limacher M "Nitroglycerin-induced hypotension, bradycardia, and asystole: report of a case and review of the literature." Clin Cardiol 13 (1990):  741-4|"Product Information. Isordil (isosorbide dinitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. ISMO (isosorbide mononitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58658, 21008, 'Isosorbide dinitrate', 'Myocardial Infarction', 'The benefits of organic nitrates and nitrites in patients with acute myocardial infarction (AMI) or congestive heart failure have not been established and its use is not recommended in these settings.  If used, it should be accompanied by careful clinical and hemodynamic monitoring to avoid the hazards of systemic hypotension and tachycardia, which in AMI can exacerbate myocardial ischemia.  In general, oral or long-acting formulations of these drugs should not be used in the early management of AMI because of the difficulty in precisely controlling and rapidly terminating their hemodynamic effects should adverse reactions occur.  Sublingual and other immediate- onset nitrates or nitrites should typically be avoided in suspected AMI with marked bradycardia or tachycardia, and should be used with extreme caution, if at all, in patients with right ventricular or inferior wall infarction.  Rarely, sublingual nitroglycerin has produced hypotension accompanied by paradoxical bradycardia in patients with AMI and especially right ventricular infarction.  The latter group of patients are also particularly dependent on adequate right ventricular preload to maintain cardiac output and can experience profound hypotension with nitrate or nitrite administration due to reduction of right ventricular preload.', '3', 'Scardi S, Zingone B, Pandullo C "Myocardial infarction following sublingual administration of isosorbide dinitrate." Int J Cardiol 26 (1990):  378-9|Berisso MZ, Cavallini A, Iannetti M "Sudden death during continuous Holter monitoring out of hospital after nitroglycerin consumption." Am J Cardiol 54 (1984):  677-9|Buckley R, Roberts R "Symptomatic bradycardia following the administration of sublingual nitroglycerin." Am J Emerg Med 11 (1993):  253-5|Ong EA, Canlas C, Smith W "Nitroglycerin-induced asystole ." Arch Intern Med 145 (1985):  954|von Arnim T, Autenrieth G, Bolte HD "Acute myocardial infarction during continuous electrocardiographic ST segment recording. Possible role of bradycardia and hypotension induced by glyceryl trinitrate." Br Heart J 51 (1984):  575-7|Lancaster L, Fenster PE "Complete heart block after sublingual nitroglycerin." Chest 84 (1983):  111-2|Brandes W, Santiago T, Limacher M "Nitroglycerin-induced hypotension, bradycardia, and asystole: report of a case and review of the literature." Clin Cardiol 13 (1990):  741-4|"Product Information. Isordil (isosorbide dinitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. ISMO (isosorbide mononitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58659, 21031, 'Isosorbide dinitrate', 'Myocardial Infarction', 'The benefits of organic nitrates and nitrites in patients with acute myocardial infarction (AMI) or congestive heart failure have not been established and its use is not recommended in these settings.  If used, it should be accompanied by careful clinical and hemodynamic monitoring to avoid the hazards of systemic hypotension and tachycardia, which in AMI can exacerbate myocardial ischemia.  In general, oral or long-acting formulations of these drugs should not be used in the early management of AMI because of the difficulty in precisely controlling and rapidly terminating their hemodynamic effects should adverse reactions occur.  Sublingual and other immediate- onset nitrates or nitrites should typically be avoided in suspected AMI with marked bradycardia or tachycardia, and should be used with extreme caution, if at all, in patients with right ventricular or inferior wall infarction.  Rarely, sublingual nitroglycerin has produced hypotension accompanied by paradoxical bradycardia in patients with AMI and especially right ventricular infarction.  The latter group of patients are also particularly dependent on adequate right ventricular preload to maintain cardiac output and can experience profound hypotension with nitrate or nitrite administration due to reduction of right ventricular preload.', '3', 'Scardi S, Zingone B, Pandullo C "Myocardial infarction following sublingual administration of isosorbide dinitrate." Int J Cardiol 26 (1990):  378-9|Berisso MZ, Cavallini A, Iannetti M "Sudden death during continuous Holter monitoring out of hospital after nitroglycerin consumption." Am J Cardiol 54 (1984):  677-9|Buckley R, Roberts R "Symptomatic bradycardia following the administration of sublingual nitroglycerin." Am J Emerg Med 11 (1993):  253-5|Ong EA, Canlas C, Smith W "Nitroglycerin-induced asystole ." Arch Intern Med 145 (1985):  954|von Arnim T, Autenrieth G, Bolte HD "Acute myocardial infarction during continuous electrocardiographic ST segment recording. Possible role of bradycardia and hypotension induced by glyceryl trinitrate." Br Heart J 51 (1984):  575-7|Lancaster L, Fenster PE "Complete heart block after sublingual nitroglycerin." Chest 84 (1983):  111-2|Brandes W, Santiago T, Limacher M "Nitroglycerin-induced hypotension, bradycardia, and asystole: report of a case and review of the literature." Clin Cardiol 13 (1990):  741-4|"Product Information. Isordil (isosorbide dinitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. ISMO (isosorbide mononitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58660, 30354, 'Isosorbide dinitrate', 'Myocardial Infarction', 'The benefits of organic nitrates and nitrites in patients with acute myocardial infarction (AMI) or congestive heart failure have not been established and its use is not recommended in these settings.  If used, it should be accompanied by careful clinical and hemodynamic monitoring to avoid the hazards of systemic hypotension and tachycardia, which in AMI can exacerbate myocardial ischemia.  In general, oral or long-acting formulations of these drugs should not be used in the early management of AMI because of the difficulty in precisely controlling and rapidly terminating their hemodynamic effects should adverse reactions occur.  Sublingual and other immediate- onset nitrates or nitrites should typically be avoided in suspected AMI with marked bradycardia or tachycardia, and should be used with extreme caution, if at all, in patients with right ventricular or inferior wall infarction.  Rarely, sublingual nitroglycerin has produced hypotension accompanied by paradoxical bradycardia in patients with AMI and especially right ventricular infarction.  The latter group of patients are also particularly dependent on adequate right ventricular preload to maintain cardiac output and can experience profound hypotension with nitrate or nitrite administration due to reduction of right ventricular preload.', '3', 'Scardi S, Zingone B, Pandullo C "Myocardial infarction following sublingual administration of isosorbide dinitrate." Int J Cardiol 26 (1990):  378-9|Berisso MZ, Cavallini A, Iannetti M "Sudden death during continuous Holter monitoring out of hospital after nitroglycerin consumption." Am J Cardiol 54 (1984):  677-9|Buckley R, Roberts R "Symptomatic bradycardia following the administration of sublingual nitroglycerin." Am J Emerg Med 11 (1993):  253-5|Ong EA, Canlas C, Smith W "Nitroglycerin-induced asystole ." Arch Intern Med 145 (1985):  954|von Arnim T, Autenrieth G, Bolte HD "Acute myocardial infarction during continuous electrocardiographic ST segment recording. Possible role of bradycardia and hypotension induced by glyceryl trinitrate." Br Heart J 51 (1984):  575-7|Lancaster L, Fenster PE "Complete heart block after sublingual nitroglycerin." Chest 84 (1983):  111-2|Brandes W, Santiago T, Limacher M "Nitroglycerin-induced hypotension, bradycardia, and asystole: report of a case and review of the literature." Clin Cardiol 13 (1990):  741-4|"Product Information. Isordil (isosorbide dinitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. ISMO (isosorbide mononitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58661, 2053, 'Isosorbide dinitrate', 'Anemia', 'Some manufacturers and medical references consider the use of nitrates and nitrites to be contraindicated in patients with severe anemia.  Nitrates and nitrites can cause methemoglobinemia, primarily in high-dose intravenous therapy or acute poisoning and in patients with NADH reductase deficiency.  However, elevations of methemoglobin may also occur with commonly used dosages.  While probably not of routine clinical significance, the increases may be important in certain patient populations such as those with coronary insufficiency or anemia.', '3', 'Fibuch EE, Cecil WT, Reed WA "Methemoglobinemia associated with organic nitrate therapy." Anesth Analg 58 (1979):  521-3|Arsura E, Lichstein E, Guadagnino V, Nicchi V, Sanders M, Hollander G, Greengart A "Methemoglobin levels produced by organic nitrates in patients with coronary artery disease." J Clin Pharmacol 24 (1984):  160-4|Curry SC, Arnold-Capell P "Toxic effects of drugs used in the ICU. Nitroprusside, nitroglycerin, and angiotensin-converting enzyme inhibitors." Crit Care Clin 7 (1991):  555-81|Kaplan K, Davison R "Nitroglycerin and methemoglobinemia." Am J Cardiol 57 (1986):  1004|Saxon SA, Silverman ME "Effects of continuous infusion of intravenous nitroglycerin on methemoglobin levels." Am J Cardiol 56 (1985):  461-4|Gibson GR, Hunter JB, Raabe DS, Jr  Manjoney DL, Ittleman FP "Methemoglobinemia produced by high-dose intravenous nitroglycerin." Ann Intern Med 96 (1982):  615-6|Robicsek F "Acute methemoglobinemia during cardiopulmonary bypass caused by intravenous nitroglycerin infusion." J Thorac Cardiovasc Surg 90 (1985):  931-4|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):|Forsyth RJ, Moulden A "Methaemoglobinaemia after ingestion of amyl nitrite." Arch Dis Child 66 (1991):  152|Pierce JM, Nielsen MS "Acute acquired methaemoglobinaemia after amyl nitrite poisoning." BMJ 298 (1989):  1566|Sutton M, Jeffrey B "Acquired methemoglobinemia from amyl nitrate inhalation." J Emerg Nurs 18 (1992):  8-9|Sobey RJ, Campbell CM "A 37-year-old with amyl nitrite-induced methemoglobinemia." J Emerg Nurs 18 (1992):  11-3|Edwards RJ, Ujma J "Extreme methaemoglobinaemia secondary to recreational use of amyl nitrite." J Accid Emerg Med 12 (1995):  138-42|Machabert R, Testud F, Descotes J "Methaemoglobinaemia due to amyl nitrite inhalation: a case report." Hum Exp Toxicol 13 (1994):  313-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58662, 3639, 'Isosorbide dinitrate', 'Anemia', 'Some manufacturers and medical references consider the use of nitrates and nitrites to be contraindicated in patients with severe anemia.  Nitrates and nitrites can cause methemoglobinemia, primarily in high-dose intravenous therapy or acute poisoning and in patients with NADH reductase deficiency.  However, elevations of methemoglobin may also occur with commonly used dosages.  While probably not of routine clinical significance, the increases may be important in certain patient populations such as those with coronary insufficiency or anemia.', '3', 'Fibuch EE, Cecil WT, Reed WA "Methemoglobinemia associated with organic nitrate therapy." Anesth Analg 58 (1979):  521-3|Arsura E, Lichstein E, Guadagnino V, Nicchi V, Sanders M, Hollander G, Greengart A "Methemoglobin levels produced by organic nitrates in patients with coronary artery disease." J Clin Pharmacol 24 (1984):  160-4|Curry SC, Arnold-Capell P "Toxic effects of drugs used in the ICU. Nitroprusside, nitroglycerin, and angiotensin-converting enzyme inhibitors." Crit Care Clin 7 (1991):  555-81|Kaplan K, Davison R "Nitroglycerin and methemoglobinemia." Am J Cardiol 57 (1986):  1004|Saxon SA, Silverman ME "Effects of continuous infusion of intravenous nitroglycerin on methemoglobin levels." Am J Cardiol 56 (1985):  461-4|Gibson GR, Hunter JB, Raabe DS, Jr  Manjoney DL, Ittleman FP "Methemoglobinemia produced by high-dose intravenous nitroglycerin." Ann Intern Med 96 (1982):  615-6|Robicsek F "Acute methemoglobinemia during cardiopulmonary bypass caused by intravenous nitroglycerin infusion." J Thorac Cardiovasc Surg 90 (1985):  931-4|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):|Forsyth RJ, Moulden A "Methaemoglobinaemia after ingestion of amyl nitrite." Arch Dis Child 66 (1991):  152|Pierce JM, Nielsen MS "Acute acquired methaemoglobinaemia after amyl nitrite poisoning." BMJ 298 (1989):  1566|Sutton M, Jeffrey B "Acquired methemoglobinemia from amyl nitrate inhalation." J Emerg Nurs 18 (1992):  8-9|Sobey RJ, Campbell CM "A 37-year-old with amyl nitrite-induced methemoglobinemia." J Emerg Nurs 18 (1992):  11-3|Edwards RJ, Ujma J "Extreme methaemoglobinaemia secondary to recreational use of amyl nitrite." J Accid Emerg Med 12 (1995):  138-42|Machabert R, Testud F, Descotes J "Methaemoglobinaemia due to amyl nitrite inhalation: a case report." Hum Exp Toxicol 13 (1994):  313-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58663, 3707, 'Isosorbide dinitrate', 'Anemia', 'Some manufacturers and medical references consider the use of nitrates and nitrites to be contraindicated in patients with severe anemia.  Nitrates and nitrites can cause methemoglobinemia, primarily in high-dose intravenous therapy or acute poisoning and in patients with NADH reductase deficiency.  However, elevations of methemoglobin may also occur with commonly used dosages.  While probably not of routine clinical significance, the increases may be important in certain patient populations such as those with coronary insufficiency or anemia.', '3', 'Fibuch EE, Cecil WT, Reed WA "Methemoglobinemia associated with organic nitrate therapy." Anesth Analg 58 (1979):  521-3|Arsura E, Lichstein E, Guadagnino V, Nicchi V, Sanders M, Hollander G, Greengart A "Methemoglobin levels produced by organic nitrates in patients with coronary artery disease." J Clin Pharmacol 24 (1984):  160-4|Curry SC, Arnold-Capell P "Toxic effects of drugs used in the ICU. Nitroprusside, nitroglycerin, and angiotensin-converting enzyme inhibitors." Crit Care Clin 7 (1991):  555-81|Kaplan K, Davison R "Nitroglycerin and methemoglobinemia." Am J Cardiol 57 (1986):  1004|Saxon SA, Silverman ME "Effects of continuous infusion of intravenous nitroglycerin on methemoglobin levels." Am J Cardiol 56 (1985):  461-4|Gibson GR, Hunter JB, Raabe DS, Jr  Manjoney DL, Ittleman FP "Methemoglobinemia produced by high-dose intravenous nitroglycerin." Ann Intern Med 96 (1982):  615-6|Robicsek F "Acute methemoglobinemia during cardiopulmonary bypass caused by intravenous nitroglycerin infusion." J Thorac Cardiovasc Surg 90 (1985):  931-4|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):|Forsyth RJ, Moulden A "Methaemoglobinaemia after ingestion of amyl nitrite." Arch Dis Child 66 (1991):  152|Pierce JM, Nielsen MS "Acute acquired methaemoglobinaemia after amyl nitrite poisoning." BMJ 298 (1989):  1566|Sutton M, Jeffrey B "Acquired methemoglobinemia from amyl nitrate inhalation." J Emerg Nurs 18 (1992):  8-9|Sobey RJ, Campbell CM "A 37-year-old with amyl nitrite-induced methemoglobinemia." J Emerg Nurs 18 (1992):  11-3|Edwards RJ, Ujma J "Extreme methaemoglobinaemia secondary to recreational use of amyl nitrite." J Accid Emerg Med 12 (1995):  138-42|Machabert R, Testud F, Descotes J "Methaemoglobinaemia due to amyl nitrite inhalation: a case report." Hum Exp Toxicol 13 (1994):  313-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58664, 3708, 'Isosorbide dinitrate', 'Anemia', 'Some manufacturers and medical references consider the use of nitrates and nitrites to be contraindicated in patients with severe anemia.  Nitrates and nitrites can cause methemoglobinemia, primarily in high-dose intravenous therapy or acute poisoning and in patients with NADH reductase deficiency.  However, elevations of methemoglobin may also occur with commonly used dosages.  While probably not of routine clinical significance, the increases may be important in certain patient populations such as those with coronary insufficiency or anemia.', '3', 'Fibuch EE, Cecil WT, Reed WA "Methemoglobinemia associated with organic nitrate therapy." Anesth Analg 58 (1979):  521-3|Arsura E, Lichstein E, Guadagnino V, Nicchi V, Sanders M, Hollander G, Greengart A "Methemoglobin levels produced by organic nitrates in patients with coronary artery disease." J Clin Pharmacol 24 (1984):  160-4|Curry SC, Arnold-Capell P "Toxic effects of drugs used in the ICU. Nitroprusside, nitroglycerin, and angiotensin-converting enzyme inhibitors." Crit Care Clin 7 (1991):  555-81|Kaplan K, Davison R "Nitroglycerin and methemoglobinemia." Am J Cardiol 57 (1986):  1004|Saxon SA, Silverman ME "Effects of continuous infusion of intravenous nitroglycerin on methemoglobin levels." Am J Cardiol 56 (1985):  461-4|Gibson GR, Hunter JB, Raabe DS, Jr  Manjoney DL, Ittleman FP "Methemoglobinemia produced by high-dose intravenous nitroglycerin." Ann Intern Med 96 (1982):  615-6|Robicsek F "Acute methemoglobinemia during cardiopulmonary bypass caused by intravenous nitroglycerin infusion." J Thorac Cardiovasc Surg 90 (1985):  931-4|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):|Forsyth RJ, Moulden A "Methaemoglobinaemia after ingestion of amyl nitrite." Arch Dis Child 66 (1991):  152|Pierce JM, Nielsen MS "Acute acquired methaemoglobinaemia after amyl nitrite poisoning." BMJ 298 (1989):  1566|Sutton M, Jeffrey B "Acquired methemoglobinemia from amyl nitrate inhalation." J Emerg Nurs 18 (1992):  8-9|Sobey RJ, Campbell CM "A 37-year-old with amyl nitrite-induced methemoglobinemia." J Emerg Nurs 18 (1992):  11-3|Edwards RJ, Ujma J "Extreme methaemoglobinaemia secondary to recreational use of amyl nitrite." J Accid Emerg Med 12 (1995):  138-42|Machabert R, Testud F, Descotes J "Methaemoglobinaemia due to amyl nitrite inhalation: a case report." Hum Exp Toxicol 13 (1994):  313-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58665, 3709, 'Isosorbide dinitrate', 'Anemia', 'Some manufacturers and medical references consider the use of nitrates and nitrites to be contraindicated in patients with severe anemia.  Nitrates and nitrites can cause methemoglobinemia, primarily in high-dose intravenous therapy or acute poisoning and in patients with NADH reductase deficiency.  However, elevations of methemoglobin may also occur with commonly used dosages.  While probably not of routine clinical significance, the increases may be important in certain patient populations such as those with coronary insufficiency or anemia.', '3', 'Fibuch EE, Cecil WT, Reed WA "Methemoglobinemia associated with organic nitrate therapy." Anesth Analg 58 (1979):  521-3|Arsura E, Lichstein E, Guadagnino V, Nicchi V, Sanders M, Hollander G, Greengart A "Methemoglobin levels produced by organic nitrates in patients with coronary artery disease." J Clin Pharmacol 24 (1984):  160-4|Curry SC, Arnold-Capell P "Toxic effects of drugs used in the ICU. Nitroprusside, nitroglycerin, and angiotensin-converting enzyme inhibitors." Crit Care Clin 7 (1991):  555-81|Kaplan K, Davison R "Nitroglycerin and methemoglobinemia." Am J Cardiol 57 (1986):  1004|Saxon SA, Silverman ME "Effects of continuous infusion of intravenous nitroglycerin on methemoglobin levels." Am J Cardiol 56 (1985):  461-4|Gibson GR, Hunter JB, Raabe DS, Jr  Manjoney DL, Ittleman FP "Methemoglobinemia produced by high-dose intravenous nitroglycerin." Ann Intern Med 96 (1982):  615-6|Robicsek F "Acute methemoglobinemia during cardiopulmonary bypass caused by intravenous nitroglycerin infusion." J Thorac Cardiovasc Surg 90 (1985):  931-4|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):|Forsyth RJ, Moulden A "Methaemoglobinaemia after ingestion of amyl nitrite." Arch Dis Child 66 (1991):  152|Pierce JM, Nielsen MS "Acute acquired methaemoglobinaemia after amyl nitrite poisoning." BMJ 298 (1989):  1566|Sutton M, Jeffrey B "Acquired methemoglobinemia from amyl nitrate inhalation." J Emerg Nurs 18 (1992):  8-9|Sobey RJ, Campbell CM "A 37-year-old with amyl nitrite-induced methemoglobinemia." J Emerg Nurs 18 (1992):  11-3|Edwards RJ, Ujma J "Extreme methaemoglobinaemia secondary to recreational use of amyl nitrite." J Accid Emerg Med 12 (1995):  138-42|Machabert R, Testud F, Descotes J "Methaemoglobinaemia due to amyl nitrite inhalation: a case report." Hum Exp Toxicol 13 (1994):  313-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58666, 3984, 'Isosorbide dinitrate', 'Anemia', 'Some manufacturers and medical references consider the use of nitrates and nitrites to be contraindicated in patients with severe anemia.  Nitrates and nitrites can cause methemoglobinemia, primarily in high-dose intravenous therapy or acute poisoning and in patients with NADH reductase deficiency.  However, elevations of methemoglobin may also occur with commonly used dosages.  While probably not of routine clinical significance, the increases may be important in certain patient populations such as those with coronary insufficiency or anemia.', '3', 'Fibuch EE, Cecil WT, Reed WA "Methemoglobinemia associated with organic nitrate therapy." Anesth Analg 58 (1979):  521-3|Arsura E, Lichstein E, Guadagnino V, Nicchi V, Sanders M, Hollander G, Greengart A "Methemoglobin levels produced by organic nitrates in patients with coronary artery disease." J Clin Pharmacol 24 (1984):  160-4|Curry SC, Arnold-Capell P "Toxic effects of drugs used in the ICU. Nitroprusside, nitroglycerin, and angiotensin-converting enzyme inhibitors." Crit Care Clin 7 (1991):  555-81|Kaplan K, Davison R "Nitroglycerin and methemoglobinemia." Am J Cardiol 57 (1986):  1004|Saxon SA, Silverman ME "Effects of continuous infusion of intravenous nitroglycerin on methemoglobin levels." Am J Cardiol 56 (1985):  461-4|Gibson GR, Hunter JB, Raabe DS, Jr  Manjoney DL, Ittleman FP "Methemoglobinemia produced by high-dose intravenous nitroglycerin." Ann Intern Med 96 (1982):  615-6|Robicsek F "Acute methemoglobinemia during cardiopulmonary bypass caused by intravenous nitroglycerin infusion." J Thorac Cardiovasc Surg 90 (1985):  931-4|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):|Forsyth RJ, Moulden A "Methaemoglobinaemia after ingestion of amyl nitrite." Arch Dis Child 66 (1991):  152|Pierce JM, Nielsen MS "Acute acquired methaemoglobinaemia after amyl nitrite poisoning." BMJ 298 (1989):  1566|Sutton M, Jeffrey B "Acquired methemoglobinemia from amyl nitrate inhalation." J Emerg Nurs 18 (1992):  8-9|Sobey RJ, Campbell CM "A 37-year-old with amyl nitrite-induced methemoglobinemia." J Emerg Nurs 18 (1992):  11-3|Edwards RJ, Ujma J "Extreme methaemoglobinaemia secondary to recreational use of amyl nitrite." J Accid Emerg Med 12 (1995):  138-42|Machabert R, Testud F, Descotes J "Methaemoglobinaemia due to amyl nitrite inhalation: a case report." Hum Exp Toxicol 13 (1994):  313-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58667, 6608, 'Isosorbide dinitrate', 'Anemia', 'Some manufacturers and medical references consider the use of nitrates and nitrites to be contraindicated in patients with severe anemia.  Nitrates and nitrites can cause methemoglobinemia, primarily in high-dose intravenous therapy or acute poisoning and in patients with NADH reductase deficiency.  However, elevations of methemoglobin may also occur with commonly used dosages.  While probably not of routine clinical significance, the increases may be important in certain patient populations such as those with coronary insufficiency or anemia.', '3', 'Fibuch EE, Cecil WT, Reed WA "Methemoglobinemia associated with organic nitrate therapy." Anesth Analg 58 (1979):  521-3|Arsura E, Lichstein E, Guadagnino V, Nicchi V, Sanders M, Hollander G, Greengart A "Methemoglobin levels produced by organic nitrates in patients with coronary artery disease." J Clin Pharmacol 24 (1984):  160-4|Curry SC, Arnold-Capell P "Toxic effects of drugs used in the ICU. Nitroprusside, nitroglycerin, and angiotensin-converting enzyme inhibitors." Crit Care Clin 7 (1991):  555-81|Kaplan K, Davison R "Nitroglycerin and methemoglobinemia." Am J Cardiol 57 (1986):  1004|Saxon SA, Silverman ME "Effects of continuous infusion of intravenous nitroglycerin on methemoglobin levels." Am J Cardiol 56 (1985):  461-4|Gibson GR, Hunter JB, Raabe DS, Jr  Manjoney DL, Ittleman FP "Methemoglobinemia produced by high-dose intravenous nitroglycerin." Ann Intern Med 96 (1982):  615-6|Robicsek F "Acute methemoglobinemia during cardiopulmonary bypass caused by intravenous nitroglycerin infusion." J Thorac Cardiovasc Surg 90 (1985):  931-4|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):|Forsyth RJ, Moulden A "Methaemoglobinaemia after ingestion of amyl nitrite." Arch Dis Child 66 (1991):  152|Pierce JM, Nielsen MS "Acute acquired methaemoglobinaemia after amyl nitrite poisoning." BMJ 298 (1989):  1566|Sutton M, Jeffrey B "Acquired methemoglobinemia from amyl nitrate inhalation." J Emerg Nurs 18 (1992):  8-9|Sobey RJ, Campbell CM "A 37-year-old with amyl nitrite-induced methemoglobinemia." J Emerg Nurs 18 (1992):  11-3|Edwards RJ, Ujma J "Extreme methaemoglobinaemia secondary to recreational use of amyl nitrite." J Accid Emerg Med 12 (1995):  138-42|Machabert R, Testud F, Descotes J "Methaemoglobinaemia due to amyl nitrite inhalation: a case report." Hum Exp Toxicol 13 (1994):  313-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58668, 14162, 'Isosorbide dinitrate', 'Anemia', 'Some manufacturers and medical references consider the use of nitrates and nitrites to be contraindicated in patients with severe anemia.  Nitrates and nitrites can cause methemoglobinemia, primarily in high-dose intravenous therapy or acute poisoning and in patients with NADH reductase deficiency.  However, elevations of methemoglobin may also occur with commonly used dosages.  While probably not of routine clinical significance, the increases may be important in certain patient populations such as those with coronary insufficiency or anemia.', '3', 'Fibuch EE, Cecil WT, Reed WA "Methemoglobinemia associated with organic nitrate therapy." Anesth Analg 58 (1979):  521-3|Arsura E, Lichstein E, Guadagnino V, Nicchi V, Sanders M, Hollander G, Greengart A "Methemoglobin levels produced by organic nitrates in patients with coronary artery disease." J Clin Pharmacol 24 (1984):  160-4|Curry SC, Arnold-Capell P "Toxic effects of drugs used in the ICU. Nitroprusside, nitroglycerin, and angiotensin-converting enzyme inhibitors." Crit Care Clin 7 (1991):  555-81|Kaplan K, Davison R "Nitroglycerin and methemoglobinemia." Am J Cardiol 57 (1986):  1004|Saxon SA, Silverman ME "Effects of continuous infusion of intravenous nitroglycerin on methemoglobin levels." Am J Cardiol 56 (1985):  461-4|Gibson GR, Hunter JB, Raabe DS, Jr  Manjoney DL, Ittleman FP "Methemoglobinemia produced by high-dose intravenous nitroglycerin." Ann Intern Med 96 (1982):  615-6|Robicsek F "Acute methemoglobinemia during cardiopulmonary bypass caused by intravenous nitroglycerin infusion." J Thorac Cardiovasc Surg 90 (1985):  931-4|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):|Forsyth RJ, Moulden A "Methaemoglobinaemia after ingestion of amyl nitrite." Arch Dis Child 66 (1991):  152|Pierce JM, Nielsen MS "Acute acquired methaemoglobinaemia after amyl nitrite poisoning." BMJ 298 (1989):  1566|Sutton M, Jeffrey B "Acquired methemoglobinemia from amyl nitrate inhalation." J Emerg Nurs 18 (1992):  8-9|Sobey RJ, Campbell CM "A 37-year-old with amyl nitrite-induced methemoglobinemia." J Emerg Nurs 18 (1992):  11-3|Edwards RJ, Ujma J "Extreme methaemoglobinaemia secondary to recreational use of amyl nitrite." J Accid Emerg Med 12 (1995):  138-42|Machabert R, Testud F, Descotes J "Methaemoglobinaemia due to amyl nitrite inhalation: a case report." Hum Exp Toxicol 13 (1994):  313-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58669, 15837, 'Isosorbide dinitrate', 'Anemia', 'Some manufacturers and medical references consider the use of nitrates and nitrites to be contraindicated in patients with severe anemia.  Nitrates and nitrites can cause methemoglobinemia, primarily in high-dose intravenous therapy or acute poisoning and in patients with NADH reductase deficiency.  However, elevations of methemoglobin may also occur with commonly used dosages.  While probably not of routine clinical significance, the increases may be important in certain patient populations such as those with coronary insufficiency or anemia.', '3', 'Fibuch EE, Cecil WT, Reed WA "Methemoglobinemia associated with organic nitrate therapy." Anesth Analg 58 (1979):  521-3|Arsura E, Lichstein E, Guadagnino V, Nicchi V, Sanders M, Hollander G, Greengart A "Methemoglobin levels produced by organic nitrates in patients with coronary artery disease." J Clin Pharmacol 24 (1984):  160-4|Curry SC, Arnold-Capell P "Toxic effects of drugs used in the ICU. Nitroprusside, nitroglycerin, and angiotensin-converting enzyme inhibitors." Crit Care Clin 7 (1991):  555-81|Kaplan K, Davison R "Nitroglycerin and methemoglobinemia." Am J Cardiol 57 (1986):  1004|Saxon SA, Silverman ME "Effects of continuous infusion of intravenous nitroglycerin on methemoglobin levels." Am J Cardiol 56 (1985):  461-4|Gibson GR, Hunter JB, Raabe DS, Jr  Manjoney DL, Ittleman FP "Methemoglobinemia produced by high-dose intravenous nitroglycerin." Ann Intern Med 96 (1982):  615-6|Robicsek F "Acute methemoglobinemia during cardiopulmonary bypass caused by intravenous nitroglycerin infusion." J Thorac Cardiovasc Surg 90 (1985):  931-4|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):|Forsyth RJ, Moulden A "Methaemoglobinaemia after ingestion of amyl nitrite." Arch Dis Child 66 (1991):  152|Pierce JM, Nielsen MS "Acute acquired methaemoglobinaemia after amyl nitrite poisoning." BMJ 298 (1989):  1566|Sutton M, Jeffrey B "Acquired methemoglobinemia from amyl nitrate inhalation." J Emerg Nurs 18 (1992):  8-9|Sobey RJ, Campbell CM "A 37-year-old with amyl nitrite-induced methemoglobinemia." J Emerg Nurs 18 (1992):  11-3|Edwards RJ, Ujma J "Extreme methaemoglobinaemia secondary to recreational use of amyl nitrite." J Accid Emerg Med 12 (1995):  138-42|Machabert R, Testud F, Descotes J "Methaemoglobinaemia due to amyl nitrite inhalation: a case report." Hum Exp Toxicol 13 (1994):  313-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58670, 15838, 'Isosorbide dinitrate', 'Anemia', 'Some manufacturers and medical references consider the use of nitrates and nitrites to be contraindicated in patients with severe anemia.  Nitrates and nitrites can cause methemoglobinemia, primarily in high-dose intravenous therapy or acute poisoning and in patients with NADH reductase deficiency.  However, elevations of methemoglobin may also occur with commonly used dosages.  While probably not of routine clinical significance, the increases may be important in certain patient populations such as those with coronary insufficiency or anemia.', '3', 'Fibuch EE, Cecil WT, Reed WA "Methemoglobinemia associated with organic nitrate therapy." Anesth Analg 58 (1979):  521-3|Arsura E, Lichstein E, Guadagnino V, Nicchi V, Sanders M, Hollander G, Greengart A "Methemoglobin levels produced by organic nitrates in patients with coronary artery disease." J Clin Pharmacol 24 (1984):  160-4|Curry SC, Arnold-Capell P "Toxic effects of drugs used in the ICU. Nitroprusside, nitroglycerin, and angiotensin-converting enzyme inhibitors." Crit Care Clin 7 (1991):  555-81|Kaplan K, Davison R "Nitroglycerin and methemoglobinemia." Am J Cardiol 57 (1986):  1004|Saxon SA, Silverman ME "Effects of continuous infusion of intravenous nitroglycerin on methemoglobin levels." Am J Cardiol 56 (1985):  461-4|Gibson GR, Hunter JB, Raabe DS, Jr  Manjoney DL, Ittleman FP "Methemoglobinemia produced by high-dose intravenous nitroglycerin." Ann Intern Med 96 (1982):  615-6|Robicsek F "Acute methemoglobinemia during cardiopulmonary bypass caused by intravenous nitroglycerin infusion." J Thorac Cardiovasc Surg 90 (1985):  931-4|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):|Forsyth RJ, Moulden A "Methaemoglobinaemia after ingestion of amyl nitrite." Arch Dis Child 66 (1991):  152|Pierce JM, Nielsen MS "Acute acquired methaemoglobinaemia after amyl nitrite poisoning." BMJ 298 (1989):  1566|Sutton M, Jeffrey B "Acquired methemoglobinemia from amyl nitrate inhalation." J Emerg Nurs 18 (1992):  8-9|Sobey RJ, Campbell CM "A 37-year-old with amyl nitrite-induced methemoglobinemia." J Emerg Nurs 18 (1992):  11-3|Edwards RJ, Ujma J "Extreme methaemoglobinaemia secondary to recreational use of amyl nitrite." J Accid Emerg Med 12 (1995):  138-42|Machabert R, Testud F, Descotes J "Methaemoglobinaemia due to amyl nitrite inhalation: a case report." Hum Exp Toxicol 13 (1994):  313-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58671, 16808, 'Isosorbide dinitrate', 'Anemia', 'Some manufacturers and medical references consider the use of nitrates and nitrites to be contraindicated in patients with severe anemia.  Nitrates and nitrites can cause methemoglobinemia, primarily in high-dose intravenous therapy or acute poisoning and in patients with NADH reductase deficiency.  However, elevations of methemoglobin may also occur with commonly used dosages.  While probably not of routine clinical significance, the increases may be important in certain patient populations such as those with coronary insufficiency or anemia.', '3', 'Fibuch EE, Cecil WT, Reed WA "Methemoglobinemia associated with organic nitrate therapy." Anesth Analg 58 (1979):  521-3|Arsura E, Lichstein E, Guadagnino V, Nicchi V, Sanders M, Hollander G, Greengart A "Methemoglobin levels produced by organic nitrates in patients with coronary artery disease." J Clin Pharmacol 24 (1984):  160-4|Curry SC, Arnold-Capell P "Toxic effects of drugs used in the ICU. Nitroprusside, nitroglycerin, and angiotensin-converting enzyme inhibitors." Crit Care Clin 7 (1991):  555-81|Kaplan K, Davison R "Nitroglycerin and methemoglobinemia." Am J Cardiol 57 (1986):  1004|Saxon SA, Silverman ME "Effects of continuous infusion of intravenous nitroglycerin on methemoglobin levels." Am J Cardiol 56 (1985):  461-4|Gibson GR, Hunter JB, Raabe DS, Jr  Manjoney DL, Ittleman FP "Methemoglobinemia produced by high-dose intravenous nitroglycerin." Ann Intern Med 96 (1982):  615-6|Robicsek F "Acute methemoglobinemia during cardiopulmonary bypass caused by intravenous nitroglycerin infusion." J Thorac Cardiovasc Surg 90 (1985):  931-4|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):|Forsyth RJ, Moulden A "Methaemoglobinaemia after ingestion of amyl nitrite." Arch Dis Child 66 (1991):  152|Pierce JM, Nielsen MS "Acute acquired methaemoglobinaemia after amyl nitrite poisoning." BMJ 298 (1989):  1566|Sutton M, Jeffrey B "Acquired methemoglobinemia from amyl nitrate inhalation." J Emerg Nurs 18 (1992):  8-9|Sobey RJ, Campbell CM "A 37-year-old with amyl nitrite-induced methemoglobinemia." J Emerg Nurs 18 (1992):  11-3|Edwards RJ, Ujma J "Extreme methaemoglobinaemia secondary to recreational use of amyl nitrite." J Accid Emerg Med 12 (1995):  138-42|Machabert R, Testud F, Descotes J "Methaemoglobinaemia due to amyl nitrite inhalation: a case report." Hum Exp Toxicol 13 (1994):  313-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58672, 21002, 'Isosorbide dinitrate', 'Anemia', 'Some manufacturers and medical references consider the use of nitrates and nitrites to be contraindicated in patients with severe anemia.  Nitrates and nitrites can cause methemoglobinemia, primarily in high-dose intravenous therapy or acute poisoning and in patients with NADH reductase deficiency.  However, elevations of methemoglobin may also occur with commonly used dosages.  While probably not of routine clinical significance, the increases may be important in certain patient populations such as those with coronary insufficiency or anemia.', '3', 'Fibuch EE, Cecil WT, Reed WA "Methemoglobinemia associated with organic nitrate therapy." Anesth Analg 58 (1979):  521-3|Arsura E, Lichstein E, Guadagnino V, Nicchi V, Sanders M, Hollander G, Greengart A "Methemoglobin levels produced by organic nitrates in patients with coronary artery disease." J Clin Pharmacol 24 (1984):  160-4|Curry SC, Arnold-Capell P "Toxic effects of drugs used in the ICU. Nitroprusside, nitroglycerin, and angiotensin-converting enzyme inhibitors." Crit Care Clin 7 (1991):  555-81|Kaplan K, Davison R "Nitroglycerin and methemoglobinemia." Am J Cardiol 57 (1986):  1004|Saxon SA, Silverman ME "Effects of continuous infusion of intravenous nitroglycerin on methemoglobin levels." Am J Cardiol 56 (1985):  461-4|Gibson GR, Hunter JB, Raabe DS, Jr  Manjoney DL, Ittleman FP "Methemoglobinemia produced by high-dose intravenous nitroglycerin." Ann Intern Med 96 (1982):  615-6|Robicsek F "Acute methemoglobinemia during cardiopulmonary bypass caused by intravenous nitroglycerin infusion." J Thorac Cardiovasc Surg 90 (1985):  931-4|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):|Forsyth RJ, Moulden A "Methaemoglobinaemia after ingestion of amyl nitrite." Arch Dis Child 66 (1991):  152|Pierce JM, Nielsen MS "Acute acquired methaemoglobinaemia after amyl nitrite poisoning." BMJ 298 (1989):  1566|Sutton M, Jeffrey B "Acquired methemoglobinemia from amyl nitrate inhalation." J Emerg Nurs 18 (1992):  8-9|Sobey RJ, Campbell CM "A 37-year-old with amyl nitrite-induced methemoglobinemia." J Emerg Nurs 18 (1992):  11-3|Edwards RJ, Ujma J "Extreme methaemoglobinaemia secondary to recreational use of amyl nitrite." J Accid Emerg Med 12 (1995):  138-42|Machabert R, Testud F, Descotes J "Methaemoglobinaemia due to amyl nitrite inhalation: a case report." Hum Exp Toxicol 13 (1994):  313-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58673, 21007, 'Isosorbide dinitrate', 'Anemia', 'Some manufacturers and medical references consider the use of nitrates and nitrites to be contraindicated in patients with severe anemia.  Nitrates and nitrites can cause methemoglobinemia, primarily in high-dose intravenous therapy or acute poisoning and in patients with NADH reductase deficiency.  However, elevations of methemoglobin may also occur with commonly used dosages.  While probably not of routine clinical significance, the increases may be important in certain patient populations such as those with coronary insufficiency or anemia.', '3', 'Fibuch EE, Cecil WT, Reed WA "Methemoglobinemia associated with organic nitrate therapy." Anesth Analg 58 (1979):  521-3|Arsura E, Lichstein E, Guadagnino V, Nicchi V, Sanders M, Hollander G, Greengart A "Methemoglobin levels produced by organic nitrates in patients with coronary artery disease." J Clin Pharmacol 24 (1984):  160-4|Curry SC, Arnold-Capell P "Toxic effects of drugs used in the ICU. Nitroprusside, nitroglycerin, and angiotensin-converting enzyme inhibitors." Crit Care Clin 7 (1991):  555-81|Kaplan K, Davison R "Nitroglycerin and methemoglobinemia." Am J Cardiol 57 (1986):  1004|Saxon SA, Silverman ME "Effects of continuous infusion of intravenous nitroglycerin on methemoglobin levels." Am J Cardiol 56 (1985):  461-4|Gibson GR, Hunter JB, Raabe DS, Jr  Manjoney DL, Ittleman FP "Methemoglobinemia produced by high-dose intravenous nitroglycerin." Ann Intern Med 96 (1982):  615-6|Robicsek F "Acute methemoglobinemia during cardiopulmonary bypass caused by intravenous nitroglycerin infusion." J Thorac Cardiovasc Surg 90 (1985):  931-4|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):|Forsyth RJ, Moulden A "Methaemoglobinaemia after ingestion of amyl nitrite." Arch Dis Child 66 (1991):  152|Pierce JM, Nielsen MS "Acute acquired methaemoglobinaemia after amyl nitrite poisoning." BMJ 298 (1989):  1566|Sutton M, Jeffrey B "Acquired methemoglobinemia from amyl nitrate inhalation." J Emerg Nurs 18 (1992):  8-9|Sobey RJ, Campbell CM "A 37-year-old with amyl nitrite-induced methemoglobinemia." J Emerg Nurs 18 (1992):  11-3|Edwards RJ, Ujma J "Extreme methaemoglobinaemia secondary to recreational use of amyl nitrite." J Accid Emerg Med 12 (1995):  138-42|Machabert R, Testud F, Descotes J "Methaemoglobinaemia due to amyl nitrite inhalation: a case report." Hum Exp Toxicol 13 (1994):  313-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58674, 21008, 'Isosorbide dinitrate', 'Anemia', 'Some manufacturers and medical references consider the use of nitrates and nitrites to be contraindicated in patients with severe anemia.  Nitrates and nitrites can cause methemoglobinemia, primarily in high-dose intravenous therapy or acute poisoning and in patients with NADH reductase deficiency.  However, elevations of methemoglobin may also occur with commonly used dosages.  While probably not of routine clinical significance, the increases may be important in certain patient populations such as those with coronary insufficiency or anemia.', '3', 'Fibuch EE, Cecil WT, Reed WA "Methemoglobinemia associated with organic nitrate therapy." Anesth Analg 58 (1979):  521-3|Arsura E, Lichstein E, Guadagnino V, Nicchi V, Sanders M, Hollander G, Greengart A "Methemoglobin levels produced by organic nitrates in patients with coronary artery disease." J Clin Pharmacol 24 (1984):  160-4|Curry SC, Arnold-Capell P "Toxic effects of drugs used in the ICU. Nitroprusside, nitroglycerin, and angiotensin-converting enzyme inhibitors." Crit Care Clin 7 (1991):  555-81|Kaplan K, Davison R "Nitroglycerin and methemoglobinemia." Am J Cardiol 57 (1986):  1004|Saxon SA, Silverman ME "Effects of continuous infusion of intravenous nitroglycerin on methemoglobin levels." Am J Cardiol 56 (1985):  461-4|Gibson GR, Hunter JB, Raabe DS, Jr  Manjoney DL, Ittleman FP "Methemoglobinemia produced by high-dose intravenous nitroglycerin." Ann Intern Med 96 (1982):  615-6|Robicsek F "Acute methemoglobinemia during cardiopulmonary bypass caused by intravenous nitroglycerin infusion." J Thorac Cardiovasc Surg 90 (1985):  931-4|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):|Forsyth RJ, Moulden A "Methaemoglobinaemia after ingestion of amyl nitrite." Arch Dis Child 66 (1991):  152|Pierce JM, Nielsen MS "Acute acquired methaemoglobinaemia after amyl nitrite poisoning." BMJ 298 (1989):  1566|Sutton M, Jeffrey B "Acquired methemoglobinemia from amyl nitrate inhalation." J Emerg Nurs 18 (1992):  8-9|Sobey RJ, Campbell CM "A 37-year-old with amyl nitrite-induced methemoglobinemia." J Emerg Nurs 18 (1992):  11-3|Edwards RJ, Ujma J "Extreme methaemoglobinaemia secondary to recreational use of amyl nitrite." J Accid Emerg Med 12 (1995):  138-42|Machabert R, Testud F, Descotes J "Methaemoglobinaemia due to amyl nitrite inhalation: a case report." Hum Exp Toxicol 13 (1994):  313-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58675, 21031, 'Isosorbide dinitrate', 'Anemia', 'Some manufacturers and medical references consider the use of nitrates and nitrites to be contraindicated in patients with severe anemia.  Nitrates and nitrites can cause methemoglobinemia, primarily in high-dose intravenous therapy or acute poisoning and in patients with NADH reductase deficiency.  However, elevations of methemoglobin may also occur with commonly used dosages.  While probably not of routine clinical significance, the increases may be important in certain patient populations such as those with coronary insufficiency or anemia.', '3', 'Fibuch EE, Cecil WT, Reed WA "Methemoglobinemia associated with organic nitrate therapy." Anesth Analg 58 (1979):  521-3|Arsura E, Lichstein E, Guadagnino V, Nicchi V, Sanders M, Hollander G, Greengart A "Methemoglobin levels produced by organic nitrates in patients with coronary artery disease." J Clin Pharmacol 24 (1984):  160-4|Curry SC, Arnold-Capell P "Toxic effects of drugs used in the ICU. Nitroprusside, nitroglycerin, and angiotensin-converting enzyme inhibitors." Crit Care Clin 7 (1991):  555-81|Kaplan K, Davison R "Nitroglycerin and methemoglobinemia." Am J Cardiol 57 (1986):  1004|Saxon SA, Silverman ME "Effects of continuous infusion of intravenous nitroglycerin on methemoglobin levels." Am J Cardiol 56 (1985):  461-4|Gibson GR, Hunter JB, Raabe DS, Jr  Manjoney DL, Ittleman FP "Methemoglobinemia produced by high-dose intravenous nitroglycerin." Ann Intern Med 96 (1982):  615-6|Robicsek F "Acute methemoglobinemia during cardiopulmonary bypass caused by intravenous nitroglycerin infusion." J Thorac Cardiovasc Surg 90 (1985):  931-4|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):|Forsyth RJ, Moulden A "Methaemoglobinaemia after ingestion of amyl nitrite." Arch Dis Child 66 (1991):  152|Pierce JM, Nielsen MS "Acute acquired methaemoglobinaemia after amyl nitrite poisoning." BMJ 298 (1989):  1566|Sutton M, Jeffrey B "Acquired methemoglobinemia from amyl nitrate inhalation." J Emerg Nurs 18 (1992):  8-9|Sobey RJ, Campbell CM "A 37-year-old with amyl nitrite-induced methemoglobinemia." J Emerg Nurs 18 (1992):  11-3|Edwards RJ, Ujma J "Extreme methaemoglobinaemia secondary to recreational use of amyl nitrite." J Accid Emerg Med 12 (1995):  138-42|Machabert R, Testud F, Descotes J "Methaemoglobinaemia due to amyl nitrite inhalation: a case report." Hum Exp Toxicol 13 (1994):  313-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58676, 30354, 'Isosorbide dinitrate', 'Anemia', 'Some manufacturers and medical references consider the use of nitrates and nitrites to be contraindicated in patients with severe anemia.  Nitrates and nitrites can cause methemoglobinemia, primarily in high-dose intravenous therapy or acute poisoning and in patients with NADH reductase deficiency.  However, elevations of methemoglobin may also occur with commonly used dosages.  While probably not of routine clinical significance, the increases may be important in certain patient populations such as those with coronary insufficiency or anemia.', '3', 'Fibuch EE, Cecil WT, Reed WA "Methemoglobinemia associated with organic nitrate therapy." Anesth Analg 58 (1979):  521-3|Arsura E, Lichstein E, Guadagnino V, Nicchi V, Sanders M, Hollander G, Greengart A "Methemoglobin levels produced by organic nitrates in patients with coronary artery disease." J Clin Pharmacol 24 (1984):  160-4|Curry SC, Arnold-Capell P "Toxic effects of drugs used in the ICU. Nitroprusside, nitroglycerin, and angiotensin-converting enzyme inhibitors." Crit Care Clin 7 (1991):  555-81|Kaplan K, Davison R "Nitroglycerin and methemoglobinemia." Am J Cardiol 57 (1986):  1004|Saxon SA, Silverman ME "Effects of continuous infusion of intravenous nitroglycerin on methemoglobin levels." Am J Cardiol 56 (1985):  461-4|Gibson GR, Hunter JB, Raabe DS, Jr  Manjoney DL, Ittleman FP "Methemoglobinemia produced by high-dose intravenous nitroglycerin." Ann Intern Med 96 (1982):  615-6|Robicsek F "Acute methemoglobinemia during cardiopulmonary bypass caused by intravenous nitroglycerin infusion." J Thorac Cardiovasc Surg 90 (1985):  931-4|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):|Forsyth RJ, Moulden A "Methaemoglobinaemia after ingestion of amyl nitrite." Arch Dis Child 66 (1991):  152|Pierce JM, Nielsen MS "Acute acquired methaemoglobinaemia after amyl nitrite poisoning." BMJ 298 (1989):  1566|Sutton M, Jeffrey B "Acquired methemoglobinemia from amyl nitrate inhalation." J Emerg Nurs 18 (1992):  8-9|Sobey RJ, Campbell CM "A 37-year-old with amyl nitrite-induced methemoglobinemia." J Emerg Nurs 18 (1992):  11-3|Edwards RJ, Ujma J "Extreme methaemoglobinaemia secondary to recreational use of amyl nitrite." J Accid Emerg Med 12 (1995):  138-42|Machabert R, Testud F, Descotes J "Methaemoglobinaemia due to amyl nitrite inhalation: a case report." Hum Exp Toxicol 13 (1994):  313-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58677, 2053, 'Isosorbide dinitrate', 'Diseases requiring hemodialysis', 'The combined effect of organic nitrates or nitrites with hemodialysis, which often lowers blood pressure, can cause life-threatening hypotension.  Therapy with these agents should be administered cautiously in patients requiring hemodialysis.  The medication should be withheld before undergoing dialysis, and hemodynamic stability should be established prior to resumption of medication following dialysis.  Nitroglycerin and isosorbide dinitrate are moderately dialyzed.', '3', 'Imamura T, Tamura K, Taguchi T, Minoda M, Seita M "Reduction of nitroglycerin and isosorbide dinitrate by hemodialysis in refractory angina pectoris after acute myocardial infarction." Am J Cardiol 61 (1988):  954-5|Dunetz PS "Dialysis patients and nitrates." Nursing 22 (1992):  4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58678, 3639, 'Isosorbide dinitrate', 'Diseases requiring hemodialysis', 'The combined effect of organic nitrates or nitrites with hemodialysis, which often lowers blood pressure, can cause life-threatening hypotension.  Therapy with these agents should be administered cautiously in patients requiring hemodialysis.  The medication should be withheld before undergoing dialysis, and hemodynamic stability should be established prior to resumption of medication following dialysis.  Nitroglycerin and isosorbide dinitrate are moderately dialyzed.', '3', 'Imamura T, Tamura K, Taguchi T, Minoda M, Seita M "Reduction of nitroglycerin and isosorbide dinitrate by hemodialysis in refractory angina pectoris after acute myocardial infarction." Am J Cardiol 61 (1988):  954-5|Dunetz PS "Dialysis patients and nitrates." Nursing 22 (1992):  4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58679, 3707, 'Isosorbide dinitrate', 'Diseases requiring hemodialysis', 'The combined effect of organic nitrates or nitrites with hemodialysis, which often lowers blood pressure, can cause life-threatening hypotension.  Therapy with these agents should be administered cautiously in patients requiring hemodialysis.  The medication should be withheld before undergoing dialysis, and hemodynamic stability should be established prior to resumption of medication following dialysis.  Nitroglycerin and isosorbide dinitrate are moderately dialyzed.', '3', 'Imamura T, Tamura K, Taguchi T, Minoda M, Seita M "Reduction of nitroglycerin and isosorbide dinitrate by hemodialysis in refractory angina pectoris after acute myocardial infarction." Am J Cardiol 61 (1988):  954-5|Dunetz PS "Dialysis patients and nitrates." Nursing 22 (1992):  4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58680, 3708, 'Isosorbide dinitrate', 'Diseases requiring hemodialysis', 'The combined effect of organic nitrates or nitrites with hemodialysis, which often lowers blood pressure, can cause life-threatening hypotension.  Therapy with these agents should be administered cautiously in patients requiring hemodialysis.  The medication should be withheld before undergoing dialysis, and hemodynamic stability should be established prior to resumption of medication following dialysis.  Nitroglycerin and isosorbide dinitrate are moderately dialyzed.', '3', 'Imamura T, Tamura K, Taguchi T, Minoda M, Seita M "Reduction of nitroglycerin and isosorbide dinitrate by hemodialysis in refractory angina pectoris after acute myocardial infarction." Am J Cardiol 61 (1988):  954-5|Dunetz PS "Dialysis patients and nitrates." Nursing 22 (1992):  4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58681, 3709, 'Isosorbide dinitrate', 'Diseases requiring hemodialysis', 'The combined effect of organic nitrates or nitrites with hemodialysis, which often lowers blood pressure, can cause life-threatening hypotension.  Therapy with these agents should be administered cautiously in patients requiring hemodialysis.  The medication should be withheld before undergoing dialysis, and hemodynamic stability should be established prior to resumption of medication following dialysis.  Nitroglycerin and isosorbide dinitrate are moderately dialyzed.', '3', 'Imamura T, Tamura K, Taguchi T, Minoda M, Seita M "Reduction of nitroglycerin and isosorbide dinitrate by hemodialysis in refractory angina pectoris after acute myocardial infarction." Am J Cardiol 61 (1988):  954-5|Dunetz PS "Dialysis patients and nitrates." Nursing 22 (1992):  4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58682, 3984, 'Isosorbide dinitrate', 'Diseases requiring hemodialysis', 'The combined effect of organic nitrates or nitrites with hemodialysis, which often lowers blood pressure, can cause life-threatening hypotension.  Therapy with these agents should be administered cautiously in patients requiring hemodialysis.  The medication should be withheld before undergoing dialysis, and hemodynamic stability should be established prior to resumption of medication following dialysis.  Nitroglycerin and isosorbide dinitrate are moderately dialyzed.', '3', 'Imamura T, Tamura K, Taguchi T, Minoda M, Seita M "Reduction of nitroglycerin and isosorbide dinitrate by hemodialysis in refractory angina pectoris after acute myocardial infarction." Am J Cardiol 61 (1988):  954-5|Dunetz PS "Dialysis patients and nitrates." Nursing 22 (1992):  4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58683, 6608, 'Isosorbide dinitrate', 'Diseases requiring hemodialysis', 'The combined effect of organic nitrates or nitrites with hemodialysis, which often lowers blood pressure, can cause life-threatening hypotension.  Therapy with these agents should be administered cautiously in patients requiring hemodialysis.  The medication should be withheld before undergoing dialysis, and hemodynamic stability should be established prior to resumption of medication following dialysis.  Nitroglycerin and isosorbide dinitrate are moderately dialyzed.', '3', 'Imamura T, Tamura K, Taguchi T, Minoda M, Seita M "Reduction of nitroglycerin and isosorbide dinitrate by hemodialysis in refractory angina pectoris after acute myocardial infarction." Am J Cardiol 61 (1988):  954-5|Dunetz PS "Dialysis patients and nitrates." Nursing 22 (1992):  4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58684, 14162, 'Isosorbide dinitrate', 'Diseases requiring hemodialysis', 'The combined effect of organic nitrates or nitrites with hemodialysis, which often lowers blood pressure, can cause life-threatening hypotension.  Therapy with these agents should be administered cautiously in patients requiring hemodialysis.  The medication should be withheld before undergoing dialysis, and hemodynamic stability should be established prior to resumption of medication following dialysis.  Nitroglycerin and isosorbide dinitrate are moderately dialyzed.', '3', 'Imamura T, Tamura K, Taguchi T, Minoda M, Seita M "Reduction of nitroglycerin and isosorbide dinitrate by hemodialysis in refractory angina pectoris after acute myocardial infarction." Am J Cardiol 61 (1988):  954-5|Dunetz PS "Dialysis patients and nitrates." Nursing 22 (1992):  4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58685, 15837, 'Isosorbide dinitrate', 'Diseases requiring hemodialysis', 'The combined effect of organic nitrates or nitrites with hemodialysis, which often lowers blood pressure, can cause life-threatening hypotension.  Therapy with these agents should be administered cautiously in patients requiring hemodialysis.  The medication should be withheld before undergoing dialysis, and hemodynamic stability should be established prior to resumption of medication following dialysis.  Nitroglycerin and isosorbide dinitrate are moderately dialyzed.', '3', 'Imamura T, Tamura K, Taguchi T, Minoda M, Seita M "Reduction of nitroglycerin and isosorbide dinitrate by hemodialysis in refractory angina pectoris after acute myocardial infarction." Am J Cardiol 61 (1988):  954-5|Dunetz PS "Dialysis patients and nitrates." Nursing 22 (1992):  4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58686, 15838, 'Isosorbide dinitrate', 'Diseases requiring hemodialysis', 'The combined effect of organic nitrates or nitrites with hemodialysis, which often lowers blood pressure, can cause life-threatening hypotension.  Therapy with these agents should be administered cautiously in patients requiring hemodialysis.  The medication should be withheld before undergoing dialysis, and hemodynamic stability should be established prior to resumption of medication following dialysis.  Nitroglycerin and isosorbide dinitrate are moderately dialyzed.', '3', 'Imamura T, Tamura K, Taguchi T, Minoda M, Seita M "Reduction of nitroglycerin and isosorbide dinitrate by hemodialysis in refractory angina pectoris after acute myocardial infarction." Am J Cardiol 61 (1988):  954-5|Dunetz PS "Dialysis patients and nitrates." Nursing 22 (1992):  4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58687, 16808, 'Isosorbide dinitrate', 'Diseases requiring hemodialysis', 'The combined effect of organic nitrates or nitrites with hemodialysis, which often lowers blood pressure, can cause life-threatening hypotension.  Therapy with these agents should be administered cautiously in patients requiring hemodialysis.  The medication should be withheld before undergoing dialysis, and hemodynamic stability should be established prior to resumption of medication following dialysis.  Nitroglycerin and isosorbide dinitrate are moderately dialyzed.', '3', 'Imamura T, Tamura K, Taguchi T, Minoda M, Seita M "Reduction of nitroglycerin and isosorbide dinitrate by hemodialysis in refractory angina pectoris after acute myocardial infarction." Am J Cardiol 61 (1988):  954-5|Dunetz PS "Dialysis patients and nitrates." Nursing 22 (1992):  4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58688, 21002, 'Isosorbide dinitrate', 'Diseases requiring hemodialysis', 'The combined effect of organic nitrates or nitrites with hemodialysis, which often lowers blood pressure, can cause life-threatening hypotension.  Therapy with these agents should be administered cautiously in patients requiring hemodialysis.  The medication should be withheld before undergoing dialysis, and hemodynamic stability should be established prior to resumption of medication following dialysis.  Nitroglycerin and isosorbide dinitrate are moderately dialyzed.', '3', 'Imamura T, Tamura K, Taguchi T, Minoda M, Seita M "Reduction of nitroglycerin and isosorbide dinitrate by hemodialysis in refractory angina pectoris after acute myocardial infarction." Am J Cardiol 61 (1988):  954-5|Dunetz PS "Dialysis patients and nitrates." Nursing 22 (1992):  4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58689, 21007, 'Isosorbide dinitrate', 'Diseases requiring hemodialysis', 'The combined effect of organic nitrates or nitrites with hemodialysis, which often lowers blood pressure, can cause life-threatening hypotension.  Therapy with these agents should be administered cautiously in patients requiring hemodialysis.  The medication should be withheld before undergoing dialysis, and hemodynamic stability should be established prior to resumption of medication following dialysis.  Nitroglycerin and isosorbide dinitrate are moderately dialyzed.', '3', 'Imamura T, Tamura K, Taguchi T, Minoda M, Seita M "Reduction of nitroglycerin and isosorbide dinitrate by hemodialysis in refractory angina pectoris after acute myocardial infarction." Am J Cardiol 61 (1988):  954-5|Dunetz PS "Dialysis patients and nitrates." Nursing 22 (1992):  4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58690, 21008, 'Isosorbide dinitrate', 'Diseases requiring hemodialysis', 'The combined effect of organic nitrates or nitrites with hemodialysis, which often lowers blood pressure, can cause life-threatening hypotension.  Therapy with these agents should be administered cautiously in patients requiring hemodialysis.  The medication should be withheld before undergoing dialysis, and hemodynamic stability should be established prior to resumption of medication following dialysis.  Nitroglycerin and isosorbide dinitrate are moderately dialyzed.', '3', 'Imamura T, Tamura K, Taguchi T, Minoda M, Seita M "Reduction of nitroglycerin and isosorbide dinitrate by hemodialysis in refractory angina pectoris after acute myocardial infarction." Am J Cardiol 61 (1988):  954-5|Dunetz PS "Dialysis patients and nitrates." Nursing 22 (1992):  4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58691, 21031, 'Isosorbide dinitrate', 'Diseases requiring hemodialysis', 'The combined effect of organic nitrates or nitrites with hemodialysis, which often lowers blood pressure, can cause life-threatening hypotension.  Therapy with these agents should be administered cautiously in patients requiring hemodialysis.  The medication should be withheld before undergoing dialysis, and hemodynamic stability should be established prior to resumption of medication following dialysis.  Nitroglycerin and isosorbide dinitrate are moderately dialyzed.', '3', 'Imamura T, Tamura K, Taguchi T, Minoda M, Seita M "Reduction of nitroglycerin and isosorbide dinitrate by hemodialysis in refractory angina pectoris after acute myocardial infarction." Am J Cardiol 61 (1988):  954-5|Dunetz PS "Dialysis patients and nitrates." Nursing 22 (1992):  4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58692, 30354, 'Isosorbide dinitrate', 'Diseases requiring hemodialysis', 'The combined effect of organic nitrates or nitrites with hemodialysis, which often lowers blood pressure, can cause life-threatening hypotension.  Therapy with these agents should be administered cautiously in patients requiring hemodialysis.  The medication should be withheld before undergoing dialysis, and hemodynamic stability should be established prior to resumption of medication following dialysis.  Nitroglycerin and isosorbide dinitrate are moderately dialyzed.', '3', 'Imamura T, Tamura K, Taguchi T, Minoda M, Seita M "Reduction of nitroglycerin and isosorbide dinitrate by hemodialysis in refractory angina pectoris after acute myocardial infarction." Am J Cardiol 61 (1988):  954-5|Dunetz PS "Dialysis patients and nitrates." Nursing 22 (1992):  4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58693, 2053, 'Isosorbide dinitrate', 'Hypotension', 'Organic nitrates and nitrites may cause severe hypotension, syncope and shock, even with small doses.  Hypotension induced by these agents may be accompanied by paradoxical bradycardia and increased angina pectoris.  Therapy with nitrates and nitrites should be administered cautiously in patients who are volume-depleted or hypotensive (e.g., systolic blood pressure <90 mm Hg) or who, because of inadequate circulation to the brain or to other vital organs, would be unusually compromised by undue hypotension.  Patients should be in a sitting or recumbent position during and immediately after drug administration, and monitored for symptoms of severe hypotension such as nausea, vomiting, weakness, pallor, perspiration, and syncope.  Nitrate or nitrite therapy is considered contraindicated in patients with acute circulatory failure or shock.', '3', 'Purvin VA, Dunn DW "Nitrate-induced transient ischemic attacks." South Med J 74 (1981):  1130-1|Buckley R, Roberts R "Symptomatic bradycardia following the administration of sublingual nitroglycerin." Am J Emerg Med 11 (1993):  253-5|von Arnim T, Autenrieth G, Bolte HD "Acute myocardial infarction during continuous electrocardiographic ST segment recording. Possible role of bradycardia and hypotension induced by glyceryl trinitrate." Br Heart J 51 (1984):  575-7|Lancaster L, Fenster PE "Complete heart block after sublingual nitroglycerin." Chest 84 (1983):  111-2|Ong EA, Bass S "Nitroglycerin-induced bradycardia and hypotension in acute myocardial infarction." Chest 77 (1980):  244|Cunningham J "Hypotension following administration of sublingual nitroglycerin ." Heart Lung 8 (1979):  364|Nemerovski M, Shah PK "Syndrome of severe bradycardia and hypotension following sublingual nitroglycerin administration." Cardiology 67 (1981):  180-9|Brandes W, Santiago T, Limacher M "Nitroglycerin-induced hypotension, bradycardia, and asystole: report of a case and review of the literature." Clin Cardiol 13 (1990):  741-4|"Product Information. Isordil (isosorbide dinitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. ISMO (isosorbide mononitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58694, 3639, 'Isosorbide dinitrate', 'Hypotension', 'Organic nitrates and nitrites may cause severe hypotension, syncope and shock, even with small doses.  Hypotension induced by these agents may be accompanied by paradoxical bradycardia and increased angina pectoris.  Therapy with nitrates and nitrites should be administered cautiously in patients who are volume-depleted or hypotensive (e.g., systolic blood pressure <90 mm Hg) or who, because of inadequate circulation to the brain or to other vital organs, would be unusually compromised by undue hypotension.  Patients should be in a sitting or recumbent position during and immediately after drug administration, and monitored for symptoms of severe hypotension such as nausea, vomiting, weakness, pallor, perspiration, and syncope.  Nitrate or nitrite therapy is considered contraindicated in patients with acute circulatory failure or shock.', '3', 'Purvin VA, Dunn DW "Nitrate-induced transient ischemic attacks." South Med J 74 (1981):  1130-1|Buckley R, Roberts R "Symptomatic bradycardia following the administration of sublingual nitroglycerin." Am J Emerg Med 11 (1993):  253-5|von Arnim T, Autenrieth G, Bolte HD "Acute myocardial infarction during continuous electrocardiographic ST segment recording. Possible role of bradycardia and hypotension induced by glyceryl trinitrate." Br Heart J 51 (1984):  575-7|Lancaster L, Fenster PE "Complete heart block after sublingual nitroglycerin." Chest 84 (1983):  111-2|Ong EA, Bass S "Nitroglycerin-induced bradycardia and hypotension in acute myocardial infarction." Chest 77 (1980):  244|Cunningham J "Hypotension following administration of sublingual nitroglycerin ." Heart Lung 8 (1979):  364|Nemerovski M, Shah PK "Syndrome of severe bradycardia and hypotension following sublingual nitroglycerin administration." Cardiology 67 (1981):  180-9|Brandes W, Santiago T, Limacher M "Nitroglycerin-induced hypotension, bradycardia, and asystole: report of a case and review of the literature." Clin Cardiol 13 (1990):  741-4|"Product Information. Isordil (isosorbide dinitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. ISMO (isosorbide mononitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58695, 3707, 'Isosorbide dinitrate', 'Hypotension', 'Organic nitrates and nitrites may cause severe hypotension, syncope and shock, even with small doses.  Hypotension induced by these agents may be accompanied by paradoxical bradycardia and increased angina pectoris.  Therapy with nitrates and nitrites should be administered cautiously in patients who are volume-depleted or hypotensive (e.g., systolic blood pressure <90 mm Hg) or who, because of inadequate circulation to the brain or to other vital organs, would be unusually compromised by undue hypotension.  Patients should be in a sitting or recumbent position during and immediately after drug administration, and monitored for symptoms of severe hypotension such as nausea, vomiting, weakness, pallor, perspiration, and syncope.  Nitrate or nitrite therapy is considered contraindicated in patients with acute circulatory failure or shock.', '3', 'Purvin VA, Dunn DW "Nitrate-induced transient ischemic attacks." South Med J 74 (1981):  1130-1|Buckley R, Roberts R "Symptomatic bradycardia following the administration of sublingual nitroglycerin." Am J Emerg Med 11 (1993):  253-5|von Arnim T, Autenrieth G, Bolte HD "Acute myocardial infarction during continuous electrocardiographic ST segment recording. Possible role of bradycardia and hypotension induced by glyceryl trinitrate." Br Heart J 51 (1984):  575-7|Lancaster L, Fenster PE "Complete heart block after sublingual nitroglycerin." Chest 84 (1983):  111-2|Ong EA, Bass S "Nitroglycerin-induced bradycardia and hypotension in acute myocardial infarction." Chest 77 (1980):  244|Cunningham J "Hypotension following administration of sublingual nitroglycerin ." Heart Lung 8 (1979):  364|Nemerovski M, Shah PK "Syndrome of severe bradycardia and hypotension following sublingual nitroglycerin administration." Cardiology 67 (1981):  180-9|Brandes W, Santiago T, Limacher M "Nitroglycerin-induced hypotension, bradycardia, and asystole: report of a case and review of the literature." Clin Cardiol 13 (1990):  741-4|"Product Information. Isordil (isosorbide dinitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. ISMO (isosorbide mononitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58696, 3708, 'Isosorbide dinitrate', 'Hypotension', 'Organic nitrates and nitrites may cause severe hypotension, syncope and shock, even with small doses.  Hypotension induced by these agents may be accompanied by paradoxical bradycardia and increased angina pectoris.  Therapy with nitrates and nitrites should be administered cautiously in patients who are volume-depleted or hypotensive (e.g., systolic blood pressure <90 mm Hg) or who, because of inadequate circulation to the brain or to other vital organs, would be unusually compromised by undue hypotension.  Patients should be in a sitting or recumbent position during and immediately after drug administration, and monitored for symptoms of severe hypotension such as nausea, vomiting, weakness, pallor, perspiration, and syncope.  Nitrate or nitrite therapy is considered contraindicated in patients with acute circulatory failure or shock.', '3', 'Purvin VA, Dunn DW "Nitrate-induced transient ischemic attacks." South Med J 74 (1981):  1130-1|Buckley R, Roberts R "Symptomatic bradycardia following the administration of sublingual nitroglycerin." Am J Emerg Med 11 (1993):  253-5|von Arnim T, Autenrieth G, Bolte HD "Acute myocardial infarction during continuous electrocardiographic ST segment recording. Possible role of bradycardia and hypotension induced by glyceryl trinitrate." Br Heart J 51 (1984):  575-7|Lancaster L, Fenster PE "Complete heart block after sublingual nitroglycerin." Chest 84 (1983):  111-2|Ong EA, Bass S "Nitroglycerin-induced bradycardia and hypotension in acute myocardial infarction." Chest 77 (1980):  244|Cunningham J "Hypotension following administration of sublingual nitroglycerin ." Heart Lung 8 (1979):  364|Nemerovski M, Shah PK "Syndrome of severe bradycardia and hypotension following sublingual nitroglycerin administration." Cardiology 67 (1981):  180-9|Brandes W, Santiago T, Limacher M "Nitroglycerin-induced hypotension, bradycardia, and asystole: report of a case and review of the literature." Clin Cardiol 13 (1990):  741-4|"Product Information. Isordil (isosorbide dinitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. ISMO (isosorbide mononitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58697, 3709, 'Isosorbide dinitrate', 'Hypotension', 'Organic nitrates and nitrites may cause severe hypotension, syncope and shock, even with small doses.  Hypotension induced by these agents may be accompanied by paradoxical bradycardia and increased angina pectoris.  Therapy with nitrates and nitrites should be administered cautiously in patients who are volume-depleted or hypotensive (e.g., systolic blood pressure <90 mm Hg) or who, because of inadequate circulation to the brain or to other vital organs, would be unusually compromised by undue hypotension.  Patients should be in a sitting or recumbent position during and immediately after drug administration, and monitored for symptoms of severe hypotension such as nausea, vomiting, weakness, pallor, perspiration, and syncope.  Nitrate or nitrite therapy is considered contraindicated in patients with acute circulatory failure or shock.', '3', 'Purvin VA, Dunn DW "Nitrate-induced transient ischemic attacks." South Med J 74 (1981):  1130-1|Buckley R, Roberts R "Symptomatic bradycardia following the administration of sublingual nitroglycerin." Am J Emerg Med 11 (1993):  253-5|von Arnim T, Autenrieth G, Bolte HD "Acute myocardial infarction during continuous electrocardiographic ST segment recording. Possible role of bradycardia and hypotension induced by glyceryl trinitrate." Br Heart J 51 (1984):  575-7|Lancaster L, Fenster PE "Complete heart block after sublingual nitroglycerin." Chest 84 (1983):  111-2|Ong EA, Bass S "Nitroglycerin-induced bradycardia and hypotension in acute myocardial infarction." Chest 77 (1980):  244|Cunningham J "Hypotension following administration of sublingual nitroglycerin ." Heart Lung 8 (1979):  364|Nemerovski M, Shah PK "Syndrome of severe bradycardia and hypotension following sublingual nitroglycerin administration." Cardiology 67 (1981):  180-9|Brandes W, Santiago T, Limacher M "Nitroglycerin-induced hypotension, bradycardia, and asystole: report of a case and review of the literature." Clin Cardiol 13 (1990):  741-4|"Product Information. Isordil (isosorbide dinitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. ISMO (isosorbide mononitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58698, 3984, 'Isosorbide dinitrate', 'Hypotension', 'Organic nitrates and nitrites may cause severe hypotension, syncope and shock, even with small doses.  Hypotension induced by these agents may be accompanied by paradoxical bradycardia and increased angina pectoris.  Therapy with nitrates and nitrites should be administered cautiously in patients who are volume-depleted or hypotensive (e.g., systolic blood pressure <90 mm Hg) or who, because of inadequate circulation to the brain or to other vital organs, would be unusually compromised by undue hypotension.  Patients should be in a sitting or recumbent position during and immediately after drug administration, and monitored for symptoms of severe hypotension such as nausea, vomiting, weakness, pallor, perspiration, and syncope.  Nitrate or nitrite therapy is considered contraindicated in patients with acute circulatory failure or shock.', '3', 'Purvin VA, Dunn DW "Nitrate-induced transient ischemic attacks." South Med J 74 (1981):  1130-1|Buckley R, Roberts R "Symptomatic bradycardia following the administration of sublingual nitroglycerin." Am J Emerg Med 11 (1993):  253-5|von Arnim T, Autenrieth G, Bolte HD "Acute myocardial infarction during continuous electrocardiographic ST segment recording. Possible role of bradycardia and hypotension induced by glyceryl trinitrate." Br Heart J 51 (1984):  575-7|Lancaster L, Fenster PE "Complete heart block after sublingual nitroglycerin." Chest 84 (1983):  111-2|Ong EA, Bass S "Nitroglycerin-induced bradycardia and hypotension in acute myocardial infarction." Chest 77 (1980):  244|Cunningham J "Hypotension following administration of sublingual nitroglycerin ." Heart Lung 8 (1979):  364|Nemerovski M, Shah PK "Syndrome of severe bradycardia and hypotension following sublingual nitroglycerin administration." Cardiology 67 (1981):  180-9|Brandes W, Santiago T, Limacher M "Nitroglycerin-induced hypotension, bradycardia, and asystole: report of a case and review of the literature." Clin Cardiol 13 (1990):  741-4|"Product Information. Isordil (isosorbide dinitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. ISMO (isosorbide mononitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58699, 6608, 'Isosorbide dinitrate', 'Hypotension', 'Organic nitrates and nitrites may cause severe hypotension, syncope and shock, even with small doses.  Hypotension induced by these agents may be accompanied by paradoxical bradycardia and increased angina pectoris.  Therapy with nitrates and nitrites should be administered cautiously in patients who are volume-depleted or hypotensive (e.g., systolic blood pressure <90 mm Hg) or who, because of inadequate circulation to the brain or to other vital organs, would be unusually compromised by undue hypotension.  Patients should be in a sitting or recumbent position during and immediately after drug administration, and monitored for symptoms of severe hypotension such as nausea, vomiting, weakness, pallor, perspiration, and syncope.  Nitrate or nitrite therapy is considered contraindicated in patients with acute circulatory failure or shock.', '3', 'Purvin VA, Dunn DW "Nitrate-induced transient ischemic attacks." South Med J 74 (1981):  1130-1|Buckley R, Roberts R "Symptomatic bradycardia following the administration of sublingual nitroglycerin." Am J Emerg Med 11 (1993):  253-5|von Arnim T, Autenrieth G, Bolte HD "Acute myocardial infarction during continuous electrocardiographic ST segment recording. Possible role of bradycardia and hypotension induced by glyceryl trinitrate." Br Heart J 51 (1984):  575-7|Lancaster L, Fenster PE "Complete heart block after sublingual nitroglycerin." Chest 84 (1983):  111-2|Ong EA, Bass S "Nitroglycerin-induced bradycardia and hypotension in acute myocardial infarction." Chest 77 (1980):  244|Cunningham J "Hypotension following administration of sublingual nitroglycerin ." Heart Lung 8 (1979):  364|Nemerovski M, Shah PK "Syndrome of severe bradycardia and hypotension following sublingual nitroglycerin administration." Cardiology 67 (1981):  180-9|Brandes W, Santiago T, Limacher M "Nitroglycerin-induced hypotension, bradycardia, and asystole: report of a case and review of the literature." Clin Cardiol 13 (1990):  741-4|"Product Information. Isordil (isosorbide dinitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. ISMO (isosorbide mononitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58700, 14162, 'Isosorbide dinitrate', 'Hypotension', 'Organic nitrates and nitrites may cause severe hypotension, syncope and shock, even with small doses.  Hypotension induced by these agents may be accompanied by paradoxical bradycardia and increased angina pectoris.  Therapy with nitrates and nitrites should be administered cautiously in patients who are volume-depleted or hypotensive (e.g., systolic blood pressure <90 mm Hg) or who, because of inadequate circulation to the brain or to other vital organs, would be unusually compromised by undue hypotension.  Patients should be in a sitting or recumbent position during and immediately after drug administration, and monitored for symptoms of severe hypotension such as nausea, vomiting, weakness, pallor, perspiration, and syncope.  Nitrate or nitrite therapy is considered contraindicated in patients with acute circulatory failure or shock.', '3', 'Purvin VA, Dunn DW "Nitrate-induced transient ischemic attacks." South Med J 74 (1981):  1130-1|Buckley R, Roberts R "Symptomatic bradycardia following the administration of sublingual nitroglycerin." Am J Emerg Med 11 (1993):  253-5|von Arnim T, Autenrieth G, Bolte HD "Acute myocardial infarction during continuous electrocardiographic ST segment recording. Possible role of bradycardia and hypotension induced by glyceryl trinitrate." Br Heart J 51 (1984):  575-7|Lancaster L, Fenster PE "Complete heart block after sublingual nitroglycerin." Chest 84 (1983):  111-2|Ong EA, Bass S "Nitroglycerin-induced bradycardia and hypotension in acute myocardial infarction." Chest 77 (1980):  244|Cunningham J "Hypotension following administration of sublingual nitroglycerin ." Heart Lung 8 (1979):  364|Nemerovski M, Shah PK "Syndrome of severe bradycardia and hypotension following sublingual nitroglycerin administration." Cardiology 67 (1981):  180-9|Brandes W, Santiago T, Limacher M "Nitroglycerin-induced hypotension, bradycardia, and asystole: report of a case and review of the literature." Clin Cardiol 13 (1990):  741-4|"Product Information. Isordil (isosorbide dinitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. ISMO (isosorbide mononitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58701, 15837, 'Isosorbide dinitrate', 'Hypotension', 'Organic nitrates and nitrites may cause severe hypotension, syncope and shock, even with small doses.  Hypotension induced by these agents may be accompanied by paradoxical bradycardia and increased angina pectoris.  Therapy with nitrates and nitrites should be administered cautiously in patients who are volume-depleted or hypotensive (e.g., systolic blood pressure <90 mm Hg) or who, because of inadequate circulation to the brain or to other vital organs, would be unusually compromised by undue hypotension.  Patients should be in a sitting or recumbent position during and immediately after drug administration, and monitored for symptoms of severe hypotension such as nausea, vomiting, weakness, pallor, perspiration, and syncope.  Nitrate or nitrite therapy is considered contraindicated in patients with acute circulatory failure or shock.', '3', 'Purvin VA, Dunn DW "Nitrate-induced transient ischemic attacks." South Med J 74 (1981):  1130-1|Buckley R, Roberts R "Symptomatic bradycardia following the administration of sublingual nitroglycerin." Am J Emerg Med 11 (1993):  253-5|von Arnim T, Autenrieth G, Bolte HD "Acute myocardial infarction during continuous electrocardiographic ST segment recording. Possible role of bradycardia and hypotension induced by glyceryl trinitrate." Br Heart J 51 (1984):  575-7|Lancaster L, Fenster PE "Complete heart block after sublingual nitroglycerin." Chest 84 (1983):  111-2|Ong EA, Bass S "Nitroglycerin-induced bradycardia and hypotension in acute myocardial infarction." Chest 77 (1980):  244|Cunningham J "Hypotension following administration of sublingual nitroglycerin ." Heart Lung 8 (1979):  364|Nemerovski M, Shah PK "Syndrome of severe bradycardia and hypotension following sublingual nitroglycerin administration." Cardiology 67 (1981):  180-9|Brandes W, Santiago T, Limacher M "Nitroglycerin-induced hypotension, bradycardia, and asystole: report of a case and review of the literature." Clin Cardiol 13 (1990):  741-4|"Product Information. Isordil (isosorbide dinitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. ISMO (isosorbide mononitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58702, 15838, 'Isosorbide dinitrate', 'Hypotension', 'Organic nitrates and nitrites may cause severe hypotension, syncope and shock, even with small doses.  Hypotension induced by these agents may be accompanied by paradoxical bradycardia and increased angina pectoris.  Therapy with nitrates and nitrites should be administered cautiously in patients who are volume-depleted or hypotensive (e.g., systolic blood pressure <90 mm Hg) or who, because of inadequate circulation to the brain or to other vital organs, would be unusually compromised by undue hypotension.  Patients should be in a sitting or recumbent position during and immediately after drug administration, and monitored for symptoms of severe hypotension such as nausea, vomiting, weakness, pallor, perspiration, and syncope.  Nitrate or nitrite therapy is considered contraindicated in patients with acute circulatory failure or shock.', '3', 'Purvin VA, Dunn DW "Nitrate-induced transient ischemic attacks." South Med J 74 (1981):  1130-1|Buckley R, Roberts R "Symptomatic bradycardia following the administration of sublingual nitroglycerin." Am J Emerg Med 11 (1993):  253-5|von Arnim T, Autenrieth G, Bolte HD "Acute myocardial infarction during continuous electrocardiographic ST segment recording. Possible role of bradycardia and hypotension induced by glyceryl trinitrate." Br Heart J 51 (1984):  575-7|Lancaster L, Fenster PE "Complete heart block after sublingual nitroglycerin." Chest 84 (1983):  111-2|Ong EA, Bass S "Nitroglycerin-induced bradycardia and hypotension in acute myocardial infarction." Chest 77 (1980):  244|Cunningham J "Hypotension following administration of sublingual nitroglycerin ." Heart Lung 8 (1979):  364|Nemerovski M, Shah PK "Syndrome of severe bradycardia and hypotension following sublingual nitroglycerin administration." Cardiology 67 (1981):  180-9|Brandes W, Santiago T, Limacher M "Nitroglycerin-induced hypotension, bradycardia, and asystole: report of a case and review of the literature." Clin Cardiol 13 (1990):  741-4|"Product Information. Isordil (isosorbide dinitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. ISMO (isosorbide mononitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58703, 16808, 'Isosorbide dinitrate', 'Hypotension', 'Organic nitrates and nitrites may cause severe hypotension, syncope and shock, even with small doses.  Hypotension induced by these agents may be accompanied by paradoxical bradycardia and increased angina pectoris.  Therapy with nitrates and nitrites should be administered cautiously in patients who are volume-depleted or hypotensive (e.g., systolic blood pressure <90 mm Hg) or who, because of inadequate circulation to the brain or to other vital organs, would be unusually compromised by undue hypotension.  Patients should be in a sitting or recumbent position during and immediately after drug administration, and monitored for symptoms of severe hypotension such as nausea, vomiting, weakness, pallor, perspiration, and syncope.  Nitrate or nitrite therapy is considered contraindicated in patients with acute circulatory failure or shock.', '3', 'Purvin VA, Dunn DW "Nitrate-induced transient ischemic attacks." South Med J 74 (1981):  1130-1|Buckley R, Roberts R "Symptomatic bradycardia following the administration of sublingual nitroglycerin." Am J Emerg Med 11 (1993):  253-5|von Arnim T, Autenrieth G, Bolte HD "Acute myocardial infarction during continuous electrocardiographic ST segment recording. Possible role of bradycardia and hypotension induced by glyceryl trinitrate." Br Heart J 51 (1984):  575-7|Lancaster L, Fenster PE "Complete heart block after sublingual nitroglycerin." Chest 84 (1983):  111-2|Ong EA, Bass S "Nitroglycerin-induced bradycardia and hypotension in acute myocardial infarction." Chest 77 (1980):  244|Cunningham J "Hypotension following administration of sublingual nitroglycerin ." Heart Lung 8 (1979):  364|Nemerovski M, Shah PK "Syndrome of severe bradycardia and hypotension following sublingual nitroglycerin administration." Cardiology 67 (1981):  180-9|Brandes W, Santiago T, Limacher M "Nitroglycerin-induced hypotension, bradycardia, and asystole: report of a case and review of the literature." Clin Cardiol 13 (1990):  741-4|"Product Information. Isordil (isosorbide dinitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. ISMO (isosorbide mononitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58704, 21002, 'Isosorbide dinitrate', 'Hypotension', 'Organic nitrates and nitrites may cause severe hypotension, syncope and shock, even with small doses.  Hypotension induced by these agents may be accompanied by paradoxical bradycardia and increased angina pectoris.  Therapy with nitrates and nitrites should be administered cautiously in patients who are volume-depleted or hypotensive (e.g., systolic blood pressure <90 mm Hg) or who, because of inadequate circulation to the brain or to other vital organs, would be unusually compromised by undue hypotension.  Patients should be in a sitting or recumbent position during and immediately after drug administration, and monitored for symptoms of severe hypotension such as nausea, vomiting, weakness, pallor, perspiration, and syncope.  Nitrate or nitrite therapy is considered contraindicated in patients with acute circulatory failure or shock.', '3', 'Purvin VA, Dunn DW "Nitrate-induced transient ischemic attacks." South Med J 74 (1981):  1130-1|Buckley R, Roberts R "Symptomatic bradycardia following the administration of sublingual nitroglycerin." Am J Emerg Med 11 (1993):  253-5|von Arnim T, Autenrieth G, Bolte HD "Acute myocardial infarction during continuous electrocardiographic ST segment recording. Possible role of bradycardia and hypotension induced by glyceryl trinitrate." Br Heart J 51 (1984):  575-7|Lancaster L, Fenster PE "Complete heart block after sublingual nitroglycerin." Chest 84 (1983):  111-2|Ong EA, Bass S "Nitroglycerin-induced bradycardia and hypotension in acute myocardial infarction." Chest 77 (1980):  244|Cunningham J "Hypotension following administration of sublingual nitroglycerin ." Heart Lung 8 (1979):  364|Nemerovski M, Shah PK "Syndrome of severe bradycardia and hypotension following sublingual nitroglycerin administration." Cardiology 67 (1981):  180-9|Brandes W, Santiago T, Limacher M "Nitroglycerin-induced hypotension, bradycardia, and asystole: report of a case and review of the literature." Clin Cardiol 13 (1990):  741-4|"Product Information. Isordil (isosorbide dinitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. ISMO (isosorbide mononitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58705, 21007, 'Isosorbide dinitrate', 'Hypotension', 'Organic nitrates and nitrites may cause severe hypotension, syncope and shock, even with small doses.  Hypotension induced by these agents may be accompanied by paradoxical bradycardia and increased angina pectoris.  Therapy with nitrates and nitrites should be administered cautiously in patients who are volume-depleted or hypotensive (e.g., systolic blood pressure <90 mm Hg) or who, because of inadequate circulation to the brain or to other vital organs, would be unusually compromised by undue hypotension.  Patients should be in a sitting or recumbent position during and immediately after drug administration, and monitored for symptoms of severe hypotension such as nausea, vomiting, weakness, pallor, perspiration, and syncope.  Nitrate or nitrite therapy is considered contraindicated in patients with acute circulatory failure or shock.', '3', 'Purvin VA, Dunn DW "Nitrate-induced transient ischemic attacks." South Med J 74 (1981):  1130-1|Buckley R, Roberts R "Symptomatic bradycardia following the administration of sublingual nitroglycerin." Am J Emerg Med 11 (1993):  253-5|von Arnim T, Autenrieth G, Bolte HD "Acute myocardial infarction during continuous electrocardiographic ST segment recording. Possible role of bradycardia and hypotension induced by glyceryl trinitrate." Br Heart J 51 (1984):  575-7|Lancaster L, Fenster PE "Complete heart block after sublingual nitroglycerin." Chest 84 (1983):  111-2|Ong EA, Bass S "Nitroglycerin-induced bradycardia and hypotension in acute myocardial infarction." Chest 77 (1980):  244|Cunningham J "Hypotension following administration of sublingual nitroglycerin ." Heart Lung 8 (1979):  364|Nemerovski M, Shah PK "Syndrome of severe bradycardia and hypotension following sublingual nitroglycerin administration." Cardiology 67 (1981):  180-9|Brandes W, Santiago T, Limacher M "Nitroglycerin-induced hypotension, bradycardia, and asystole: report of a case and review of the literature." Clin Cardiol 13 (1990):  741-4|"Product Information. Isordil (isosorbide dinitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. ISMO (isosorbide mononitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58706, 21008, 'Isosorbide dinitrate', 'Hypotension', 'Organic nitrates and nitrites may cause severe hypotension, syncope and shock, even with small doses.  Hypotension induced by these agents may be accompanied by paradoxical bradycardia and increased angina pectoris.  Therapy with nitrates and nitrites should be administered cautiously in patients who are volume-depleted or hypotensive (e.g., systolic blood pressure <90 mm Hg) or who, because of inadequate circulation to the brain or to other vital organs, would be unusually compromised by undue hypotension.  Patients should be in a sitting or recumbent position during and immediately after drug administration, and monitored for symptoms of severe hypotension such as nausea, vomiting, weakness, pallor, perspiration, and syncope.  Nitrate or nitrite therapy is considered contraindicated in patients with acute circulatory failure or shock.', '3', 'Purvin VA, Dunn DW "Nitrate-induced transient ischemic attacks." South Med J 74 (1981):  1130-1|Buckley R, Roberts R "Symptomatic bradycardia following the administration of sublingual nitroglycerin." Am J Emerg Med 11 (1993):  253-5|von Arnim T, Autenrieth G, Bolte HD "Acute myocardial infarction during continuous electrocardiographic ST segment recording. Possible role of bradycardia and hypotension induced by glyceryl trinitrate." Br Heart J 51 (1984):  575-7|Lancaster L, Fenster PE "Complete heart block after sublingual nitroglycerin." Chest 84 (1983):  111-2|Ong EA, Bass S "Nitroglycerin-induced bradycardia and hypotension in acute myocardial infarction." Chest 77 (1980):  244|Cunningham J "Hypotension following administration of sublingual nitroglycerin ." Heart Lung 8 (1979):  364|Nemerovski M, Shah PK "Syndrome of severe bradycardia and hypotension following sublingual nitroglycerin administration." Cardiology 67 (1981):  180-9|Brandes W, Santiago T, Limacher M "Nitroglycerin-induced hypotension, bradycardia, and asystole: report of a case and review of the literature." Clin Cardiol 13 (1990):  741-4|"Product Information. Isordil (isosorbide dinitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. ISMO (isosorbide mononitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58707, 21031, 'Isosorbide dinitrate', 'Hypotension', 'Organic nitrates and nitrites may cause severe hypotension, syncope and shock, even with small doses.  Hypotension induced by these agents may be accompanied by paradoxical bradycardia and increased angina pectoris.  Therapy with nitrates and nitrites should be administered cautiously in patients who are volume-depleted or hypotensive (e.g., systolic blood pressure <90 mm Hg) or who, because of inadequate circulation to the brain or to other vital organs, would be unusually compromised by undue hypotension.  Patients should be in a sitting or recumbent position during and immediately after drug administration, and monitored for symptoms of severe hypotension such as nausea, vomiting, weakness, pallor, perspiration, and syncope.  Nitrate or nitrite therapy is considered contraindicated in patients with acute circulatory failure or shock.', '3', 'Purvin VA, Dunn DW "Nitrate-induced transient ischemic attacks." South Med J 74 (1981):  1130-1|Buckley R, Roberts R "Symptomatic bradycardia following the administration of sublingual nitroglycerin." Am J Emerg Med 11 (1993):  253-5|von Arnim T, Autenrieth G, Bolte HD "Acute myocardial infarction during continuous electrocardiographic ST segment recording. Possible role of bradycardia and hypotension induced by glyceryl trinitrate." Br Heart J 51 (1984):  575-7|Lancaster L, Fenster PE "Complete heart block after sublingual nitroglycerin." Chest 84 (1983):  111-2|Ong EA, Bass S "Nitroglycerin-induced bradycardia and hypotension in acute myocardial infarction." Chest 77 (1980):  244|Cunningham J "Hypotension following administration of sublingual nitroglycerin ." Heart Lung 8 (1979):  364|Nemerovski M, Shah PK "Syndrome of severe bradycardia and hypotension following sublingual nitroglycerin administration." Cardiology 67 (1981):  180-9|Brandes W, Santiago T, Limacher M "Nitroglycerin-induced hypotension, bradycardia, and asystole: report of a case and review of the literature." Clin Cardiol 13 (1990):  741-4|"Product Information. Isordil (isosorbide dinitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. ISMO (isosorbide mononitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58708, 30354, 'Isosorbide dinitrate', 'Hypotension', 'Organic nitrates and nitrites may cause severe hypotension, syncope and shock, even with small doses.  Hypotension induced by these agents may be accompanied by paradoxical bradycardia and increased angina pectoris.  Therapy with nitrates and nitrites should be administered cautiously in patients who are volume-depleted or hypotensive (e.g., systolic blood pressure <90 mm Hg) or who, because of inadequate circulation to the brain or to other vital organs, would be unusually compromised by undue hypotension.  Patients should be in a sitting or recumbent position during and immediately after drug administration, and monitored for symptoms of severe hypotension such as nausea, vomiting, weakness, pallor, perspiration, and syncope.  Nitrate or nitrite therapy is considered contraindicated in patients with acute circulatory failure or shock.', '3', 'Purvin VA, Dunn DW "Nitrate-induced transient ischemic attacks." South Med J 74 (1981):  1130-1|Buckley R, Roberts R "Symptomatic bradycardia following the administration of sublingual nitroglycerin." Am J Emerg Med 11 (1993):  253-5|von Arnim T, Autenrieth G, Bolte HD "Acute myocardial infarction during continuous electrocardiographic ST segment recording. Possible role of bradycardia and hypotension induced by glyceryl trinitrate." Br Heart J 51 (1984):  575-7|Lancaster L, Fenster PE "Complete heart block after sublingual nitroglycerin." Chest 84 (1983):  111-2|Ong EA, Bass S "Nitroglycerin-induced bradycardia and hypotension in acute myocardial infarction." Chest 77 (1980):  244|Cunningham J "Hypotension following administration of sublingual nitroglycerin ." Heart Lung 8 (1979):  364|Nemerovski M, Shah PK "Syndrome of severe bradycardia and hypotension following sublingual nitroglycerin administration." Cardiology 67 (1981):  180-9|Brandes W, Santiago T, Limacher M "Nitroglycerin-induced hypotension, bradycardia, and asystole: report of a case and review of the literature." Clin Cardiol 13 (1990):  741-4|"Product Information. Isordil (isosorbide dinitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. ISMO (isosorbide mononitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58709, 2053, 'Isosorbide dinitrate', 'Intracranial Hypertension', 'Organic nitrates and nitrites can increase cerebrospinal fluid pressure.  Therapy with these agents should be administered cautiously, if at all, in patients with or at risk for intracranial hypertension, including those with cerebral hemorrhage, intracranial lesions, or recent head trauma.', '3', 'Ahmad S "Nitroglycerin and intracranial hypertension ." Am Heart J 121 (1991):  1850-1|Gagnon RL, Marsh ML, Smith RW, Shapiro HM "Intracranial hypertension caused by nitroglycerin." Anesthesiology 51 (1979):  86-7|Boggild M "Intracerebral haemorrhage after dermal nitrate application." BMJ 305 (1992):  1000|Hannerz J, Greitz D "Cerebrospinal fluid pressure and venous pressure in "dynamite headache" and cluster headache attacks." Headache 32 (1992):  436-8|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58710, 3639, 'Isosorbide dinitrate', 'Intracranial Hypertension', 'Organic nitrates and nitrites can increase cerebrospinal fluid pressure.  Therapy with these agents should be administered cautiously, if at all, in patients with or at risk for intracranial hypertension, including those with cerebral hemorrhage, intracranial lesions, or recent head trauma.', '3', 'Ahmad S "Nitroglycerin and intracranial hypertension ." Am Heart J 121 (1991):  1850-1|Gagnon RL, Marsh ML, Smith RW, Shapiro HM "Intracranial hypertension caused by nitroglycerin." Anesthesiology 51 (1979):  86-7|Boggild M "Intracerebral haemorrhage after dermal nitrate application." BMJ 305 (1992):  1000|Hannerz J, Greitz D "Cerebrospinal fluid pressure and venous pressure in "dynamite headache" and cluster headache attacks." Headache 32 (1992):  436-8|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58711, 3707, 'Isosorbide dinitrate', 'Intracranial Hypertension', 'Organic nitrates and nitrites can increase cerebrospinal fluid pressure.  Therapy with these agents should be administered cautiously, if at all, in patients with or at risk for intracranial hypertension, including those with cerebral hemorrhage, intracranial lesions, or recent head trauma.', '3', 'Ahmad S "Nitroglycerin and intracranial hypertension ." Am Heart J 121 (1991):  1850-1|Gagnon RL, Marsh ML, Smith RW, Shapiro HM "Intracranial hypertension caused by nitroglycerin." Anesthesiology 51 (1979):  86-7|Boggild M "Intracerebral haemorrhage after dermal nitrate application." BMJ 305 (1992):  1000|Hannerz J, Greitz D "Cerebrospinal fluid pressure and venous pressure in "dynamite headache" and cluster headache attacks." Headache 32 (1992):  436-8|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58712, 3708, 'Isosorbide dinitrate', 'Intracranial Hypertension', 'Organic nitrates and nitrites can increase cerebrospinal fluid pressure.  Therapy with these agents should be administered cautiously, if at all, in patients with or at risk for intracranial hypertension, including those with cerebral hemorrhage, intracranial lesions, or recent head trauma.', '3', 'Ahmad S "Nitroglycerin and intracranial hypertension ." Am Heart J 121 (1991):  1850-1|Gagnon RL, Marsh ML, Smith RW, Shapiro HM "Intracranial hypertension caused by nitroglycerin." Anesthesiology 51 (1979):  86-7|Boggild M "Intracerebral haemorrhage after dermal nitrate application." BMJ 305 (1992):  1000|Hannerz J, Greitz D "Cerebrospinal fluid pressure and venous pressure in "dynamite headache" and cluster headache attacks." Headache 32 (1992):  436-8|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58713, 3709, 'Isosorbide dinitrate', 'Intracranial Hypertension', 'Organic nitrates and nitrites can increase cerebrospinal fluid pressure.  Therapy with these agents should be administered cautiously, if at all, in patients with or at risk for intracranial hypertension, including those with cerebral hemorrhage, intracranial lesions, or recent head trauma.', '3', 'Ahmad S "Nitroglycerin and intracranial hypertension ." Am Heart J 121 (1991):  1850-1|Gagnon RL, Marsh ML, Smith RW, Shapiro HM "Intracranial hypertension caused by nitroglycerin." Anesthesiology 51 (1979):  86-7|Boggild M "Intracerebral haemorrhage after dermal nitrate application." BMJ 305 (1992):  1000|Hannerz J, Greitz D "Cerebrospinal fluid pressure and venous pressure in "dynamite headache" and cluster headache attacks." Headache 32 (1992):  436-8|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58714, 3984, 'Isosorbide dinitrate', 'Intracranial Hypertension', 'Organic nitrates and nitrites can increase cerebrospinal fluid pressure.  Therapy with these agents should be administered cautiously, if at all, in patients with or at risk for intracranial hypertension, including those with cerebral hemorrhage, intracranial lesions, or recent head trauma.', '3', 'Ahmad S "Nitroglycerin and intracranial hypertension ." Am Heart J 121 (1991):  1850-1|Gagnon RL, Marsh ML, Smith RW, Shapiro HM "Intracranial hypertension caused by nitroglycerin." Anesthesiology 51 (1979):  86-7|Boggild M "Intracerebral haemorrhage after dermal nitrate application." BMJ 305 (1992):  1000|Hannerz J, Greitz D "Cerebrospinal fluid pressure and venous pressure in "dynamite headache" and cluster headache attacks." Headache 32 (1992):  436-8|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58715, 6608, 'Isosorbide dinitrate', 'Intracranial Hypertension', 'Organic nitrates and nitrites can increase cerebrospinal fluid pressure.  Therapy with these agents should be administered cautiously, if at all, in patients with or at risk for intracranial hypertension, including those with cerebral hemorrhage, intracranial lesions, or recent head trauma.', '3', 'Ahmad S "Nitroglycerin and intracranial hypertension ." Am Heart J 121 (1991):  1850-1|Gagnon RL, Marsh ML, Smith RW, Shapiro HM "Intracranial hypertension caused by nitroglycerin." Anesthesiology 51 (1979):  86-7|Boggild M "Intracerebral haemorrhage after dermal nitrate application." BMJ 305 (1992):  1000|Hannerz J, Greitz D "Cerebrospinal fluid pressure and venous pressure in "dynamite headache" and cluster headache attacks." Headache 32 (1992):  436-8|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58716, 14162, 'Isosorbide dinitrate', 'Intracranial Hypertension', 'Organic nitrates and nitrites can increase cerebrospinal fluid pressure.  Therapy with these agents should be administered cautiously, if at all, in patients with or at risk for intracranial hypertension, including those with cerebral hemorrhage, intracranial lesions, or recent head trauma.', '3', 'Ahmad S "Nitroglycerin and intracranial hypertension ." Am Heart J 121 (1991):  1850-1|Gagnon RL, Marsh ML, Smith RW, Shapiro HM "Intracranial hypertension caused by nitroglycerin." Anesthesiology 51 (1979):  86-7|Boggild M "Intracerebral haemorrhage after dermal nitrate application." BMJ 305 (1992):  1000|Hannerz J, Greitz D "Cerebrospinal fluid pressure and venous pressure in "dynamite headache" and cluster headache attacks." Headache 32 (1992):  436-8|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58717, 15837, 'Isosorbide dinitrate', 'Intracranial Hypertension', 'Organic nitrates and nitrites can increase cerebrospinal fluid pressure.  Therapy with these agents should be administered cautiously, if at all, in patients with or at risk for intracranial hypertension, including those with cerebral hemorrhage, intracranial lesions, or recent head trauma.', '3', 'Ahmad S "Nitroglycerin and intracranial hypertension ." Am Heart J 121 (1991):  1850-1|Gagnon RL, Marsh ML, Smith RW, Shapiro HM "Intracranial hypertension caused by nitroglycerin." Anesthesiology 51 (1979):  86-7|Boggild M "Intracerebral haemorrhage after dermal nitrate application." BMJ 305 (1992):  1000|Hannerz J, Greitz D "Cerebrospinal fluid pressure and venous pressure in "dynamite headache" and cluster headache attacks." Headache 32 (1992):  436-8|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58718, 15838, 'Isosorbide dinitrate', 'Intracranial Hypertension', 'Organic nitrates and nitrites can increase cerebrospinal fluid pressure.  Therapy with these agents should be administered cautiously, if at all, in patients with or at risk for intracranial hypertension, including those with cerebral hemorrhage, intracranial lesions, or recent head trauma.', '3', 'Ahmad S "Nitroglycerin and intracranial hypertension ." Am Heart J 121 (1991):  1850-1|Gagnon RL, Marsh ML, Smith RW, Shapiro HM "Intracranial hypertension caused by nitroglycerin." Anesthesiology 51 (1979):  86-7|Boggild M "Intracerebral haemorrhage after dermal nitrate application." BMJ 305 (1992):  1000|Hannerz J, Greitz D "Cerebrospinal fluid pressure and venous pressure in "dynamite headache" and cluster headache attacks." Headache 32 (1992):  436-8|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58719, 16808, 'Isosorbide dinitrate', 'Intracranial Hypertension', 'Organic nitrates and nitrites can increase cerebrospinal fluid pressure.  Therapy with these agents should be administered cautiously, if at all, in patients with or at risk for intracranial hypertension, including those with cerebral hemorrhage, intracranial lesions, or recent head trauma.', '3', 'Ahmad S "Nitroglycerin and intracranial hypertension ." Am Heart J 121 (1991):  1850-1|Gagnon RL, Marsh ML, Smith RW, Shapiro HM "Intracranial hypertension caused by nitroglycerin." Anesthesiology 51 (1979):  86-7|Boggild M "Intracerebral haemorrhage after dermal nitrate application." BMJ 305 (1992):  1000|Hannerz J, Greitz D "Cerebrospinal fluid pressure and venous pressure in "dynamite headache" and cluster headache attacks." Headache 32 (1992):  436-8|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58720, 21002, 'Isosorbide dinitrate', 'Intracranial Hypertension', 'Organic nitrates and nitrites can increase cerebrospinal fluid pressure.  Therapy with these agents should be administered cautiously, if at all, in patients with or at risk for intracranial hypertension, including those with cerebral hemorrhage, intracranial lesions, or recent head trauma.', '3', 'Ahmad S "Nitroglycerin and intracranial hypertension ." Am Heart J 121 (1991):  1850-1|Gagnon RL, Marsh ML, Smith RW, Shapiro HM "Intracranial hypertension caused by nitroglycerin." Anesthesiology 51 (1979):  86-7|Boggild M "Intracerebral haemorrhage after dermal nitrate application." BMJ 305 (1992):  1000|Hannerz J, Greitz D "Cerebrospinal fluid pressure and venous pressure in "dynamite headache" and cluster headache attacks." Headache 32 (1992):  436-8|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58721, 21007, 'Isosorbide dinitrate', 'Intracranial Hypertension', 'Organic nitrates and nitrites can increase cerebrospinal fluid pressure.  Therapy with these agents should be administered cautiously, if at all, in patients with or at risk for intracranial hypertension, including those with cerebral hemorrhage, intracranial lesions, or recent head trauma.', '3', 'Ahmad S "Nitroglycerin and intracranial hypertension ." Am Heart J 121 (1991):  1850-1|Gagnon RL, Marsh ML, Smith RW, Shapiro HM "Intracranial hypertension caused by nitroglycerin." Anesthesiology 51 (1979):  86-7|Boggild M "Intracerebral haemorrhage after dermal nitrate application." BMJ 305 (1992):  1000|Hannerz J, Greitz D "Cerebrospinal fluid pressure and venous pressure in "dynamite headache" and cluster headache attacks." Headache 32 (1992):  436-8|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58722, 21008, 'Isosorbide dinitrate', 'Intracranial Hypertension', 'Organic nitrates and nitrites can increase cerebrospinal fluid pressure.  Therapy with these agents should be administered cautiously, if at all, in patients with or at risk for intracranial hypertension, including those with cerebral hemorrhage, intracranial lesions, or recent head trauma.', '3', 'Ahmad S "Nitroglycerin and intracranial hypertension ." Am Heart J 121 (1991):  1850-1|Gagnon RL, Marsh ML, Smith RW, Shapiro HM "Intracranial hypertension caused by nitroglycerin." Anesthesiology 51 (1979):  86-7|Boggild M "Intracerebral haemorrhage after dermal nitrate application." BMJ 305 (1992):  1000|Hannerz J, Greitz D "Cerebrospinal fluid pressure and venous pressure in "dynamite headache" and cluster headache attacks." Headache 32 (1992):  436-8|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58723, 21031, 'Isosorbide dinitrate', 'Intracranial Hypertension', 'Organic nitrates and nitrites can increase cerebrospinal fluid pressure.  Therapy with these agents should be administered cautiously, if at all, in patients with or at risk for intracranial hypertension, including those with cerebral hemorrhage, intracranial lesions, or recent head trauma.', '3', 'Ahmad S "Nitroglycerin and intracranial hypertension ." Am Heart J 121 (1991):  1850-1|Gagnon RL, Marsh ML, Smith RW, Shapiro HM "Intracranial hypertension caused by nitroglycerin." Anesthesiology 51 (1979):  86-7|Boggild M "Intracerebral haemorrhage after dermal nitrate application." BMJ 305 (1992):  1000|Hannerz J, Greitz D "Cerebrospinal fluid pressure and venous pressure in "dynamite headache" and cluster headache attacks." Headache 32 (1992):  436-8|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58724, 30354, 'Isosorbide dinitrate', 'Intracranial Hypertension', 'Organic nitrates and nitrites can increase cerebrospinal fluid pressure.  Therapy with these agents should be administered cautiously, if at all, in patients with or at risk for intracranial hypertension, including those with cerebral hemorrhage, intracranial lesions, or recent head trauma.', '3', 'Ahmad S "Nitroglycerin and intracranial hypertension ." Am Heart J 121 (1991):  1850-1|Gagnon RL, Marsh ML, Smith RW, Shapiro HM "Intracranial hypertension caused by nitroglycerin." Anesthesiology 51 (1979):  86-7|Boggild M "Intracerebral haemorrhage after dermal nitrate application." BMJ 305 (1992):  1000|Hannerz J, Greitz D "Cerebrospinal fluid pressure and venous pressure in "dynamite headache" and cluster headache attacks." Headache 32 (1992):  436-8|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58725, 2053, 'Isosorbide dinitrate', 'Cardiomyopathy, Hypertrophic', 'Organic nitrates and nitrites may aggravate the angina associated with hypertrophic cardiomyopathy and should be administered cautiously in patients with this condition.', '2', '"Product Information. Isordil (isosorbide dinitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. ISMO (isosorbide mononitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58726, 3639, 'Isosorbide dinitrate', 'Cardiomyopathy, Hypertrophic', 'Organic nitrates and nitrites may aggravate the angina associated with hypertrophic cardiomyopathy and should be administered cautiously in patients with this condition.', '2', '"Product Information. Isordil (isosorbide dinitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. ISMO (isosorbide mononitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58727, 3707, 'Isosorbide dinitrate', 'Cardiomyopathy, Hypertrophic', 'Organic nitrates and nitrites may aggravate the angina associated with hypertrophic cardiomyopathy and should be administered cautiously in patients with this condition.', '2', '"Product Information. Isordil (isosorbide dinitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. ISMO (isosorbide mononitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58728, 3708, 'Isosorbide dinitrate', 'Cardiomyopathy, Hypertrophic', 'Organic nitrates and nitrites may aggravate the angina associated with hypertrophic cardiomyopathy and should be administered cautiously in patients with this condition.', '2', '"Product Information. Isordil (isosorbide dinitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. ISMO (isosorbide mononitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58729, 3709, 'Isosorbide dinitrate', 'Cardiomyopathy, Hypertrophic', 'Organic nitrates and nitrites may aggravate the angina associated with hypertrophic cardiomyopathy and should be administered cautiously in patients with this condition.', '2', '"Product Information. Isordil (isosorbide dinitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. ISMO (isosorbide mononitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58730, 3984, 'Isosorbide dinitrate', 'Cardiomyopathy, Hypertrophic', 'Organic nitrates and nitrites may aggravate the angina associated with hypertrophic cardiomyopathy and should be administered cautiously in patients with this condition.', '2', '"Product Information. Isordil (isosorbide dinitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. ISMO (isosorbide mononitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58731, 6608, 'Isosorbide dinitrate', 'Cardiomyopathy, Hypertrophic', 'Organic nitrates and nitrites may aggravate the angina associated with hypertrophic cardiomyopathy and should be administered cautiously in patients with this condition.', '2', '"Product Information. Isordil (isosorbide dinitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. ISMO (isosorbide mononitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58732, 14162, 'Isosorbide dinitrate', 'Cardiomyopathy, Hypertrophic', 'Organic nitrates and nitrites may aggravate the angina associated with hypertrophic cardiomyopathy and should be administered cautiously in patients with this condition.', '2', '"Product Information. Isordil (isosorbide dinitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. ISMO (isosorbide mononitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58733, 15837, 'Isosorbide dinitrate', 'Cardiomyopathy, Hypertrophic', 'Organic nitrates and nitrites may aggravate the angina associated with hypertrophic cardiomyopathy and should be administered cautiously in patients with this condition.', '2', '"Product Information. Isordil (isosorbide dinitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. ISMO (isosorbide mononitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58734, 15838, 'Isosorbide dinitrate', 'Cardiomyopathy, Hypertrophic', 'Organic nitrates and nitrites may aggravate the angina associated with hypertrophic cardiomyopathy and should be administered cautiously in patients with this condition.', '2', '"Product Information. Isordil (isosorbide dinitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. ISMO (isosorbide mononitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58735, 16808, 'Isosorbide dinitrate', 'Cardiomyopathy, Hypertrophic', 'Organic nitrates and nitrites may aggravate the angina associated with hypertrophic cardiomyopathy and should be administered cautiously in patients with this condition.', '2', '"Product Information. Isordil (isosorbide dinitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. ISMO (isosorbide mononitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58736, 21002, 'Isosorbide dinitrate', 'Cardiomyopathy, Hypertrophic', 'Organic nitrates and nitrites may aggravate the angina associated with hypertrophic cardiomyopathy and should be administered cautiously in patients with this condition.', '2', '"Product Information. Isordil (isosorbide dinitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. ISMO (isosorbide mononitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58737, 21007, 'Isosorbide dinitrate', 'Cardiomyopathy, Hypertrophic', 'Organic nitrates and nitrites may aggravate the angina associated with hypertrophic cardiomyopathy and should be administered cautiously in patients with this condition.', '2', '"Product Information. Isordil (isosorbide dinitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. ISMO (isosorbide mononitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58738, 21008, 'Isosorbide dinitrate', 'Cardiomyopathy, Hypertrophic', 'Organic nitrates and nitrites may aggravate the angina associated with hypertrophic cardiomyopathy and should be administered cautiously in patients with this condition.', '2', '"Product Information. Isordil (isosorbide dinitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. ISMO (isosorbide mononitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58739, 21031, 'Isosorbide dinitrate', 'Cardiomyopathy, Hypertrophic', 'Organic nitrates and nitrites may aggravate the angina associated with hypertrophic cardiomyopathy and should be administered cautiously in patients with this condition.', '2', '"Product Information. Isordil (isosorbide dinitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. ISMO (isosorbide mononitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58740, 30354, 'Isosorbide dinitrate', 'Cardiomyopathy, Hypertrophic', 'Organic nitrates and nitrites may aggravate the angina associated with hypertrophic cardiomyopathy and should be administered cautiously in patients with this condition.', '2', '"Product Information. Isordil (isosorbide dinitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. ISMO (isosorbide mononitrate)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Tridil (nitroglycerin)." DuPont Pharmaceuticals  (2002):|"Product Information. Nitrostat (nitroglycerin)." Parke-Davis  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58741, 2053, 'Isosorbide dinitrate', 'Glaucoma', 'Some medical references state that organic nitrates and nitrites may increase intraocular pressure and should be used with caution in patients with glaucoma.  However, the effect on intraocular pressure is variable and brief, and there is no evidence that these drugs precipitate narrow-angle glaucoma.  Amyl nitrate typically may cause a slight rise of 3+ mm for several seconds followed by a fall in intraocular pressure for 10 to 20 minutes, the latter secondary to a fall in blood pressure.  Nitroglycerin rarely produces ocular side effects, and oral nitroglycerin appears to have few to no significant ocular side effects.', '1', 'Fraunfelder FT, Fraunfelder FW; Randall JA "Drug-Induced Ocular Side Effects" Boston, MA: Butterworth-Heinemann  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58742, 3639, 'Isosorbide dinitrate', 'Glaucoma', 'Some medical references state that organic nitrates and nitrites may increase intraocular pressure and should be used with caution in patients with glaucoma.  However, the effect on intraocular pressure is variable and brief, and there is no evidence that these drugs precipitate narrow-angle glaucoma.  Amyl nitrate typically may cause a slight rise of 3+ mm for several seconds followed by a fall in intraocular pressure for 10 to 20 minutes, the latter secondary to a fall in blood pressure.  Nitroglycerin rarely produces ocular side effects, and oral nitroglycerin appears to have few to no significant ocular side effects.', '1', 'Fraunfelder FT, Fraunfelder FW; Randall JA "Drug-Induced Ocular Side Effects" Boston, MA: Butterworth-Heinemann  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58743, 3707, 'Isosorbide dinitrate', 'Glaucoma', 'Some medical references state that organic nitrates and nitrites may increase intraocular pressure and should be used with caution in patients with glaucoma.  However, the effect on intraocular pressure is variable and brief, and there is no evidence that these drugs precipitate narrow-angle glaucoma.  Amyl nitrate typically may cause a slight rise of 3+ mm for several seconds followed by a fall in intraocular pressure for 10 to 20 minutes, the latter secondary to a fall in blood pressure.  Nitroglycerin rarely produces ocular side effects, and oral nitroglycerin appears to have few to no significant ocular side effects.', '1', 'Fraunfelder FT, Fraunfelder FW; Randall JA "Drug-Induced Ocular Side Effects" Boston, MA: Butterworth-Heinemann  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58744, 3708, 'Isosorbide dinitrate', 'Glaucoma', 'Some medical references state that organic nitrates and nitrites may increase intraocular pressure and should be used with caution in patients with glaucoma.  However, the effect on intraocular pressure is variable and brief, and there is no evidence that these drugs precipitate narrow-angle glaucoma.  Amyl nitrate typically may cause a slight rise of 3+ mm for several seconds followed by a fall in intraocular pressure for 10 to 20 minutes, the latter secondary to a fall in blood pressure.  Nitroglycerin rarely produces ocular side effects, and oral nitroglycerin appears to have few to no significant ocular side effects.', '1', 'Fraunfelder FT, Fraunfelder FW; Randall JA "Drug-Induced Ocular Side Effects" Boston, MA: Butterworth-Heinemann  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58745, 3709, 'Isosorbide dinitrate', 'Glaucoma', 'Some medical references state that organic nitrates and nitrites may increase intraocular pressure and should be used with caution in patients with glaucoma.  However, the effect on intraocular pressure is variable and brief, and there is no evidence that these drugs precipitate narrow-angle glaucoma.  Amyl nitrate typically may cause a slight rise of 3+ mm for several seconds followed by a fall in intraocular pressure for 10 to 20 minutes, the latter secondary to a fall in blood pressure.  Nitroglycerin rarely produces ocular side effects, and oral nitroglycerin appears to have few to no significant ocular side effects.', '1', 'Fraunfelder FT, Fraunfelder FW; Randall JA "Drug-Induced Ocular Side Effects" Boston, MA: Butterworth-Heinemann  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58746, 3984, 'Isosorbide dinitrate', 'Glaucoma', 'Some medical references state that organic nitrates and nitrites may increase intraocular pressure and should be used with caution in patients with glaucoma.  However, the effect on intraocular pressure is variable and brief, and there is no evidence that these drugs precipitate narrow-angle glaucoma.  Amyl nitrate typically may cause a slight rise of 3+ mm for several seconds followed by a fall in intraocular pressure for 10 to 20 minutes, the latter secondary to a fall in blood pressure.  Nitroglycerin rarely produces ocular side effects, and oral nitroglycerin appears to have few to no significant ocular side effects.', '1', 'Fraunfelder FT, Fraunfelder FW; Randall JA "Drug-Induced Ocular Side Effects" Boston, MA: Butterworth-Heinemann  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58747, 6608, 'Isosorbide dinitrate', 'Glaucoma', 'Some medical references state that organic nitrates and nitrites may increase intraocular pressure and should be used with caution in patients with glaucoma.  However, the effect on intraocular pressure is variable and brief, and there is no evidence that these drugs precipitate narrow-angle glaucoma.  Amyl nitrate typically may cause a slight rise of 3+ mm for several seconds followed by a fall in intraocular pressure for 10 to 20 minutes, the latter secondary to a fall in blood pressure.  Nitroglycerin rarely produces ocular side effects, and oral nitroglycerin appears to have few to no significant ocular side effects.', '1', 'Fraunfelder FT, Fraunfelder FW; Randall JA "Drug-Induced Ocular Side Effects" Boston, MA: Butterworth-Heinemann  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58748, 14162, 'Isosorbide dinitrate', 'Glaucoma', 'Some medical references state that organic nitrates and nitrites may increase intraocular pressure and should be used with caution in patients with glaucoma.  However, the effect on intraocular pressure is variable and brief, and there is no evidence that these drugs precipitate narrow-angle glaucoma.  Amyl nitrate typically may cause a slight rise of 3+ mm for several seconds followed by a fall in intraocular pressure for 10 to 20 minutes, the latter secondary to a fall in blood pressure.  Nitroglycerin rarely produces ocular side effects, and oral nitroglycerin appears to have few to no significant ocular side effects.', '1', 'Fraunfelder FT, Fraunfelder FW; Randall JA "Drug-Induced Ocular Side Effects" Boston, MA: Butterworth-Heinemann  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58749, 15837, 'Isosorbide dinitrate', 'Glaucoma', 'Some medical references state that organic nitrates and nitrites may increase intraocular pressure and should be used with caution in patients with glaucoma.  However, the effect on intraocular pressure is variable and brief, and there is no evidence that these drugs precipitate narrow-angle glaucoma.  Amyl nitrate typically may cause a slight rise of 3+ mm for several seconds followed by a fall in intraocular pressure for 10 to 20 minutes, the latter secondary to a fall in blood pressure.  Nitroglycerin rarely produces ocular side effects, and oral nitroglycerin appears to have few to no significant ocular side effects.', '1', 'Fraunfelder FT, Fraunfelder FW; Randall JA "Drug-Induced Ocular Side Effects" Boston, MA: Butterworth-Heinemann  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58750, 15838, 'Isosorbide dinitrate', 'Glaucoma', 'Some medical references state that organic nitrates and nitrites may increase intraocular pressure and should be used with caution in patients with glaucoma.  However, the effect on intraocular pressure is variable and brief, and there is no evidence that these drugs precipitate narrow-angle glaucoma.  Amyl nitrate typically may cause a slight rise of 3+ mm for several seconds followed by a fall in intraocular pressure for 10 to 20 minutes, the latter secondary to a fall in blood pressure.  Nitroglycerin rarely produces ocular side effects, and oral nitroglycerin appears to have few to no significant ocular side effects.', '1', 'Fraunfelder FT, Fraunfelder FW; Randall JA "Drug-Induced Ocular Side Effects" Boston, MA: Butterworth-Heinemann  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58751, 16808, 'Isosorbide dinitrate', 'Glaucoma', 'Some medical references state that organic nitrates and nitrites may increase intraocular pressure and should be used with caution in patients with glaucoma.  However, the effect on intraocular pressure is variable and brief, and there is no evidence that these drugs precipitate narrow-angle glaucoma.  Amyl nitrate typically may cause a slight rise of 3+ mm for several seconds followed by a fall in intraocular pressure for 10 to 20 minutes, the latter secondary to a fall in blood pressure.  Nitroglycerin rarely produces ocular side effects, and oral nitroglycerin appears to have few to no significant ocular side effects.', '1', 'Fraunfelder FT, Fraunfelder FW; Randall JA "Drug-Induced Ocular Side Effects" Boston, MA: Butterworth-Heinemann  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58752, 21002, 'Isosorbide dinitrate', 'Glaucoma', 'Some medical references state that organic nitrates and nitrites may increase intraocular pressure and should be used with caution in patients with glaucoma.  However, the effect on intraocular pressure is variable and brief, and there is no evidence that these drugs precipitate narrow-angle glaucoma.  Amyl nitrate typically may cause a slight rise of 3+ mm for several seconds followed by a fall in intraocular pressure for 10 to 20 minutes, the latter secondary to a fall in blood pressure.  Nitroglycerin rarely produces ocular side effects, and oral nitroglycerin appears to have few to no significant ocular side effects.', '1', 'Fraunfelder FT, Fraunfelder FW; Randall JA "Drug-Induced Ocular Side Effects" Boston, MA: Butterworth-Heinemann  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58753, 21007, 'Isosorbide dinitrate', 'Glaucoma', 'Some medical references state that organic nitrates and nitrites may increase intraocular pressure and should be used with caution in patients with glaucoma.  However, the effect on intraocular pressure is variable and brief, and there is no evidence that these drugs precipitate narrow-angle glaucoma.  Amyl nitrate typically may cause a slight rise of 3+ mm for several seconds followed by a fall in intraocular pressure for 10 to 20 minutes, the latter secondary to a fall in blood pressure.  Nitroglycerin rarely produces ocular side effects, and oral nitroglycerin appears to have few to no significant ocular side effects.', '1', 'Fraunfelder FT, Fraunfelder FW; Randall JA "Drug-Induced Ocular Side Effects" Boston, MA: Butterworth-Heinemann  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58754, 21008, 'Isosorbide dinitrate', 'Glaucoma', 'Some medical references state that organic nitrates and nitrites may increase intraocular pressure and should be used with caution in patients with glaucoma.  However, the effect on intraocular pressure is variable and brief, and there is no evidence that these drugs precipitate narrow-angle glaucoma.  Amyl nitrate typically may cause a slight rise of 3+ mm for several seconds followed by a fall in intraocular pressure for 10 to 20 minutes, the latter secondary to a fall in blood pressure.  Nitroglycerin rarely produces ocular side effects, and oral nitroglycerin appears to have few to no significant ocular side effects.', '1', 'Fraunfelder FT, Fraunfelder FW; Randall JA "Drug-Induced Ocular Side Effects" Boston, MA: Butterworth-Heinemann  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58755, 21031, 'Isosorbide dinitrate', 'Glaucoma', 'Some medical references state that organic nitrates and nitrites may increase intraocular pressure and should be used with caution in patients with glaucoma.  However, the effect on intraocular pressure is variable and brief, and there is no evidence that these drugs precipitate narrow-angle glaucoma.  Amyl nitrate typically may cause a slight rise of 3+ mm for several seconds followed by a fall in intraocular pressure for 10 to 20 minutes, the latter secondary to a fall in blood pressure.  Nitroglycerin rarely produces ocular side effects, and oral nitroglycerin appears to have few to no significant ocular side effects.', '1', 'Fraunfelder FT, Fraunfelder FW; Randall JA "Drug-Induced Ocular Side Effects" Boston, MA: Butterworth-Heinemann  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (58756, 30354, 'Isosorbide dinitrate', 'Glaucoma', 'Some medical references state that organic nitrates and nitrites may increase intraocular pressure and should be used with caution in patients with glaucoma.  However, the effect on intraocular pressure is variable and brief, and there is no evidence that these drugs precipitate narrow-angle glaucoma.  Amyl nitrate typically may cause a slight rise of 3+ mm for several seconds followed by a fall in intraocular pressure for 10 to 20 minutes, the latter secondary to a fall in blood pressure.  Nitroglycerin rarely produces ocular side effects, and oral nitroglycerin appears to have few to no significant ocular side effects.', '1', 'Fraunfelder FT, Fraunfelder FW; Randall JA "Drug-Induced Ocular Side Effects" Boston, MA: Butterworth-Heinemann  (2001):', 'DDInter', 0);
